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ABSTRACT 
 
There has been a longstanding research interest in understanding the exact 
mechanisms underlying the correct development of the eye, with the goal of treating 
eye disease and blindness. While there have been enormous advances in the field of 
regenerative medicine, there is still some way to go before these advances can be 
translated into clinical applications. Very little is currently known about the 
regulatory mechanisms controlling the very early stages of eye development. While 
the genes, which regulate eye field development have been well characterised, their 
induction and mechanism of action, including downstream signalling targets and 
associated downstream signalling systems, still largely remain to be elucidated.  
 
The small leucine-rich repeat proteoglycan (SLRP) family of proteins play important 
roles in a number of biological events, such as proliferation, growth and 
differentiation. Class I SLRP Asporin (ASPN) has so far been mainly associated with 
research relating to cartilage homeostasis, osteoarthritis susceptibility and more 
recently cancer. In this study, I introduce ASPN as a new important factor in 
Xenopus laevis early eye development. 
 
During frog embryogenesis, ASPN is broadly expressed in the neuroectoderm of the 
embryo. The overexpression of ASPN causes the induction of ectopic eyes. In 
contrast, blocking ASPN function with morpholino-oligonucleotides inhibits eye 
formation, indicating that ASPN is an essential factor for eye development. Detailed 
molecular analyses revealed that ASPN interacts with insulin growth factor receptor 
(IGF1R) and is essential for activating the IGF-receptor mediated intracellular 
signalling pathway. Furthermore, ASPN perturbed the Wnt, BMP, and Activin 
signalling pathways, suggesting that ASPN thereby creates a favourable environment 
in which the IGF signal can dominate.  
 
ASPN is thus a novel secreted molecule critical for eye induction through the 
coordination of multiple signalling pathways. 
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1.1 Preface 
A recent statistic from the eye research charity ‘Fight for Sight’ estimates that 
someone in the world goes blind every five seconds. Millions of adults and children 
struggle with the effects of their eye conditions. The eye forms part of the central 
nervous system and relays around one fifth of all sensory information, making it the 
most important sensory organ for humans to perceive their environment 
(Cunningham, 2001). Vision is certainly one of our most treasured senses and 
surveys consistently show that loss of sight ranks in third place on the list of most 
feared conditions – just behind cancer and cognitive impairment. Loss of vision has a 
severe impact on social as well as work-related aspects of life (e.g. use of computers, 
driving cars, etc.). A study by Langelaan (Langelaan et al., 2007) found that health 
related quality of life is considerably reduced in vision-impaired patients. Compared 
to other chronic conditions like Diabetes type II, coronary syndrome and hearing 
impairment, quality of life in patients with impaired sight received the lowest rating.  
 
The eye is composed of a number of different specialised cell types, such as neurons 
and glia cells, which develop in a strictly controlled and precise manner (Kohwi and 
Doe, 2013, Reese, 2011). Unsurprisingly, there has been a longstanding research 
interest in understanding the exact mechanisms underlying the correct development 
of the eye, with the goal of mastering the growth of eye tissue in test tubes for 
clinical transplantation and other therapeutic purposes. Thanks to enormous research 
efforts and technical advances in the field of regenerative medicine, the future for 
treating blindness is looking promising. However, there is still some way to go 
before these advances can be translated into clinical applications.   
 
Little is currently known about the regulatory mechanisms controlling the very early 
stages of eye development, i.e. eye induction and in particular the induction of eye 
determining genes.  While the genes that regulate eye field development have been 
well characterised, their induction and mechanism of action, including downstream 
signalling targets and associated downstream signalling systems, still largely remain 
to be elucidated.  
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In this project I introduce the small leucine-rich repeat proteoglycan (SLRP) 
‘Asporin’ (ASPN) as a new important factor in Xenopus laevis early eye 
development. I will explore its role and importance by means of gain-of-function, as 
well as loss-of-function studies and then delve in to explore some of the underlying 
molecular signalling pathways through which it transduces its effects, in particular 
the IGF signalling pathway. 
 
In the following general introduction the vertebrate visual system and principles of 
eye development shall be introduced in more detail. Naturally, the proteoglycan of 
interest in this study, ASPN, and its SLRP family will also be covered. Finally, I will 
describe IGF signalling and its importance during early neural development, and in 
particular its role during eye development. 
 
 
1.2 Introduction to the visual system 
The ability to see is crucial for most species and offers a definite evolutionary 
advantage over organisms who do not possess vision (Fernald, 2000). While the eye 
as a sensory organ is widespread amongst metazoans, there is a huge variety and 
diversity in eye types in terms of their anatomical, developmental and organisational 
features. In the following paragraphs the structure and evolutionary origin of the eye 
as a sensory organ shall be discussed and then the advantages of the frog Xenopus 
laevis as a model organism to study eye will be introduced. 
 
1.2.1 Structure and evolution of eyes 
The basic principle of the eye as a sensory organ can be summarised as follows: 
Light is collected through a kind of aperture, then often focused with the help of a 
lens and thereby directed onto specialised photoreceptor cells containing opsins 
(photon capturing visual pigments), which convert the photons into a neural signal 
(Fernald, 2000).  
 
The simplest type of eye found in nature, consists of a single photoreceptor cell in 
close proximity to another cell; expressing a dark shielding pigment. Darwin referred 
to this as the eye prototype in his work “The origin of species” (Jonasova and 
	 19	
Kozmik, 2008, Darwin, 1859).  This protypic eye can be found in species such as the 
planarian Polycelis auricularia, as seen in Figure 1.1 by Gehring (2014).  
 
The first image forming eyes are suggested to have appeared after the Cambrian 
explosion around 540 Million years ago (Mya). Eyes developed in different ways in 
different species, though the underlying genetic networks including Pax and Rx 
transcription factor family members were preserved. A vertebrate camera-type eye, 
very similar to the modern vertebrate eye, probably already existed by 500 Mya 
(Land, 2012, Martinez-Morales and Wittbrodt, 2009, Lamb et al., 2007). 
 
Today, there are three main types of eye found amongst metazoans: the compound 
eye, as found in the fruit fly Drosophila; the mirror eye, as found in the scallops of 
the Pecten genus; and finally the camera or lens eye, as found in humans and other 
vertebrates (Gehring and Seimiya, 2010). These main eye types are further illustrated 
in Figure 1.2. The camera-type eye found in vertebrates is by far the most successful 
and high performing eye prototype, which yields the highest resolution compared to 
other eye types. Its success can be traced back to the convergent lens, which focuses 
the light onto a hemispheric retina, which contains a high density of photoreceptors. 
While chambered eyes also developed in invertebrate species, vertebrates are the 
only phylum to possess bilateral chambered eyes (Martinez-Morales and Wittbrodt, 
2009). 
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Figure 1.1: The protypic eyes found in planarian Polycelis auricularia. Protypic eyes are 
shown in the planarian Polycelis auricularia (A, B, C). Also a histological section of an eye 
of Planaria torva can be seen in (D). Pc, pigment cell; PcN, pigment cell nucleus; Mv, 
microvilli; Ph, photoreceptor cell; PhN, photoreceptor cell nucleus. Adapted from Gehring 
(2014).  
 
Figure 1.2: Schematic diagram of the evolution of different eye prototypes. Darwin’s 
protypic eye, consisting only of two cells (pigment and photoreceptor cell) can be seen in 
(A). The main types of eyes found amongst metazoans today are the compound eye (B), 
which is found in insects; the mirror eye (D), which occurs in sea scallops; and finally the 
chambered lens eye (C), as found in vertebrates and humans. After Gehring (2014).  
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The evolutionary addition of a refractory lens and cornea greatly enhanced the 
function of the eye as a sensory organ and contributed to an image producing vision 
system. Until this point, organisms could only sense the intensity and direction of the 
light (Jonasova and Kozmik, 2008). The level of eye complexity is not directly 
correlated with the level of complexity of the rest of the organism’s body plan, e.g. 
velvet worms (onychophorans) possess paired eyes with secreted cuticular corneas 
and acellular lenses formed of granular material. There is also a great diversity 
amongst mollusc species: squids have sophisticated camera eyes, while scallops have 
mirror containing eyes (Jonasova and Kozmik, 2008). 
 
Depending on whether the animal is land or water based, as well as providing the eye 
with protection and nutrition, the cornea can function in an additional ‘lens-like” 
fashion. In general, terrestrial animals use both lens and cornea to refract light, while 
aquatic species only need to use the lens. The correct refractive index can 
furthermore be achieved through the presence of different concentrations of lens 
proteins (Jonasova and Kozmik, 2008). 
 
Animals today, express between two and 12 different types of opsins in their retinas, 
which distinguish themselves through the wavelengths they are able to absorb. The 
peak sensitivities of these opsins are often tailored to the animals’ respective habitats, 
e.g. the African blind naked mole rat, which lives under ground, is still capable of 
detecting the wavelengths required for determining the circadian rhythms (Fernald, 
2000). However, the opsins are remarkably homologous across species (Jonasova 
and Kozmik, 2008, Fernald, 2000), so while the anatomical features and morphology 
may differ, the molecular mechanisms underlying the capture of photons and 
conversion to a nerve signal are highly conserved amongst all organisms (Fernald, 
2000).  
 
Through evolution, two distinct broad categories of photoreceptor cells have 
developed: microvillar photoreceptors, which are most often found in invertebrate 
species, and ciliary photoreceptors, which are found in vertebrates such as humans 
(Fernald, 2000). The photoreceptor classes are also referred to as rhabdomeric 
(containing apical microvilli) and ciliary, which were initially thought to only occur 
in invertebrates and vertebrates, respectively. However, it is now known that they 
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can co-exist, such as in molluscs and anthropods (Lamb et al., 2007). The two types 
of receptor cells differ not only in morphology, but also in their method of signal 
transduction. The main difference is the type of G-protein used (Lamb et al., 2007), 
as well as the second messenger systems: vertebrates use cyclic GMP, while 
invertebrates use inositol triphosphate (Fernald, 2000). 
 
Another significant difference is the tissue from which the eye originates during 
development, as this differs enormously between species and classes. The 
cephalopod eye – an advanced type of camera eye, not dissimilar to the human eye  – 
stems from the epidermal placode-folding, while the vertebrate eye originates from 
the neural plate and overlying epidermis (i.e. the lens placode), which eventually 
forms the lens (Fernald, 2000). 
 
The types of cells and proteins, which form the lens, again vary between species. The 
most important property of the lens is translucency and to provide the correct 
refractive index to focus the light onto the photon-transducing photoreceptor cells 
(Fernald, 2000). Often the proteins contained in lens tissue are not lens specific, and 
fulfil further activities (e.g. enzyme activities) in other tissues; this phenomenon is 
referred to as ‘gene sharing’ (Jonasova and Kozmik, 2008, Fernald, 2000). The 
crystalline proteins of the lens are not homologous across species, however the 
genetic factors, which govern eye and lens development, are remarkably similar 
amongst metazoans (Jonasova and Kozmik, 2008). 
 
The question as to whether the eye as a sensory organ is of monophyletic (i.e. 
originating from one evolutionary event) or polyphyletic (i.e. eyes developed in 
several evolutionary events separately from each other) origin has been fiercely 
debated over the years (Jonasova and Kozmik, 2008, Fernald, 2000). More recent 
findings, which revealed a conserved genetic network of transcription factors 
involved in eye development point in the direction of monophyletic eye origin 
(Fernald, 2000). In particular, the families of Pax and Rx transcription factors exhibit 
a wide conservation across species, and shall be introduced in more detail later on 
(Jonasova and Kozmik, 2008).  
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1.2.2 Xenopus laevis as a model organism – a historical perspective 
Xenopus laevis is a frog species, which is native to central and South Africa. These 
days, Xenopus populations can be found in research labs all over the word. The 
majority of developmental research is carried out using six main model organisms: 
drosophila, mouse, chick, c.elegans, zebrafish and Xenopus laevis (including its 
diploid relative Xenopus tropicalis, which has become a very attractive model for 
genomic studies). When asked, why Xenopus laevis is so popular amongst 
developmental biologists, many will refer to the ease with which they can be 
maintained, a relatively short life cycle, large number of eggs which are fertilised 
externally and large enough for microsurgery and lastly, a year round possibility for 
breeding and egg supply thanks to commercially available hormones (Gurdon and 
Hopwood, 2000). 
 
While these are all very good reasons, there is also an interesting historical 
explanation for the popularity and widespread use of Xenopus. As part of 
imperialism, many European zoologists were travelling around the world 
documenting new and exotic species of flora and fauna. Xenopus laevis was firstly 
described at the beginning of the 19th century. In the 1880s leading experimental 
biologists in Germany, like Hans Spemann, used mainly local species of amphibia 
for their experiments, such as rana and newts. Xenopus laevis was already used in 
South Africa by local physiologists and also for biology teaching at schools. Lancelot 
Hogben, a British endocrinologist, worked in South Africa for several years, where 
he was introduced to working with Xenopus. He was very excited about the 
possibilities of Xenopus laevis, referring to it as a gift from God and even named his 
house after the clawed frog species. When he eventually returned to the UK, he 
brought a population of Xenopus with him and introduced this species into 
mainstream science. A lot of work was required to domesticate Xenopus and to find 
the best conditions to induce egg laying. The true rise to fame for Xenopus occurred 
after World War II, for at that time there was an increasing demand for pregnancy 
tests. While many scientists sought to develop tests with mice and rabbits, Xenopus 
turned out to be better suited (Figure 1.3). After subcutaneous injection of a pregnant 
woman’s urine, Xenopus laevis would start laying eggs within the following four to 
12 hours. Soon the Xenopus pregnancy test became available all around Europe and 
North America. Little additional work was required by developmental biologists to 
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adopt them for their own studies: techniques which had been perfected in other 
amphibians, worked well in Xenopus and - thanks to commercially available 
hormones - eggs could be harvested all year round. The latter reason in particular 
made it the model organism of choice for a lot of initial biochemical and cellular 
biology work. Consequently, most of the work on early animal development was 
carried out in Xenopus laevis (Gurdon and Hopwood, 2000). 
 
 
Figure 1.3: Images of the African clawed frog, Lancelot Hogben and the Xenopus 
pregnancy test. (A) A Xenopus laevis female is shown (image source: 
https://www.enasco.com/product/LM00715MX; accessed 20/02/2016). (B) British 
Endocrinologist Lancelot Hogben, who introduced Xenopus laevis as a model organism into 
mainstream science. Image adapted from Wells (1978). (C) The ‘Xenopus pregnancy test’, 
whereby urine of a possible pregnant woman was injected subcutaneously into the frog. If 
pregnant, the frogs would start ovulating four to 12 hours post injection. Image adapted from 
Elkan (1938). 
 
 
1.2.3 Xenopus laevis is a great model organism to study eye development 
As previously discussed, developmental biologists have been using amphibians for 
their studies for over a century, prominent examples being Hans Spemann and Hilde 
Mangold, who performed their important early work in newts (Spemann and 
Mangold, 1924). 
 
Xenopus laevis is generally easy to maintain and culturing of the embryos is also not 
difficult.  The female frogs can be induced to lay eggs, which gives the researcher the 
power to control ovulation and is therefore no longer reliant on seasonal breeding 
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behaviours. The embryos themselves are relatively large (around 1.2 mm) and are 
cultured and fertilised externally. The embryos are also surprisingly resistant to 
various manipulations, including transplantations and excising of tissues.  Wound 
healing is also very fast in X. laevis embryos. Furthermore, Xenopus embryos exhibit 
a fast and very regular cleavage pattern, which made it possible to obtain consistent 
cell lineage/fate maps (Henry et al., 2008). Thanks to these fate mapping studies, it is 
now known which areas of the embryo later contribute to the eye. This can now be 
used to study eye development in more detail. 
 
A variety of tools are available to Xenopus researchers, particularly when it comes to 
analysing gene function. Gain-of-function experiments work really well in Xenopus, 
due to easy access and the comparative robustness of the embryos. For gain-of-
function experiments, synthetic RNA or DNA expression constructs can be 
microinjected into the embryo (often, capped synthetic RNAs are used) and the 
resulting phenotype subsequently analysed (Henry et al., 2008). Loss-of-function 
assays can also be carried out in X.laevis embryos, by injecting antisense RNA, 
morpholinos or dominant negative constructs. Morpholinos are synthetic 
oligonucleotides, which are designed to target the 5’UTR and/or the translational 
start site to prevent translation of the mRNA into protein (Gene Tools, 2016).  
 
A potential concern with X. laevis is its pseudotetraploidy, which is thought to be the 
result of a whole-genome-duplication, following the hypothesised hybridisation of 
two diploid species (Uno et al., 2013, Harland and Grainger, 2011). While some of 
the genes may still be present in a diploid state, other genes are preserved as 
duplicated “allogenes”, which can show different levels of divergence (usually less 
than 10%). Allogenes can even have distinct expression patterns (Pollet and 
Mazabraud, 2006). So the duplicated genes in the X. laevis genome may have 
slightly different sequences, but a conserved function. To overcome this in loss-of-
function experiments, it is sometimes necessary to co-inject two different 
morpholinos, which target the different allogenes (Henry et al., 2008). 
 
Eye and lens development have been studied extensively in Xenopus. Early on its 
particular ability to regenerate parts of its eye (shared with many other amphibians) 
made it of interest to researchers. While not as proficient as other amphibians, X. 
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laevis is capable of regenerating some body parts including eye tissues, especially 
while still in larval stages (Lee et al., 2013, Vergara and Del Rio-Tsonis, 2009). 
Pieter Nieuwkoop and Job Faber were the first to publish a detailed description of X. 
laevis development in their ‘Normal table of Xenopus laevis’ (Nieuwkoop and Faber, 
1967), which is still used by scientists today (Henry et al., 2008). 
 
Much of what we know today about vertebrate eye development is based on studies 
carried out in X. laevis. This includes crucial work on neural induction and the 
discovery of various BMP-inhibiting factors such as Noggin, Chordin, Follistatin and 
Cerberus (Harland, 2000, Henry et al., 2008). Another example is Zuber and 
colleagues’ study (2003) regarding the network of eye field transcription factors 
(EFTFs) in Xenopus: using double in situ hybridisation techniques they demonstrated 
the EFTFs unique overlapping expression patterns. With overexpression experiments 
they were able to construct the relationships between these factors. Xenopus work 
also contributed to a better understanding of later stages of eye development, like the 
signalling pathways and transcription factors involved in the differentiation of neural 
cell types, as well as axon guidance from eye to brain (Mann et al., 2004, Perron et 
al., 1998).  
 
Overall, Xenopus is a good model for studying eye development. Due to some 
technical advantages over other model organisms, it offers a great model to study the 
mechanisms underlying eye development, as well as the processes of development 
and regeneration. 
 
 
1.3 Early embryonic development 
During gastrulation, the simple one layered embryo, which at this stage is a spherical 
ball of cells, develops into a multi-layered organism. To achieve this transformation, 
large cell migrations take place throughout the embryo to form the three primary 
germ layers endoderm, mesoderm and ectoderm, which later give rise to the various 
differentiated parts of the embryo. Also during gastrulation, the so-called ‘primary 
embryonic induction’ takes place, which leads to cell fate determination and axis 
formation within the developing embryo. Neural induction, i.e. the specification of 
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cells to a fate of neural, brain (and also in part eye tissue) is part of these inductive 
events and shall be introduced in a bit more detail in the following paragraphs. 
 
1.3.1 Primary embryonic induction and neural induction 
The dorsal mesoderm is known as the “organizer” and is a well-known source of 
neural inducing agents. It was Hans Spemann and Hilde Mangold, who first 
discovered the organizer and neural induction, nearly a century ago. Early 
transplantation experiments in newts, carried out by Spemann and Mangold, showed 
that the dorsal lip of the blastopore has its fate autonomously determined (Harland, 
2000, Spemann and Mangold, 1924). When transplanted to a ventral site on the 
embryo, this particular tissue still retained its ‘dorsal lip’ character and was even able 
to induce gastrulation and embryongenesis in the developing embryo, eventually 
leading to a secondary axis (Gilbert, 2014, Recanzone and Harris, 1985). Spemann 
termed these dorsal lip cells and its derivatives (i.e. the notochord and head 
endomesoderm) the “organizer”; in his opinion an appropriate name since it has the 
ability to organize embryonic tissue with clear dorso-ventral and antero-posterior 
axes and can induce ventral tissue to form a neural tube and dorsal mesoderm 
(Gilbert, 2014, Spemann, 1938). 
 
Since those initial experiments, it is now known that the interaction between the 
organizer and the ectoderm is not enough to organize the whole embryo. But these 
first interactions initiate a series of inductive events, which are required for 
embryonic development. Since this first induction forms the basis for all the others 
that follow, it is traditionally referred to as primary embryonic induction (Gilbert, 
2014). 
 
1.3.2 Induction of the organizer 
The major characteristics of the organizer are the abilities to self differentiate, - to 
dorsalise the surrounding mesoderm and ectoderm (including neural tube induction), 
and to induce the gastrulation cell movements. But how exactly does the organizer 
itself form? The organizer cells are positioned directly opposite the sperm entry 
point, which is the exact location where two signalling pathways converge, namely a 
dorsalising and a mesodermal signal. Together, they seem to be key for the organizer 
tissue specification (Gilbert, 2014). 
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In more detail, the organizer is induced by the so-called “Neuwkoop center” cells 
(Gerhart et al., 1989, Nakamura and Takasaki, 1970, Nieuwkoop, 1973, Nieuwkoop, 
1977). These are the most dorsal vegetal cells (i.e. prospective endoderm), which lie 
beneath the future organizer tissue. The Nieuwkoop center induces the overlying 
animal cells to become mesodermal tissue. The mesoderm then arises at the border 
(= equator) between the animal and vegetal pole of the embryo (Gilbert, 2014). The 
Nieuwkoop-center forming molecule is β -catenin, which acts as the required 
dorsalising signal. Through several mechanisms, β-catenin accumulates at the dorsal 
side of the embryo (Larabell et al., 1997, Schneider et al., 1996) and activates the 
expression of the two genes twin and siamois, which are involved in organizer 
induction. These in turn induce other proteins to be expressed, which are important 
for organizer function, such as Goosecoid, Xlim1 (dorsal mesoderm specification), 
Noggin, Chordin (BMP inhibitors), Frzb and Cerberus (Bae et al., 2011, Engleka and 
Kessler, 2001, Gilbert, 2014). 
 
Phosphorylated Smad2 seems to be the other important mesodermal signal, which is 
required for the induction of the organizer cells. The vegetal cells of the Nieuwkoop 
center secrete nodal-related paracrine factors (high concentrations in dorsal areas 
with decreasing amounts towards ventral regions), which phosphorylate Smad2 in 
the overlying presumptive mesoderm (Brannon and Kimelman, 1996, Engleka and 
Kessler, 2001). Activated Smad2 then induces the expression of the hhex gene, 
which, together with twin and siamois, specifies the organizer cells and induces 
anterior brain development (Rankin et al., 2011, Smithers and Jones, 2002). Since 
there is a Smad2 gradient along the dorso-ventral axis, slightly lower levels of 
Smad2 seem to activate goosecoid expression in cells destined to become the 
prechordal mesoderm and notochord (Cho, 2012, Germain et al., 2000, Gilbert, 
2014). 
 
The cells of the Nieuwkoop center remain endodermal, while the organizer becomes 
dorsal mesoderm and starts its migration underneath the dorsal ectoderm. The 
organizer cells are thought to become part of the following tissues: pharyngeal 
endoderm, head mesoderm (prechordal plate), dorsal mesoderm (mainly notochord) 
and dorsal blastopore lip (Gont et al., 1993, Keller, 1976). The pharyngeal endoderm 
and prechordal plate lead the organizer tissue’s migration and induce the forebrain 
	 29	
and midbrain, while dorsal mesoderm induces the hindbrain and trunk. The 
blastopore lip eventually becomes the chordaneural hinge and induces the tip of the 
tail in Xenopus (Gilbert, 2014). 
 
In summary, dorsal mesoderm and organizer induction takes place through the 
actions of firstly the Wnt/β-catenin pathway, which activates genes coding for 
Siamois and Twin, and secondly, a vegetal pathway, which activates the secretion of 
Nodal-related paracrine factors, which activate Smad2 in mesodermal cells. The joint 
action of Smad2, Siamois and Twin define the dorsal mesoderm and organizer cells 
(Gilbert, 2014). 
 
1.3.3 Neural induction and the role of BMP inhibitors 
Neural induction can be defined as the process of multipotent embryonic cells 
differentiating into neural cell types, which eventually form the neural tube/plate. To 
explain the mechanisms of neural induction the ‘default model’ was proposed in the 
1990s. It states that ectodermal cells will automatically adopt a neural cell fate unless 
other signals are given. The ectoderm can be induced to form epidermis through the 
actions of bone morphogenic proteins (BMPs). It was thought that BMPs are active 
throughout the entire ectoderm. With the start of gastrulation, the oragnizer acts by 
secreting BMP-inhibitors in the dorsal anterior region to ‘protect’ the ectoderm from 
the epidermal induction and to secure its neural fate (Hemmati-Brivanlou and 
Melton, 1997, Hemmati-Brivanlou and Melton, 1994), thereby creating a dorsal-
ventral BMP gradient (Andoniadou and Martinez-Barbera, 2013, Harland, 2000, 
Stern, 2006). The major BMP inhibitors are Noggin, Chordin and Follistatin, which 
are downstream of the previously mentioned organizer proteins Twin and Siamois 
(Fan and Sokol, 1997, Kessler, 1997), and Norrin, TSK, Xnr1 and Cerberus (Gilbert, 
2014). The neural inducers’ inhibitory effects seem to extend to other members of 
the TGF-β family (Harland, 2000). 
 
The major epidermal inducers are the BMPs, especially BMP4 and its close relations 
BMP2 and BMP7. At late blastula stage, BMP4 expression is restricted to the 
ventrolateral marginal zone, due to the presence of Goosecoid, which represses bmp4 
and wnt8 transcription (Glavic et al., 2001, Hemmati-Brivanlou and Thomsen, 1995). 
As previously mentioned, there is a concentration gradient in the mesodermal cells, 
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whereby a lack of BMP4 results in dorsal mesoderm formation, low levels of BMP4 
in intermediate mesoderm, and high concentrations of BMP4 in lateral mesoderm 
induction (Gilbert, 2014, Hemmati-Brivanlou and Thomsen, 1995). 
 
Noggin was first identified by Smith and Harland (1992). It is a secreted protein, 
which induces the ectoderm to form neural tissue and also dorsalises mesodermal 
cells. It is first expressed in the dorsal lip and later in the notochord. Noggin binds 
BMP4 and BMP2 and thereby stops them from binding to their receptor (Gilbert, 
2014, Zimmerman et al., 1996). Out of all the organizer-secreted proteins, Chordin 
(Sasai et al., 1994) is most acutely activated by β -catenin. Like Noggin, it binds 
BMP4 and BMP2 and prevents receptor binding (Gilbert, 2014, Piccolo et al., 1996). 
Follistatin, first described by Hemmati-Brivanlou and Melton (1994, 1992), inhibits 
both the BMPs and Activin. Norrin is an exception, in that it is already present in the 
animal part of the embryo and not secreted by the organizer. It therefore blocks BMP 
activity in a cell-autonomous fashion (Gilbert, 2014, Kuroda et al., 2004, Savage and 
Phillips, 1989, Xu et al., 2012). 
 
Recent studies, however, suggest that BMP signal inhibition alone is not sufficient 
for neural induction initiation. It has become clear that the process of neural 
induction is much more complex and the default model therefore too simplistic. 
Other work indicates, that neural induction is not a single, but rather a specific 
sequence of signalling events, whereby BMP inhibition might act as a late stage 
maintenance event (Stern, 2006).  
 
While surely contributing to neural induction, ablation experiments and knockout 
studies have shown that the organizer is not essential for neural plate formation 
(Harland, 2000). Since then, some researchers proposed the existence of additional 
‘head’, ‘trunk’ and ‘tail’ organisers – an idea that is still heavily debated. More 
recent studies suggest that neural induction in the anterior part of the embryo is 
governed by BMP inhibition, while trunk and tail end neural induction is linked to 
FGF signalling (Stern, 2006). The organizer’s properties differ from species to 
species and reflect different modes in early development.  However, organizers of all 
classes of animals have the ability to recruit the surrounding ectoderm into a 
patterned neural tube (Harland, 2000). 
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1.3.4 Regional specificity of neural induction and axes formation 
An important feature of neural induction is the regional specificity with which the 
different neural regions are induced. There is obviously a great need for neural 
structures to be organised in a proper anterior to posterior, as well as dorso-ventral, 
fashion. The organizer cells do not simply induce; they also specify the different 
regions of the neural tube. Otto Mangold already demonstrated this in 1933. A few of 
the underlying principles and the molecules involved in this regional specification 
process will be introduced in the following paragraphs (Gilbert, 2014). 
 
BMPs have been shown to be very important for correct dorsal-ventral fate 
specification. Follistatin-like-product (fstl2) and Noggin1 act redundantly with 
chordin to facilitate dorsal-ventral axis (Stern, 2006). The Wnt family is involved in 
many aspects of neural development such as neural induction, axis formation and 
axon guidance. The role of Wnt signalling during neural induction is somewhat 
controversial, but differing results are most likely due to differences in timing during 
the experiments (Stern, 2006). During the early development of ectoderm to neural 
plate and then to neural tube, Wnt signalling seems to be involved in every step of 
the process, including anterior-posterior axis specification in the neural plate, 
regulation of morphology of the neural tube, neural stem cell proliferation and 
differentiation and neural migration (Mulligan and Cheyette, 2012). Wnt signalling, 
alongside retinoic acid and FGF, acts as a caudalising agent. Results from recent 
studies suggest that activated FGF and Wnt signalling pathways are needed to inhibit 
Smad1 activity, which leads to BMP inhibition (Andoniadou and Martinez-Barbera, 
2013).  
 
The role and importance of Wnt signalling in antero-posterior axis formation, seems 
to be preserved across all vertebrate species studied, including many invertebrates 
such as echinoderms, cnidarians and flatworms. In a majority of organisms, Wnts are 
produced in the posterior tissues, while Wnt antagonists block their actions in the 
anterior head regions (Petersen and Reddien, 2009). In the forebrain, the notochord 
and prechordal mesoderm not only secrete BMP, but also Wnt inhibitors (Gilbert, 
2014, Petersen and Reddien, 2009).  
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Cerberus (Bouwmeester et al., 1996) is another important factor, which is secreted by 
the organizer (the pharyngeal endomesoderm part, to be more specific). It was named 
after the three-headed mythical dog, which guards the entrance to Hades in Greek 
mythology. It promotes the development of the cement gland, eyes and olfactory 
placodes in Xenopus embryos. When overexpressed in a vegetal ventral blastomere 
of the 32-cell Xenopus embryo, Cerberus induces ectopic heads. Cerberus can bind 
BMPs, Nodal-related proteins and Wnt8. Blocking of Cerberus action, results in 
greatly increased levels of BMPs, Wnts and Nodals, and a severely inhibited head 
induction (Gilbert, 2014, Silva et al., 2003). 
 
Frzb is a small soluble form of Frizzled (the Wnt receptor) and it is capable of 
binding Wnt proteins in solution. Forced overexpression leads to embryos, which 
lack all posterior body structures due to the systematic Wnt inhibition. Dickkopf 
(Dkk) also directly interacts with the Wnt-receptor and thereby blocks Wnt signal 
transduction. Inhibition of Dkk results in head malformations or a lack of forebrain 
development. Tiki – which has been more recently discovered – forms a complex 
with Wnt proteins and prevents them from binding to their respective receptor. It 
cleaves the proteins and thereby renders them non-functional. Knockdown of Tiki 
confirmed its crucial role in head development (Gilbert, 2014, Zhang et al., 2012). 
 
Pera et al. (2001) first showed the importance of IGFs (insulin-like growth factors) 
for normal anterior neural tube development. IGFs accumulate at the dorsal midline 
of the embryo, particularly in the anterior neural tube. Their overexpression in the 
ventral mesoderm leads to the formation of ectopic heads, while a block leads to no 
head formation. IGFs seem to work through receptor tyrosine kinase (RTK) 
signalling cascades and are capable of blocking BMP and Wnt signalling (Gilbert, 
2014). The importance of IGFs will be discussed in more detail in chapter 1.6. 
 
While research into neural induction mainly focuses on signalling molecules secreted 
by the organiser, a full understanding can only be gained when the associated 
regulatory processes of gene expression are known. Neural and other cell fate 
specific gene activation or suppression, along with transcription factors and changes 
in chromatin structure, histone methylation/acetylation, need to be elucidated (Stern, 
2006).  
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1.4 Development of the eye and visual system 
The head’s sensory organs, such as the eye, develop mostly through interactions 
between the neural tube and the various cranial placodes. These include the olfactory 
placode, which gives rise to the nasal epithelium; the otic placode, which forms the 
inner ear; and the lens placode, which goes on to form the lens of the eye. Also 
crucial to the correct formation of the eye, is a reciprocal interaction between the lens 
placode and the presumptive optic vesicle, which originates from the diencephalon of 
the forebrain (Gilbert, 2014). In this chapter, the general mechanisms of vertebrate 
eye development shall be introduced, with an emphasis on the genetic network and 
molecules known to regulate the development of the visual system. Following on 
from general principles underlying vertebrate eye formation, Xenopus eye 
development will be explained in more detail. 
 
1.4.1 Vertebrate eye development 
1.4.1.1 Eye field specification 
The bilateral protrusions of the optic vesicles from early anterior forebrain, are the 
earliest visible anatomical signs of vertebrate eye development. For the last 80 years 
it has been known, however, that the eye field exists long before the optic vesicles 
become visible (Lopashov and Stroeva, 1964).  
 
The eye field forms as a result of progressive inductive events in the anterior neural 
plate. As previously described, during neural induction, embryonic ectoderm is 
exposed to various neural inducers such as Noggin and Chordin, which then induce 
the formation of the neural plate (Harland, 2000, Mulligan and Cheyette, 2012, Stern, 
2006). Increased expression of factors like Otx2 (orthodenticle homeobox 2), 
facilitate forebrain specification in the embryo.  However, the eye-field specification 
progress itself is orchestrated by the so-called ‘eye field transcription factors’ 
(EFTFs). While numerous inductive and patterning events take place in the anterior 
neural plate to ‘prepare’ for the generation of the vertebrate eye, co-ordinated 
expression of the EFTFs is crucial to eye field specification itself (Zuber et al., 
2003). Correct positional information is therefore important for the specification of 
the eye field.  
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The specification of the eye field starts around the time of neural tube specification. 
In the anterior part of the neural tube, BMP- and Wnt-pathways are inhibited through 
the actions of the different neural inducers. Noggin plays an important role for eye 
field induction as it allows Otx2 to be expressed in the anterior neural tube. It also 
inhibits ET (eye T-box) – an important eye field transcription factor - from being 
expressed too early. Only when enough Otx2 has accumulated in the ventral head 
region, is the Noggin driven inhibition of ET expression lifted. Once ET is 
expressed, the EFTF induction-signalling cascade is kick started (Gilbert, 2014). ET 
activates the next important eye field marker called Rx1 (retinal homeobox), which is 
crucial for the specification of the retina. Rx1 seems to activate Pax6 (paired box 6), 
but at the same time represses the expression of Otx2. Pax6 is a major eye field-
forming gene, which seems to be conserved across all phyla as a photoreceptor-cell 
specifying gene in both vertebrates and invertebrates (Halder et al., 1995b, Zuber, 
2010, Zuber et al., 2003). 
 
Pax6 then activates a network of other EFTFs such as Six3, Six6 and Sox2. Together, 
their actions result in one single eye field, located centrally in the ventral forebrain 
region of the embryo (Fuhrmann, 2010, Tetreault et al., 2009). Since vertebrates 
possess a pair of eyes, the eye field needs to split in two. This is where sonic 
hedgehog (Shh) signalling comes into play. Secreted from the prechordal plate, Shh 
inhibits Pax6 expression in the central part of the eye field and splits it down the 
middle. If not enough Shh is expressed, the eye fields fail to separate, which results 
in an embryo with a single eye  - a condition referred to as cyclopia (Chiang et al., 
1996, Kelley et al., 1996, Roessler and Muenke, 2001). The opposite case has also 
been observed, whereby too much Shh has been released, which leads to a complete 
inhibition of eye formation, as is the case with the blind cave fish Astyanax 
mexicanus (Yamamoto et al., 2009). 
 
1.4.1.2 Neural retina, lens and optic cup development 
Following eye field specification, the two optic vesicles of the forebrain bulge out 
and extend to the overlying surface ectoderm in the head region. The head ectoderm 
has already received ‘lens forming competency’ during gastrulation from the 
underlying foregut endoderm and the heart-forming mesoderm (Jacobson, 1966, 
Zygar et al., 1998).  This is probably achieved through the supply of BMP and Wnt 
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antagonists, which in turn create an environment where Pax6 can be induced (Ogino 
et al., 2012). Pax6 was shown to be critical for the conferral of the lens forming 
competence to the head ectoderm, thereby enabling it to respond to optic cup 
inducers (Gilbert, 2014). 
 
The Rx1 protein, which is expressed in the two – now separated - eye fields, 
activates the Nlcam gene, whose cell-surface product is required for the evagination 
of the optic vesicles from the forebrain (Brown et al., 2010). They extend towards the 
surface ectoderm and upon contact flatten out against it.  
 
The optic vesicles then release paracrine factors such as BMP4, FGF8 and Notch, 
which induce the overlying head ectoderm to form the lens placode (Ogino et al., 
2012). BMP4 activates Sox2 transcription factors in the lens placode (Furuta & 
Hogan, 1998), while FGF8 induces the L-Maf transcription factor. Pax6, Sox2 and 
L-Maf expression in the ectoderm is needed to activate lens specific genes, such as 
the crystalline proteins (Ogino and Yasuda, 1998, Vogel-Hopker et al., 2000). In 
return, the newly induced lens placode also starts to secret paracrine factors such as 
FGFs, which activate the Vsx2 gene in the optic vesicles, which is needed for neural 
retina development (Gilbert, 2014). The dermal mesenchyme surrounds the optic 
vesicles and induces the expression of the Mitf gene in the outer layers, which 
instructs them to produce the pigment melanin (Burmeister et al., 1996, Nguyen and 
Arnheiter, 2000). The optic vesicles’ cells touching the surface ectoderm, will 
therefore develop to form the neural retina, while the adjacent cells of the optic 
vesicles will form the pigmented retina (Fuhrmann, 2010, Gilbert, 2014).  
 
In summary, during gastrulation, the foregut and prechordal plate interact with the 
head ectoderm to confer a lens forming bias, for which transcription factor Pax6 is 
important. The activation of the lens forming potential occurs through paracrine 
factor secretion by the two optic vesicles, which extend from the diencephalon of the 
forebrain to be right next to the future lens placode (Gilbert, 2014). The thereby 
stimulated head ectoderm lengthens upon receiving the vesicles’ paracrine signals, 
and forms the lens placode. Receiving signals itself from the lens placode, the optic 
vesicles bend inwards to form the two-layered eyecup. The lens placode is also 
drawn inwards into the eyecup invagination. The two eyecup layers start to 
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differentiate, whereby the outer layer becomes the pigmented retina and the inner 
layer the neural retina. Within the neural retina, the retinal ganglion cells extend, 
meet at the optic disc at the base of the eyecup and travel along the optic stalk, which 
will later be the optic nerve (Chauhan et al., 2009, Gilbert, 2014). 
 
1.4.1.3 Vertebrate lens, cornea and retina differentiation 
To perform its function the lens needs to be transparent. The transparency of the lens 
tissue is achieved through lens specific proteins called crystallins. When lens cells 
start to grow and differentiate, they accumulate lots of crystalline proteins until they 
fill up the entire cell. For the correct lens curvature, which is crucial for its function, 
microfilaments contract and extend accordingly along the apical-basal axis, regulated 
by the Rho-Rac signalling pathway (Chauhan et al., 2011, Gilbert, 2014). 
 
Relatively little is known about cornea development. Shortly after the lens vesicle 
detaches from the surface ectoderm, the lens vesicle induces the overlying ectoderm 
to secrete layers of collagen. Neural crest cells migrate into these layers to form a 
new cell layer and secrete corneal specific extra cellular matrix (Kanakubo et al., 
2006). As the cornea matures, this cell population condenses and forms a flat cell 
layer, which turns into cornea precursor cells (Cvekl and Tamm, 2004). As part of 
the maturation process, the cells dehydrate and form very tight junctions, which unite 
them with the surface ectoderm (Gage et al., 2005). For the correct curvature of the 
cornea, intra ocular fluid pressure is required (Gilbert, 2014).  
 
The retinal neural precursor cells have the competency to turn into any of the seven 
retinal cell types: retinal ganglion cells, bipolar cells, amacrine cells, horizontal cells, 
rod and cone photoreceptor cells and Müller glia cells (Yang, 2004). In amphibians, 
timing of gene translation and not location of gene transcription was found to 
determine which type of neuron the retinal stem cells turn into. This time dependent 
translational regulation is orchestrated by specific microRNAs (Decembrini et al., 
2006). Of course not all cells comprising the optic cup mature into neural cells; the 
tips of the optic cup adjacent to the lens form the pigmented muscular ring, known as 
iris. Also, at the junction of the neural retina and the iris lies the ciliary body, which 
secrets the aqueous humour (Gilbert, 2014). A schematic diagram of the vertebrate 
eye and retina can be seen in Figure 1.4. 
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Figure 1.4: The vertebrate eye and neural retina. (A) A schematic diagram of the 
anatomical structure of vertebrate eye is shown. (B) The neural retina consists of seven 
retinal cell types (retinal ganglion cells, bipolar cells, amacrine cells, horizontal cells, rod 
and cone photoreceptor cells and Müller glia cells), which are arranged in a layered fashion. 
After Wilkinson-Berka (2004). 
 
 
1.4.2 Xenopus eye development 
The eyes of Xenopus are very similar to those of other vertebrates such as chick, 
mouse and human, and stem from the anterior part of the neural plate. Xenopus eyes 
also originate from one single eye field located in the central forebrain (diencephalon 
to be more precise). As described above, during neurulation the eye field separates 
due to midline signals (Henry et al., 2008, Li et al., 1997, Patten and Placzek, 2000, 
Roessler and Muenke, 2001). Due to the availability of detailed fate maps of the 
Xenopus embryo, which are based on tracer studies, it is now known that the cells 
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contributing to the eye mostly arise from blastomere D1.1 and D1.2 cells, with some 
minor contributions from the V1.2 pool of cells (see Figure 1.5). For the lens, cells 
are mainly derived from the D1.2 and V1.2 blastomeres (Moody, 1987a, Moody, 
1987b). 
 
Figure 1.5: Blastomeres of the 32-cell Xenopus embryo, which contribute to lens and 
retina. Lineage tracing studies revealed that (B) tissues of the D1.1.1, D1.2.1 blastomeres 
make a major contribution (red) to the prospective retina, while blastomeres D1.1.2 and 
D1.2.2 make small contributions (green). (C) For lens, blastomere D1.2.1 mainly contributes 
(red), with small contributions from D1.1.1 and D1.2.2 (green). D1.1.2, V1.2.1 and V1.1.1 
rarely also contribute (orange) to prospective lens. Orientation and naming of blastomeres is 
shown in (A). After Moody (1987b) and Xenbase (2016). 
 
 
At early neural plate stage of Xenopus development, the initial retinal rudiment is 
found in the anterior neural plate at around stage 13/14. Prior to optic vesicle 
formation (around stage 15-19), the retinal rudiment extends to the region of the 
anterolateral folds (Brun, 1981). At stage 18/19 the optic vesicles start protruding 
from the sides of the neural tube. By stage 19-21 the optic vesicles come into contact 
with the overlying head ectoderm, which will eventually give rise to the lens and 
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cornea. The bulging optic vesicles are externally noticeable on the embryos by stage 
21 (Henry et al., 2008). 
 
Much like in other vertebrates, in Xenopus there is a reciprocal inductive relationship 
between the optic vesicles and the lens placode, which drives the development of 
lens and the optic cups. Uniquely in Xenopus, the embryonic ectoderm consists of a 
pigmented outer layer (whose final fate is not well known) and a non-pigmented 
sensorial inner layer. Also, in Xenopus the lens does not form through invagination 
of the surface ectoderm, as is the case for chick, mouse and human. A thickened lens 
placode forms at stage 26/27 in Xenopus. This lens rudiment then enlarges and 
finally separates from the sensorial ectoderm by stages 33/34. A cavity appears and 
the lens placode transforms to lens vesicle by stages 35/36. At the same time, cells 
facing the developing eye cup give rise to elongated primary lens fibres, which start 
synthesising lens crystallin proteins. The cells facing away from the eyecup, go on to 
form the lens epithelium, which is mitotically active (Henry et al., 2008). By stage 
41, the lens cavity disappears as the lens epithelium and lens fibres draw together and 
touch. The lens goes on to mature further.  
 
In Xenopus so called “free-lenses” have been observed and carefully described. 
These are lenses that have developed in the absence of an optic vesicle. The part of 
the optic vesicle that touches the lens placode, goes on to form the neural retina, 
while the more proximal region develops into RPE. First pigmentation in the RPE 
can be seen at stage 32, while it appears entirely black by stage 35/36. At stage 35/36 
the neural retina starts to differentiate and by stages 37/38 the three distinct layers 
can be seen consisting of outer-, inner-nuclear layer and ganglion cell layer. By stage 
42, the photoreceptor cells (rod and cones) are distinguishable. Before 
metamorphosis, a lot of cell proliferation takes place in the ciliary marginal zones 
(CMZ). It seems that much of the adult frog retina stems from the ventral CMZ cells 
(Henry et al., 2008). Without the presence of the lens placode, the retina does not 
form normally (Lupo et al., 2005, Mann et al., 2004, Perron et al., 1998). 
 
1.4.3 Eye field transcription factors in Xenopus 
It is known that the eye field becomes established after neurula stages. From lineage 
tracing/fate mapping experiments it is also known, that already at 32-cell stage, nine 
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of the blastomeres are competent – if not yet specified – to contribute to retinal 
development. It is at the start of the neural plate formation, that specific molecular 
events take place, which commit a population of neuroectodermal cells to a retinal 
fate. This process is also referred to as ‘eye field specification’ (Gallagher et al., 
1991, Huang and Moody, 1993, Moody, 1987a, Zuber, 2010).  
 
During gastrulation/neural induction, cells involute and travel along the inside of the 
blastocoel and finally induce the overlying cells to form neural ectoderm tissue. The 
process of neural induction is, as previously mentioned, regulated by BMP inhibitors, 
FGFs and Wnt signalling pathways. At mid-gastrula stages, all areas of the 
presumptive neural plate have the competency to form eyes. It is only at later stages, 
that the eye formation ability becomes restricted to the very anterior regions of the 
embryo (Li et al., 1997, Saha and Grainger, 1992, Zuber, 2010). 
 
Both the process of eye field specification and forebrain patterning of the neural 
plate, are governed by BMPs, FGFs, Wnts, Nodals, hedgehogs and retinoic acid 
(RA) proteins, as well as their inhibitors. A fine tuned control of these signalling 
gradients exists across the antero-posterior and dorso-ventral axes of the embryo, 
thereby regulating the patterning events. Malfunctioning of any of these signalling 
networks will not only affect the forebrain patterning process, but may also have a 
knock-on effect on eye field specification and thus eye development (Zuber, 2010). 
 
The frog retina is remarkably similar to the human retina in terms of its structure, 
function and (despite different time scales) development. The Xenopus retina 
contains all seven retinal cells types, which are also arranged in a three-layered 
retina. Importantly, a homologous network of genes seems to control eye 
development. These are referred to as the “eye field transcription factors” (EFTFs), 
which shall be introduced in more detail in the following paragraphs. Much of the 
initial work was carried out in Drosophila, where the homologs to the vertebrate 
EFTFs are known as the ‘retinal determining genes in Drosophila’ (Erclik et al., 
2009, Gehring, 2004, Zuber, 2010). 
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1.4.3.1 Otx2 (orthodenticle homeobox 2) 
The Xenopus Otx2 is a homolog of the Drosophila ‘orthodenticle’ gene. Prior to 
gastrulation Otx2 is detected in the dorsal marginal zone of the embryo (Gammill 
and Sive, 1997, Pannese et al., 1995). During gastrulation, it is expressed in the 
involuting mesoderm and later also in the overlying ectoderm, which will eventually 
form the rostral brain and eye field. Just before eye field specification starts (at stage 
12), Otx2 expression stretches from the very anterior presumptive cement gland to 
the region of the midbrain. But this expression pattern changes quickly as eye field 
specification progresses, and soon an expression gap appears in the forebrain. By 
stages 12-13, Otx2 can no longer be detected in the eye field, while other EFTFs start 
to be expressed (Pannese et al., 1995, Zuber et al., 2003). It has been shown that the 
knockdown of Otx2 results in abnormal anterior structures and eye (Carron et al., 
2005). It was also shown that in order for the eye to develop normally, it needs to be 
suppressed in the eye field as described, as continued expression of Otx2 in the eye 
fields results in a ‘no eye’ phenotype. Otx2 seems to supress the expression of other 
EFTFs at eye field specification stages. The forced overexpression of Otx2 was also 
shown to induce ectopic cement gland (Pannese et al., 1995, Zuber, 2010). 
 
1.4.3.2 Six3 (six homeobox 3) 
Xenopus Six3 is expressed in the developing neural plate at all stages, but it can be 
first detected by in situ hybridisation at stage 12 alongside other early phase EFTFs 
(Ghanbari et al., 2001, Zhou et al., 2000, Zuber et al., 2003). The miss-expression of 
Six3 seems to have a dose-dependent effect: low doses of Six3 increase the eye field 
and eventually eye size, while high doses affect the entire head region and result in 
abnormal structures (Bernier et al., 2000). It seems that excessive amounts of Six3 
convert midbrain cells to retinal progenitors. Considering the rather broad expression 
domain of Six3, together with the range of phenotypes observed following 
overexpression, suggests it plays an important role for both eye field specification 
and rostral brain development (Zuber, 2010).  
 
1.4.3.3 Rx1 (retinal homeobox 1) 
In Xenopus, two highly homologous Rx genes have been identified (referred to 
commonly as Rx1a and Rx1b), which are more than 95% identical and exhibit the 
same expression pattern (Casarosa et al., 1997, Mathers et al., 1997a, Wu et al., 
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2009). This may be a result of a partial duplication of the Xenopus laevis genome 
during evolution. For the purposes of this study, I will refer to both with ‘Rx1’. Rx1 
is first detected at stage 12 with a limited expression domain in the presumptive 
forebrain, which includes regions of telencephalon, hypothalamus, eyes and 
diencephalon, but not cement gland (Casarosa et al., 1997, Mathers et al., 1997a). 
The overexpression of Rx1 has been shown to result in hyperproliferation of the 
retina (sometimes with duplicated retinas) and ectopic RPE or retinal tissue in the 
region between eye and brain. Overexpression of Rx1 had no effect on Pax6 and 
Six3 expression domains at early stages (e.g. stage 13), while an expansion of both 
could be observed at later tailbud stages (stage 23) (Andreazzoli et al., 1999, Mathers 
et al., 1997a). The knockdown of Rx1 results in small or absent eyes. It has been 
found that Rx1 supresses Otx2 expression, and it seems to control proliferation and 
neurogenesis in the anterior neural plate. Overall, Rx1 is an important factor for eye 
specification and forebrain development (Andreazzoli et al., 1999, Zuber, 2010, 
Zuber et al., 2003). 
 
1.4.3.4 Pax6 (paired box 6) 
By in situ RNA hybridisation, Pax6 is first detectable at stage 12 in the anterior 
neural plate, where it is expressed in a band across the embryonic midline, as well as 
in two broad stripes along the presumptive neural tube (Hirsch and Harris, 1996, Li 
et al., 1997). At neural plate stages, the anterior expression domain includes regions 
for presumptive eye, telencephalon, diencephalon, olfactory bulbs and hindbrain, as 
well as the presumptive lens ectoderm (Zuber, 2010). 
 
The forced overexpression of Pax6 leads to lens induction in both the whole embryo 
and animal cap. Considering the crucial role Pax6 plays in lens induction (mentioned 
previously), this finding comes as no big surprise (Altmann et al., 1997). What was 
however surprising is that early miss-expression studies found no evidence of Pax6 
being able to induce ectopic eyes. For these studies, researchers injected the Pax6 
mRNA at the 4-cell stage of the frog embryo (Altmann et al., 1997, Halder et al., 
1995a, Hirsch and Harris, 1996, Zuber et al., 1999). However later experiments, 
where injections were carried out at 16- or 32-cell stage showed that Pax6 could 
induce ectopic eye-like structures. Both the concentration of Pax6 mRNA injected, as 
well as location of injection, proved to be critical for this. Pax6 overexpression 
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induced Otx2, Six3 and Rx1 expression. The knockdown of Pax6 reduced or even 
blocked eye formation in Xenopus (Chow et al., 1999b). Based on the Pax6 
expression domain, its ability to induce other EFTFs and ectopic eyes, it can be 
concluded that Pax6 represents a crucial factor for eye field specification (Zuber, 
2010). 
 
1.4.3.5 ET (eye T-box) 
ET can be detected by in situ hybridisation at stage 12 in two expression domains 
within the presumptive eye field and in the presumptive cement gland. Amongst the 
EFTFs, ET exhibits one of the most restricted expression domains within the anterior 
neural plate (Li et al., 1997, Zuber et al., 2003). The miss-expression of ET at the 2-
cell stage of the embryo leads to abnormal eye morphology and development, and if 
overexpressed medially, cyclopia (i.e. fused retinas). This can be explained by the 
fact that ET regulates both part of the Shh signalling pathway and the expression of 
ventral retinal markers (and vice versa - Shh regulates ET expression) (Takabatake et 
al., 2002, Wong et al., 2002). ET can act as a transcriptional repressor (He et al., 
1999), however very little is known about its role in early eye field specification. The 
miss-expression of ET has also been shown to down regulate Otx2 – whether this is a 
direct effect or an indirect effect via Rx1 remains to be seen (Takabatake et al., 2002, 
Zuber et al., 2003). There was no induction of ectopic retina or expanded eye tissue, 
when ET was overexpressed. The knockdown of ET produces headless tadpoles. In 
ET-/- knockout mice, no eye phenotype could be found (Davenport, 2003, Rana et al., 
2006, Ribeiro et al., 2007). While ET is a crucial component of the EFTF cocktail 
that regulates eye development, it may not be crucial for eye field specification itself 
– its role may be to regulate the expression of other EFTFs or other factors such as 
Shh (Zuber, 2010). 
 
1.4.3.6 Six6 (six homeobox 6) 
Six6 is the last of the EFTFs to be expressed in the Xenopus eye field. It has the 
smallest and most eye field centric expression pattern (Zuber et al., 2003). 
Overexpression of Six6 has been shown to dramatically increase eye field and 
consequently eye size (Zuber et al., 1999). It expands the Pax6, Rx1 and ET 
expression domains. The eye enlarging effects of Six6 can be reversed with the 
mitotic inhibitor hydroxyurea, which suggests that this effect is based on excessive 
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cell proliferation. It has been proposed, that Six6 (like Six3) transforms midbrain 
cells to retina (shown to down regulate midbrain markers, while up-regulating 
EFTFs) (Bernier et al., 2000). Both Six6 and Six3 seem to regulate the proliferation 
of retinal precursor cells, possibly through similar mechanisms. Due to Six6 being 
expressed only in the late stage of eye field specification, it must be assumed that it 
contributes to eye development only after initial specification processes have 
occurred (Zuber, 2010). 
 
1.4.4 Mechanisms underlying the EFTFs regulation of eye development 
A lot of the initial work regarding eye field specifying factors was carried out in 
Drosophila. Results showed that there is a tightly co-ordinated hierarchical network 
of transcription factors and feedback loops, that controls eye development in 
Drosophila. The Xenopus EFTFs Otx2, Six3/6, Rx1, Pax6, Lhx2, ET and Nr2e1 are 
in fact homologs of the Drosphila eye regulating genes orthodenticle (otd), 
sineoculis/optix (so/optix), Drosophila Rx (drx), eyeless/twin of eyeless (ey/toy), 
apterous (ap), optomotor-blind (omb) and tailless (tll), respectively (Acampora et al., 
2001, Daniel et al., 1999, Davis et al., 2003, Lunardi and Vignali, 2006). Zuber et al. 
(2003) found that the same network of regulating factors can be found in vertebrates 
(specifically Xenopus) (see Figure 1.6). They found that the miss-expression of 
‘cocktails’ of EFTFs is sufficient to induce ectopic eye field and ectopic eye-like 
structures in Xenopus. 90% of injected tadpoles had developed ectopic retinal 
pigment epithelium (RPE) on the injected side, while 20% exhibited large ectopic 
eyes of either similar or sometimes larger size than the endogenous eye. These 
ectopic structures had a cup-like structure with a tri-layered retina and expressed 
different retinal markers, such as for lens, RPE, photoreceptor and retinal ganglion 
cells. These ectopic eyes could be observed both inside and outside of the nervous 
system (Zuber, 2010). 
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Figure 1.6: The formation of the eye field in the anterior neural plate. (A) A schematic 
diagram to illustrate the dynamic formation of the eye field. Neural inducer Noggin is widely 
expressed in the neural plate (light blue) during neural induction and paves the way for Otx2 
expression (orange), as part of forebrain specification. This is followed by the orchestrated 
expression of EFTFs such as ET, Rx1, Pax6 and Six6 (dark blue) to specify the eye field, 
which eventually leads to eye formation. (B) Before stage 10, Noggin inhibits ET 
expression, but promotes Otx2 expression. Once Otx2 accumulates sufficiently, it lifts the 
noggin-induced inhibition and ET is finally expressed. ET then induces Rx1, which inhibits 
Otx2 expression, but promotes Pax6, which in turn activates a network of other eye field 
transcription factors to facilitate eye field specification (after Zuber et al. (2003) and Gilbert 
(2014). 
 
 
The EFTFs have been shown to regulate each other’s expression (see Figure 1.6): 
Rx1 is required for Six6 expression in Xenopus (Terada et al., 2006), while in the 
mouse Pax6 and Lhx2 are required for Six6 expression (Tetreault et al., 2009). Rx1 
may be transcriptionally regulated by Otx2 (Danno et al., 2008). Pax6 and Six6 can 
also work in synergy to coordinate eye size together (Zuber, 2010, Zuber et al., 
1999). 
 
It seems that the expression of EFTFs in pluripotent cells determines them to a 
retinal cell fate (Viczian et al., 2009). Otx2 and the EFTFs are required, and in some 
conditions even sufficient, for proper eye development in Xenopus. Following these 
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experiments, the question still remained through which mechanisms exactly the 
EFTFs regulate the eye field specification and development of the eye (Zuber, 2010). 
 
Some of the mechanisms have since been identified, such as controlling neural 
patterning signals. As already described in Chapter 1.3.3 about neural induction, the 
neural patterning events in the Xenopus embryo are regulated by BMPs, FGFs, Wnts, 
Nodals and RA. These proteins and their signalling systems have been shown to 
influence the expression domains of EFTFs and in some cases, vice versa (Zuber, 
2010). In order for neural induction to take place, BMP signals need to be inhibited 
in the dorsal anterior part of the embryo. But even after the forebrain patterning 
events have taken place, the BMP inhibition needs to be maintained, so that the eye 
field can develop. So when BMP4 coated beads were implanted in the forebrain 
region of the developing Xenopus embryo, Otx2, Rx1 and Pax6 expression was 
inhibited, which completely hindered eye development (Gestri et al., 2005, Hartley et 
al., 2001). It was shown that Six3 directly suppresses BMP4 and thereby preserves 
the eye field. In summary, the signalling factors that pattern the neural plate have a 
continual influence on the eye field and the EFTFs do in part ‘protect’ the eye field 
from these invading factors (Zuber, 2010). There needs to be a balance of these 
factors for the patterning/development process to occur properly. 
 
EFTFs have also been shown to take part in the regulation of cell migration in the 
neural plate. During gastrulation and neurulation, large numbers of cells migrate 
within the embryo. It has been found that EFTFs play a role in regulating the 
migration and mobility of retinal precursors. Cells expressing Otx2, Rx1 and Pax6 
migrate into the anterior neural plate and eye field. The BMP inhibitor and neural 
inducer Noggin was shown to have a similar effect (Kenyon et al., 2001, Zuber, 
2010). It is known that FGF, ephrin and Wnt signalling pathways are all important 
for the proper positioning of the retinal progenitor cells within the eye field (Lee et 
al., 2006, Lee et al., 2009, Moore et al., 2004). While there is no direct link yet to 
show that EFTFs are directly involved in this process, it is known that EFTFs are 
regulated by and can themselves regulate parts of these pathways (Zuber, 2010). 
 
Some EFTFs have been shown to maintain the proliferative state of the eye field cell 
population. Neural differentiation begins soon after gastrulation in the posterior 
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regions of the neuroectoderm. However, cells of the eye field continue to proliferate 
to achieve the large eye size. Therefore, proneural genes, which facilitate neural 
differentiation, such as Xngnr-1 and Xdeta-1, are not expressed in the eye field. Rx1 
seems to be able to repress the expression of these pro-neural genes (Andreazzoli et 
al., 2003). Six3/Six6, as previously mentioned, regulate retinal progenitor 
proliferation. Not only do they inhibit BMP4, but they also promote the expression of 
anti-neurogenic genes such as Zic-2, hairy2, CyclinD1 and p27Xic1. So EFTFs use 
different mechanisms to maintain eye field cells in a proliferative state (Gestri et al., 
2005, Zuber, 2010). 
 
The EFTFs are highly conserved across species through evolution and their 
malfunctioning leads to abnormal or no eye development. While there are certainly 
species differences, most of the mechanisms mentioned have been discovered in 
other common model organisms. The EFTFs seem to be individually important, as 
they have varied roles, such as regulation of neural patterning, control of cell 
migration and proliferation, as well as controlling other EFTFs expression. In 
Xenopus at least, the EFTFs collectively seem to be sufficient to form normal eye 
(Zuber, 2010). 
 
 
1.5 Extracellular matrix and role of SLRPs 
The extracellular matrix (ECM) is a three dimensional, non-cellular structure, which 
can be found in the space in between cells. It is composed of a network of insoluble 
macromolecules, such as glycoproteins, proteoglycans (PGs) and collagens, which 
are secreted by the surrounding cells. It not only provides mechanical support and 
stability, but also creates appropriate microenvironments, controlling levels of 
growth factors, hydration, pH and electrochemical-gradients (Chen and Birk, 2013). 
 
The ECM is actively involved in the development and maintenance of differentiated 
tissues and it also regulates tissue homeostasis, i.e. the constant remodelling, 
breakdown and synthesis of tissue (Bonnans et al., 2014, Hynes, 2009). It is crucial 
for cell adhesion, as well as cell migration, as it can act as scaffolding for cells to 
attach to or migrate along, but it can also provide direction cues and signals (Gilbert, 
2014). The ECM is essential for survival, which is exemplified by loss-of-function 
	 48	
studies of various ECM components (Bateman et al., 2009, Bonnans et al., 2014, 
Jarvelainen et al., 2009). Components of the ECM continuously interact with 
epithelial cells, e.g. as ligands for cell surface receptors. The ECM signals are 
involved in all areas of a cell’s life, such as adhesion, migration, proliferation, 
survival, differentiation and apoptosis. Also, the ECM can locally secrete growth 
factors, such as EGF, FGF, Wnts and TGF-βs (Bonnans et al., 2014, Hynes, 2009). 
Cleaved parts of the ECM can regulate ECM architecture and also influence cell 
behaviour. Cells are constantly rebuilding and remodelling the surrounding ECM 
(Bonnans et al., 2014). 
 
The architecture of the ECM is highly organised and our understanding of its key 
components, structure and detailed function is continuously increasing (Mecham, 
2001, Rozario and DeSimone, 2010). In mammals there are around 300 proteins that 
make up the ECM – these proteins are referred to as the ‘core matrisome’. The main 
groups are collagens, PGs and glycoproteins. There are two main types of ECM, 
which differ in location and composition: firstly, the interstitial connective tissue 
matrix, which surrounds the cells and offers structural support, and secondly the 
basement membrane, which is a specialised ECM to separate the epithelium from the 
surrounding stroma (Bonnans et al., 2014). 
 
The macromolecules that make up the ECM are specialised and their relative 
composition is tissue specific (Gilbert, 2014, Mecham, 2001, Mouw et al., 2014). 
The ECM macromolecules often aggregate to form supramolecular structures. The 
ECM mainly consists of fibrous proteins such as collagens and elastin, and 
glycoproteins; such as proteoglycans, Fibronectin and Laminin. The collagens 
represent the bulk of the ECM proteins (Mecham, 2001, Mouw et al., 2014).  
 
There are 36 types of proteoglycans, which will be introduced in more detail in the 
following section, with particular emphasis on the family of small leucine-rich repeat 
proteoglycans to which Asporin belongs. Briefly, the PGs can be found in the 
interstitial space between the collagens fibres. They generally consist of a core 
protein with covalently bound glycosaminoglycan (GAG) chains. These GAG 
components readily bind water, so that the presence of PGs serves the hydration of 
the ECM and also contributes to higher resistance to compression forces. PGs are 
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very abundant in the ECM of cartilage and neural tissues (Bandtlow and 
Zimmermann, 2000, Knudson and Knudson, 2001, Mouw et al., 2014). PGs can be 
subdivided according to the type of GAG chains bound, as well as their distribution 
and density along the core protein (Cui et al., 2013, Schwartz and Domowicz, 2004). 
 
There are around 200 complex glycoproteins, with diverse functions, such as 
laminins, fibronectins and elastin. They are involved in ECM assembly, but also 
interact with cell surface receptors (Bonnans et al., 2014). Laminin and Fibronectin 
are examples of so called ‘connector proteins’, as they function as bridges between 
the different ECM proteins, thereby reinforcing the overall ECM structure, and also 
connecting it to the cells. These connector glycoproteins have multiple binding 
domains and can thereby attach to a multitude of molecules (Mecham, 2001). There 
are also many ECM-associated proteins, which are not counted part of the 
matrisome, but are none the less important for its functions (e.g. galectins, 
semaphorins, plexins) (Bonnans et al., 2014, Hynes and Naba, 2012).  
 
1.5.1 Proteoglycans 
Proteoglycans are biological molecules, which posses a protein core and covalently 
linked glycosaminoglycan (GAG) chains. The GAG chains themselves are linear, 
negatively charged polysaccharides, which belong to either of two classes (sulphated 
or non-sulphated). They consist of disaccharide repeat regions, containing acetylated 
amino sugar moieties and uronic acid. After synthesis, proteoglycans are mostly 
secreted into the extracellular space. There, they not only fulfil structural and 
supportive roles, but are also involved in cell signalling activities and other 
regulatory functions. Due to their extracellular location, proteoglycans can affect and 
regulate upstream elements of cell signalling cascades, such as intracellular 
phosphorylation (Schaefer and Schaefer, 2010). 
 
The proteoglycan family consists of 43 distinct genes in mammals, although due to 
alternative splicing the actual number of PGs is much higher. For 20 years a 
classification has been used which does not really encompass all the different 
proteoglycans. Iozzo and Schaefer (2015) therefore suggested a new and more 
encompassing proteoglycan classification, which is based on three criteria: 
cellular/subcellular location, overall gene/protein homology and the presence of 
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specific protein modules within the PG protein core. Nearly all mammalian PGs can 
be divided into four main classes: intracellular PGs, cell surface PGs, pericellular and 
basement membrane zone PGs and lastly extracellular PGs (Iozzo and Schaefer, 
2015). So far there has been only one intracellular PG identified – Serglycin 
(Douaiher et al., 2014). Heparan sulfate proteoglycans (HSPGs) are mainly 
associated with the cell surface or pericellular matrix and are usually closely linked 
to the cells (either directly or indirectly). Moving away from the cells, chondroitin 
sulfate-containing proteoglycans (CSPGs) and dermatan sulfate proteoglycans 
(DSPGs) are the next types of PGs to dominate. They are usually components of 
complex matrices such as found in cartilage, brain and cornea, and provide 
viscoelastic properties to the tissues. The largest class of PGs form the small leucine-
rich repeat proteoglycans, which are most abundant in terms of gene number. As will 
be explained in more detail later - this class of PGs has both structural and signalling 
functions. Particularly in tissue remodelling environments, such as during cancer, 
diabetes, inflammation and atherosclerosis, SLRPs are known to play roles. SLRPs 
interact with several different receptor tyrosine kinases (RTK) and toll-like receptors 
(Iozzo and Schaefer, 2015). 
 
1.5.1.1 Intracellular proteoglycans 
So far, the only known intracellular proteoglycan is Serglycin. It is substituted with 
heparin and found in mast cells where it regulates the packaging of proteases, which 
are released during inflammation (Douaiher et al., 2014). 
 
1.5.1.2 Cell surface proteoglycans 
There are 13 genes in this class, seven of which are transmembrane PGs, while the 
other six are glycosylphosphatidylinositol–anchored (GPI-anchored) PGs. With the 
exception of two PGs (NG2 and Phosphocan), all PGs in this subgroup are 
substituted with heparin sulphate side chains (Iozzo and Schaefer, 2015). To the 
transmembrane spanning PGs belong the Syndecans; this family includes four 
distinct genes for single-pass transmembrane protein cores (Couchman, 2010). 
Syndecans are involved in a huge variety of functions. In development, syndecans 
have been shown to bind growth factors and thereby influence morphogen gradients 
(Christianson and Belting, 2014). In a newly emerging role, syndecan-1 has been 
shown to transfer to the nucleus (Chen and Sanderson, 2009). Other PGs belonging 
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to this group of transmembrane PGs are CSPG4/NG2 (CSPG which has been shown 
to promote tumour vascularization), betglycan/TGFb type III receptor (which acts as 
co-receptor for members of the TGF-β family of Cys knot growth factors, such as 
activins, inhibins and BMP) and Phosphocan (a CSPG which interacts with neurons 
and neural cell adhesion molecules/N-CAMs). The glypicans are GPI-anchored 
HSPGs and are known to bind and modulate Hedgehog (Hh) as well as the canonical 
Wnt pathway via Frizzled (Iozzo and Schaefer, 2015). 
 
1.5.1.3 Pericellular and basement membrane zone proteoglycans 
In this class are four PGs, which are all closely associated with the cell’s surface and 
they are mostly HSPGs. Perlecan is a modular HSPG, with a large gene and complex 
promoter. It has various biological functions and a wide distribution. It interacts with 
various ligands and receptor tyrosine kinases and is known to be a complex regulator 
of vascular and tumour angiogenesis (Iozzo and San Antonio, 2001, Iozzo and 
Schaefer, 2015). Another member of this class is Agrin. It is also an HSPG and 
found to be responsible for acetylcholine receptor clustering. It is highly expressed in 
axons and dendrites (Marneros and Olsen, 2005). 
 
1.5.1.4 Extracellular proteoglycans 
This is the largest class amongst the proteoglycans with a total of 25 distinct genes. 
Four of these are the hyalectans, which are key structural components of cartilage, 
blood vessels and the nervous system. Three genes code for the SPOCK family of 
calcium-binding HSPGs, which are still poorly studied. The largest family form the 
SLRPs to which Asporin belongs. 18 genes have been identified so far (Iozzo and 
Schaefer, 2015). 
 
1.5.2 Small leucine-rich proteoglycans (SLRPs) 
1.5.2.1 Structure and Function 
The SLRP-family consists of 17 members of secreted proteins. Based on genomic 
and protein homologies, they can be divided into five subfamilies: traditionally 
defined classes I to III and the non-canonical classes IV and V (see Figure 1.7). 
SLRPs consist of two main structural components, one being the protein core and the 
other a varying number of GAG chains (e.g. chondroitin, keratin, dermatan and 
heparin-sulphate). SLRPs exhibit a variable number of tandem ‘leucine-rich-repeats’ 
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(LRRs) in their central protein domain, which follow a characteristic motif: LXX-
LXLXXNXL, whereby X = any amino acid, L = leucine/isoleucine/valine and N = 
asparagine/cysteine/threonine. The LRRs are considered particularly important for 
protein-protein interactions. The N-termini contain four cysteines combined with 
class conserved spacing, which has been found to vary depending on SLRP function, 
while the C-termini contain cysteine-rich capping motifs. Canonical SLRP classes I, 
II and III also contain the so-called ‘ear-repeat’. This refers to the penultimate and 
longest LRR, which extends outwards of the molecule and thereby maintains protein 
conformation and its ability to bind ligands. A mutation in the ear repeat has been 
found in human congenital stromal corneal dystrophy patients. There is great 
molecular diversity between SLRP members, which is a result of different numbers 
and combinations of GAGs with which the protein core can be substituted (Schaefer 
and Schaefer, 2010). SLRPs have been shown to be important regulators of 
biological processes. While GAG chains certainly contribute to the specific functions 
of the SLRPs, it has not been investigated in detail (Chen and Birk, 2011, Chen and 
Birk, 2013, Dellett et al., 2012, McEwan et al., 2006, Schaefer and Iozzo, 2008, 
Schaefer and Schaefer, 2010). The GAG side chains are processed in different ways 
depending on the tissue and developmental stage, thereby resulting in varying GAG 
chain lengths, number, sulphation and epimerization. SLRPs are also subject to 
modifications via N-glycosylation, which affects their conformation, stability and 
secretion (Chen and Birk, 2013). This variability in glycosylation and differential 
processing, provide SLRPs with multiple binding abilities (Krishnan et al., 1999, Seo 
et al., 2005). 
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Figure 1.7: The SLRP family of proteins. Shown is a phylogenic tree of the SLRP family 
members, which are divided into traditionally defined classes I to III, and the non-canonical 
classes IV and V. Asporin – the SLRP of interest in this study – has been highlighted in 
yellow and belongs to class I, alongside Biglycan, Decorin and ECM2. 
 
 
The division of SLRPs into families based solely on sequence might not be 
appropriate and should possibly be based on function instead. A major property 
shared by most members of SLRP classes I, II and IV, is the ability to bind collagen 
via their LRR domains with high affinity (Kd in nM range) (Lorenzo et al., 2001). 
 
Due to their proteoglycan structure, SLRPs tend to accumulate in the ECM, where 
they are mainly associated with collagens in the interstitial connective tissues, like 
cornea, bone and tendon. SLRPs were initially thought to be exclusively involved 
with collagen fibril assembly, organisation and degradation. During early 
development, however, there is also collagen independent secretion in tissues. It is 
now known that SLRPs directly regulate ligand induced signalling pathways, such as 
TGF-β family (including BMP) signalling. SLRPs coordinate several signalling 
pathways which regulate cell processes such as proliferation, growth, differentiation, 
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survival, adhesion, migration, tumour growth and metastasis formation (Chen and 
Birk, 2013, Dellett et al., 2012, Wilda et al., 2000). 
 
SLRPs are dynamically synthesised, secreted, deposited and degraded in vivo. Their 
binding ability, the speed of secretion and presence of other modulating molecules all 
affect the form and function of SLRPs. Differential splicing, variable 
polyadenylation and the use of several promoters guarantee the tissue specific 
regulation at different developmental stages. Specific surveillance chaperone 
molecules and post-transcriptional modifications take place in the endoplasmic 
reticulum as part of the secretory pathway (Chen and Birk, 2013, Tasheva et al., 
2004). Once in the extracellular matrix, SLRPs act as substrates for various proteases 
such as matrix metalloproteinases, aggrecanases, BMP-1 and Granzyme B. Some 
SLRP members are resistant to degradation from selected metalloproteinases. When 
bound they can thereby protect collagen fibrils from cleavage through collagenase 
(Boivin et al., 2012, Geng et al., 2006, Melching et al., 2006). There are structural 
similarities between SRLPs and also overlaps in properties. The spatial distribution 
of SLRPs is tissue specific and dynamically changes during development. Thereby 
SLRPs have both instructive and structural roles (Chen and Birk, 2013). 
 
1.5.2.2 Role of SLRP in matrix assembly 
Collagen fibres are the key component of extracellular matrices. Pro-collagen is 
synthesised within the cell, folded in the endoplasmic reticulum (ER), packaged in 
the Golgi apparatus and then finally transported and secreted via specialised 
elongated intracellular compartments at the cell surface. Once in the extracellular 
space, pro-collagen is converted to collagen, which in turn is then assembled to 
protofibrils. The subsequent end-to-end assembly of protofibrils, results in mature 
collagen fibrils. SLRPs play an important supportive and stabilizing role during the 
collagen assembly process through a continuum of interactions, which is both tissue 
and developmental stage dependent (Birk et al., 1995, Canty and Kadler, 2002, Chen 
and Birk, 2013). 
 
SLRPs of different classes share several binding sites, but they also contain specific 
non-shared sites. Although shared binding sites exist, their individual affinities 
towards ligands vary. This suggests some functional redundancy between SLRPs and 
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possibly a scenario where several SLRPs participate in a fine tuned regulatory 
process. SLRPs bind collagen via their central domain to regulate fibril growth 
(Svensson et al., 1995), e.g. class I SLRPs bind collagen via “d” and “e” bands 
(Pringle and Dodd, 1990). SLRPs belonging to the same class bind collagen through 
the same sites and therefore compete for collagen binding, as is the case with 
Asporin and Decorin. However, there is no competition for binding between the 
different SLRP classes. The GAG chains of SLRPs are thought to play a role in the 
regulation of fibrillogenesis and the interfibril spacing, as well as ECM organisation 
(Chen and Birk, 2013). SLRPs may also play a role in cell to matrix interactions, by 
interfering with cell surface receptors and pericellular matrix molecules (Chen and 
Birk, 2013, Kadler et al., 2008). 
 
1.5.2.3 Diseases linked to SLRPs 
There are numerous human diseases, which have been linked to SLRP mutations. 
Interestingly, a lot of inherited SLRP-linked diseases seem to be ocular 
abnormalities. In general, functional compensation seems to take place between 
SLRP members. For example, in muscle, diseased kidney and bone cells an inherited 
lack of Biglycan is compensated by an increased expression of Decorin. This 
emphasises the point that SLRPs work in a context dependent and tissue specific 
manner (Schaefer and Iozzo, 2008). 
 
As previously mentioned, SLRPs have been shown to regulate cell receptor mediated 
signalling. They can interact with some LRR receptors and their adapter molecules, 
which are involved in pathogen recognition. SLRPs are part of the innate immune 
response, by either acting as pathogen-associated-molecular-pattern (PAMP) 
analogues, or being involved in presenting PAMPs to receptor complexes. SLRPs 
may also direct neutrophil infiltration into inflamed tissue by establishing 
immobilized chemokine gradients (Schaefer and Schaefer, 2010). SLRPs also have 
the ability to bind certain pathogens and toxins, such as borrelia burgdorferi (the 
cause of Lyme disease), which is bound by Decorin in the ECM. Also, Decorin and 
Biglycan bind low-density lipoproteins and apolipoproteins to collagen, thereby 
causing their accumulation in atherosclerosis. Decorin has also been shown to have a 
crucial role in the formation of amyloid plaques in Alzheimer’s disease (Brown et al., 
2001, Chen and Birk, 2013, Snow et al., 1992). 
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1.5.2.4 Signalling pathways modulated by SLRPs 
Multiple cellular signalling pathways are modulated by SLRPs including: receptor 
tyrosine kinases, toll-like receptors and, especially, BMP/TGF-β  signalling 
pathways. Many SLRP members, including ASPN (along with Decorin and 
Biglycan), are able to bind to and block BMP/TGF-β signalling. SLRPs regulate 
several signalling networks and are involved in processes like tissue morphogenesis, 
cancer growth and native immunity. Specific spatial distribution of SLRPs and the 
resulting abundance in certain locations may favour certain pathways, while absence 
of SLRPs could allow other types of signals. If this knowledge could be translated 
into a protein-based therapy, it might be possible to target diseases like fibrosis, 
cancer and inflammatory disorders (Schaefer and Iozzo, 2008). 
 
SLRPs have been shown to execute substrate specific functions in a tissue specific 
manner. Decorin, Biglycan and Fibromodulin can bind all three isoforms of TGF-β, 
however with different binding affinities. There have been several modes of 
interactions suggested between Decorin and TGF-β, amongst them: direct binding of 
the two molecules and inactivation as a result; sequestration of the Decorin/TGF-β 
complex into the ECM; and Decorin mediated inhibition of TGF-β signalling via 
Smad2 (Schaefer and Schaefer, 2010). 
 
1.5.2.5 The role of SLRPs during development 
Most members of the SLRP family are expressed during development, and also in 
adult neural tissues – particularly ocular tissue (Le Goff and Bishop, 2007, Ohta et 
al., 2006). SLRP expression is increased in ECM rich tissues such as connecting 
tissues; e.g. cornea and vitreous, which consist of ECM proteins such as collagens. 
The reported molecular activities of SLRPs and their expression patterns, suggest an 
important role for SLRPs in neural development and maintenance. Many SLRP 
family members are highly expressed in the eye and mutations have been shown to 
lead to severe eye defects in humans, such as high myopia (Lin et al., 2010, Majava 
et al., 2007) and congenital dystrophy of the cornea (Bredrup et al., 2005), but also 
more severe diseases, such as gastric cancer (Wang et al., 2011), brain tumours 
(Castells et al., 2010), atherosclerosis and Progeria (Lewis, 2003, Singla et al., 2011). 
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The SLRP family is involved in nearly all signalling pathways of development, such 
as TFG-β and BMP signalling pathways (Moreno et al., 2005b, Morris et al., 2007, 
Yamaguchi et al., 1990). Until recently SLRPs have been studied only in respect to 
one certain signalling pathway. But a much more complex picture is emerging, 
whereby SLRP members each regulate several pathways (Brandan et al., 2006, 
Dellett et al., 2012, Desnoyers et al., 2001, Goldoni et al., 2009, Inkson et al., 2009, 
Iozzo, 1999, Kresse and Schonherr, 2001, Schaefer and Iozzo, 2008).  
 
In Xenopus, Tsukushi and Biglycan regulate the dorsal-ventral axis and secondary 
axis formation by modulating the anti-BMP4 activity of Chordin. Biglycan, for 
example, promotes the binding of BMP4 and Chordin and thereby contributes to the 
BMP signal inhibition (Moreno et al., 2005b, Morris et al., 2007, Ohta et al., 2006). 
Another SLRP – Decorin – also interacts with ECM components such as collagen 
and Fibronectin. It binds and sequesters TGF-β and thus inhibits the TGF-β 
signalling pathway (Yamaguchi et al., 1990). Developing embryos where Decorin 
was inhibited with an antibody showed disturbed anterior-posterior axes, which 
suggests a role for Decorin in convergent extension cell movements (Zagris et al., 
2011). The SLRP Tsukushi, which controls BMP and Delta activity, is thought to 
play an important role in neural crest formation (Kuriyama et al., 2006). SLRPs 
Keratocan, Lumican and Mimecan are all involved in the formation of collagen 
fibrils, the hydration of the corneal stroma and the regulation of corneal transparency 
(Ali et al., 2011, Chen et al., 2010, Tanihara et al., 2002).  
 
In addition to their role in embryonic neural development, the SLRP family also 
maintain the nervous system by regulating adult stem cell and CNS injury response. 
Neural stem cell niches are areas where embryonic stem cells reside after the 
completion of the embryonic development. In amphibians and fish, neural stem cell 
niches have been located in the retina. This peripheral region is referred to as the 
‘ciliary marginal zone’ (CMZ) and is known to produce neurons and glia cells 
continuously throughout the animal’s life. In chick and mammals, a similar structure 
termed the ‘ciliary body’ (CB) has been identified, even though there is much 
controversy regarding the mouse CB (Bilitou and Ohnuma, 2010, Dellett et al., 
2012). Tsukushi is selectively expressed at the CMZ and CB and has been shown to 
regulate proliferation through the Wnt signalling pathway (Ohta et al., 2011, Ohta et 
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al., 2008). Canonical Wnt signalling has been found to regulate retinal stem cell 
proliferation by Kubo and Nakagawa (2008).  Decorin is thought to be involved in 
the recovery processes after CNS injury, as it was found to be up-regulated widely 
around lesions in injured rat brain (Stichel et al., 1995). Decorin could also be 
contributing to the healing of damaged neural retina. It has been shown to supress 
scar formation and promotes axon growth after CNS injury (Davies et al., 2004, 
Logan et al., 1999, Minor et al., 2008). 
 
1.5.3 Asporin – a novel class 1 SLRP 
1.5.3.1 Identification and characterisation of Asporin 
The Asporin protein was first purified from human articular cartilage and meniscus. 
The name ‘Asporin’ is derived from the presence of poly-aspartate residues and its 
overall similarity to decorin. Lorenzo et al. (2001) initially classed ASPN as a non-
proteoglycan when compared to decorin and biglycan, as it lacks the typical Ser-Gly 
dipeptide and flanking amino acids needed for glycanation. However, it contains a 
stretch of aspartate residues and an acidic domain, located either near the N- or C-
terminal. Polymorphisms have been identified, whereby the number of consecutive 
aspartate residues varied from 11-15 (Lorenzo et al., 2001, Schaefer and Iozzo, 
2008).  
 
ASPN is expressed in several adult tissues but in varying amounts. High expression 
levels have been found in the liver, heart, aorta and uterus. Low levels of ASPN are 
found in lung, bone marrow and trachea. No ASPN could be found in the CNS, 
spleen and thymus. ASPN is a very acidic peptide and is closely related to its fellow 
class I SLRPs Decorin and Biglycan. ASPN’s four amino terminal cysteines show 
the typical class I pattern: C-X3-C-X-C-X6-C. Like Decorin and Biglycan, ASPN 
contains a putative pro-peptide with a conserved cleavage site for BMP-1. The ASPN 
gene (human) is divided into eight exons, whereby the introns are inserted into the 
coding sequence at exactly the same positions as found in Decorin and Biglycan. The 
human ASPN gene spans 26 kilobases and is located on chromosome 9q31.1-32. It is not 
clear, whether ASPN contains an additional alternatively spliced exon 1, as is the 
case with Decorin. Like with Biglycan, there is no TATA box found in the 5’ 
flanking region of exon 1. Several transcription factor recognition sites have been 
detected (Lorenzo et al., 2001). 
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As previously mentioned, the ASPN N-terminal is unusual as it contains an extended 
stretch of aspartate residues. mRNA similar to ASPN has been found in other 
vertebrate species, such as zebrafish, which also contains stretches of aspartate 
residues. In mouse and fish, poly-aspartate stretches are interrupted by other amino 
acids, but still exhibit a conserved number of aspartates. This suggests that the 
aspartates are important to the function of ASPN. It has no consensus sequence for 
GAG attachment between the N-terminal cysteine motif and the propeptide, but it 
does contain a conserved consensus sequence for asparagine-linked-glycosyl. This 
single linked oligo-saccharide shows variability in structure. The highest 
concentrations of ASPN mRNA have been found in articular cartilage, as well as 
aorta and uterus. Intermediate levels of mRNA were also found in other tissues, 
containing smooth muscle cells (Lorenzo et al., 2001). 
 
1.5.3.2 ASPN – known signalling properties and disease implications 
In the same way as Decorin and Biglycan, ASPN can bind type I and type II collagen 
(Kou et al., 2010) - probably via its LRR10-12. ASPN competes with Decorin, but 
not Biglycan, for collagen binding (Kalamajski et al., 2009).  
 
ASPN has been shown to inhibit TGF-β function, through a direct interaction of 
ASPN with TGF-β in vitro (Kizawa et al., 2005). ASPN inhibits the TGF-β/Smad 
signal upstream of TGF-β type I receptor activation by co-localising and directly 
binding to TGF-β1 via ASPN’s LRRs, and thereby stopping it from interacting with 
the TGF-β type II receptor (Ikegawa, 2008, Nakajima et al., 2007). The LRR motif is 
well conserved amongst species and is known to bind metal ions, DNA and proteins, 
and it exerts a variety of functions (Tomoeda et al., 2008). On the other hand, TGF-β 
was shown to increase ASPN expression in articular cartilage in vitro (Nakajima et 
al., 2007). In fact, all three isoforms of TGF-β (-1, -2 and -3) similarly induce ASPN 
mRNA expression in chondrogenic cells in human. However, TGF-β/Smad-3 
mediated ASPN induction is indirect, as it requires de novo protein synthesis (Kou et 
al., 2007). Mouse ASPN seems to bind TGF-β via LRR4-5, in contrast to fellow 
class I SLRP Decorin, which binds via LRR4-8. Upon binding of TGF-β, the protein 
conformation of ASPN is expected to be similar to that of Decorin. ASPN, Decorin, 
Biglycan and Fibromodulin are all thought to compete for TGF-β binding. The 
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ability to bind TGF-β and collagens is a trait shared amongst many SLRP family 
members (Kou et al., 2010).  
 
Irreversible destruction of cartilage, tendon and bone are hallmark signs of both 
rheumatoid and osteoarthritis. While osteoarthritis is due to chronic overuse and/or 
injury, rheumatoid arthritis is a systemic autoimmune disease. In both diseases 
inflammatory cytokine like interleukin (IL) 1β and tumour necrosis factor (TNF)-α 
stimulate matrix metalloproteinase enzymes (Torres et al., 2007). Kizawa et al. 
(2005) investigated the potential role of ASPN in osteoarthritis and found a 
significant association between (knee) osteoarthritis and the aspartic acid (D) repeat 
polymorphism in the N-terminal of the ASPN protein. The ASPN allele D14 (= 14 D 
repeats) seems to be overrepresented in patients compared to the common D13 allele. 
Furthermore, the frequency of the D14 allele was found to increase with disease 
severity. D14 is also overexpressed in patients suffering from hip osteoarthritis. 
Asporin suppresses TGF-β mediated expression of Aggrecan 1 and collagen type II 
α 1 genes and also decreased proteoglycans levels in an in vitro model of 
chondrogenesis (Torres et al., 2007). Kizawa et al. (2005) suggest that ASPN plays 
an important role in cartilage homeostasis by regulating cell and extracellular 
material regeneration via the inhibition of TGF-β. Allele variant D14 exhibits the 
strongest inhibitory effects. The stronger the TGF-β inhibition, the faster the disease 
should theoretically progress. Therefore, the multi D-repeat polymorphism has no 
direct role in the susceptibility for rheumatoid arthritis, but it influences the outcome 
of the disease (Torres et al., 2007).  The ASPN D-repeat polymorphism seems to 
play a role in disc degenerative disease (Eskola et al., 2012, Tian et al., 2013) and 
there also seems to be an association with hand osteoarthritis (Bijsterbosch et al., 
2013). Duval and colleagues (2011) examined the induction of ASPN in 
chondrocytes via both the cytokines interleukin (IL)-1β and tumour necrosis factor 
(TNF)-α. Both cytokines promote matrix degradations, while TGF-β promotes 
matrix and tissue repair. It was found that the pro-inflammatory cytokines decreased 
ASPN levels, while TGF-β increased ASPN levels in human chondrocytes (Duval et 
al., 2011). 
  
ASPN seems to have a positive effect on the mineralization of human adult dental 
pulp stem cells’ (hDPSCs) predentin and dentin (Park et al., 2009). The knockdown 
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of ASPN in hDPSCs suppressed mineralisation (Lee et al., 2011). In the periodontal 
ligament, ASPN decreased mineralization by inhibiting BMP-2 activity (Yamada et 
al., 2007). ASPN binds directly to BMP-2, most likely via LRR5, and thus prevents it 
from attaching to its BMP receptor 1B, as found in PDL cells in vitro. ASPN was 
also shown to inhibit BMP dependent Smad proteins in vitro (Tomoeda et al., 2008). 
Kalamajski and colleagues (Kalamajski et al., 2009) showed that ASPN can in fact 
bind calcium via its poly aspartate region and promote osteoblast collagen 
mineralization. Osterix, an osteoblast specific transcription factor, was later found to 
regulate ASPN and OMD expression in human osteoblasts (Zhu et al., 2012).  
 
ASPN forms a feedback loop with both TGF-β and BMP2: ASPN down-regulates 
TGF-β and BMP2, and in turn both of these proteins increase ASPN levels (Ikegawa, 
2008). FGF2, on the other hand, was shown to decrease ASPN levels (Yamada et al., 
2007). 
 
More recently, ASPN has become of interest in cancer research. Increased ASPN 
levels have been detected in the following tumour tissues: pancreatic (Turtoi et al., 
2011), breast (Dumont et al., 2012), prostate (Orr et al., 2012) and scirrhous gastric 
cancer (Satoyoshi et al., 2015). ASPN seems to play opposing roles in different types 
of cancer, for example it acts as a tumour suppressant in breast cancer (Maris et al., 
2015), but has a pro-invasive effect in scirrhous gastric cancers (Satoyoshi et al., 
2015). SLRPs offer a great potential therapeutic target as they are more accessible 
and they form the first line of physical interaction of the cancerous cells with its 
surrounding (Turtoi et al., 2011). Until now there have been no studies regarding 
ASPN’s role in early development. 
 
 
1.6 The role of insulin-like growth factor (IGF) signalling in 
development 
Research carried out over the past 20 years, shows that IGF signalling plays a crucial 
role in the normal development and growth of the central nervous system (CNS). The 
IGF signalling system includes growth factors IGF1 and IGF2, their receptors IGF1R 
and IGF2R, and the IGF binding proteins (IGFBPs). Generally, IGF signalling 
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promotes cell proliferation, maturation, survival and growth of neural cells. Most of 
its effects are mediated through the type 1 IGF receptor (IGF1R). The nature of 
IGF’s effects seems to depend on cell type, tissue microenvironment and the 
developmental stage. Even though the time course differs between species, IGF1 and 
IGF1R seem to be involved at every stage of CNS development - neurulation, 
neurogenesis, differentiation into neurons and glia, neuronal migration, dendritic and 
axon outgrowth, natural cell death, synaptogenesis and myelination (O'Kusky and 
Ye, 2012). It is now also known that IGF signals work together with other neural 
signalling systems to direct neural stem cells towards specific fates during early 
development (O'Kusky and Ye, 2012). In the following section, the IGF signalling 
system shall be introduced, with particular emphasis on its role in eye development.  
 
1.6.1 Overview of the IGF signalling system 
1.6.1.1 IGF1 and IGF2 
Growth factors IGF1 and IGF2 are anabolic peptides of 70 and 67 amino acids, 
respectively. Both share homology with pro-insulin and are produced by a single 
large gene. IGF expression starts early during development, but the exact regulatory 
mechanisms of igf1 and igf2 gene expression, are not well understood. IGF1 is 
expressed in all regions of the CNS, while peak expression often coincides with 
localised active spurts of proliferation, development and growth of neural cells. IGF1 
production seems to take place predominantly in neurons and less so in glial cells 
(O'Kusky and Ye, 2012). In post-natal development, the pituitary growth hormone 
regulates IGF1 outside of the brain and, to an extent, also within the brain. Variant 
forms of IGF1 exist in the brain, which is due to post-translational N-Terminal 
cleavage (Ballard et al., 1987, O'Kusky and Ye, 2012). IGF1 has been shown to 
promote neuron progenitor proliferation and differentiation (Arsenijevic and Weiss, 
1998, Arsenijevic et al., 2001, DiCicco-Bloom and Black, 1988, Zackenfels et al., 
1995), and has an anti-apoptotic effect, which promotes survival (Yamada et al., 
2001). IGF1 is also thought to regulate neurite outgrowth and synaptogenesis  
(Torres-Aleman et al., 1990).  
 
IGF2 is highly expressed in mesenchymal tissues. In the brain, peak levels occur 
prenatally (Ayer-le Lievre et al., 1991). As development progresses, the IGF2 
expression levels continuously decrease and eventually become restricted to the 
	 63	
meninges and choroid plexus in adults (Zhang et al., 2007). Genetic knockout studies 
showed that IGF2 is important for growth in early development (Baker et al., 1993, 
O'Kusky and Ye, 2012). In vitro, IGF2 has similar effects to IGF1 on cell growth and 
development.  Postnatal overexpression of IGF2 has no effect on brain growth in 
mice (van Buul-Offers et al., 1995). An increased amount of IGF2 at this stage may 
have no further growth enhancing effects, as IGF1 signalling through the IGF1R is 
already occurring at maximum levels. IGF2 most likely modulates important non-
growth related neuronal functions, e.g. when injected into rodent brains IGF2 was 
shown to improve memory (Chen et al., 2011). At high concentrations both IGF1 and 
IGF2 can also bind to the insulin receptor (InR), which can mediate IGF actions 
(Louvi et al., 1997, Moreno et al., 2005b, O'Kusky and Ye, 2012).   
 
1.6.1.2 IGF binding proteins 
IGF1 and IGF2 are mostly bound to IGFBPs in the extracellular space and in 
circulation. Ten IGFBPs have been identified so far, including six high affinity 
members termed IGFBP1-IGFBP6 (Jones and Clemmons, 1995), which all share 
structural homology. They specifically bind IGF1/2, with no affinity for insulin. 
IGFBP2, 3, 4, and 5 are the most abundant in the brain, while IGFBP6 can only be 
detected in low concentrations. IGFBP1 is not expressed in the brain at all. Each of 
the IGFBPs exhibits a particular temporal and spatial expression pattern within the 
CNS, but their roles still need to be elucidated in more detail (O'Kusky and Ye, 
2012). By transporting bound IGFs in plasma, IGFBPs are thought to determine 
receptor binding, tissue and cell specific localization of IGFs and to prolong IGFs 
half-life in circulation (Jones and Clemmons, 1995). When bound to an IGFBP, IGFs 
cannot readily leave the circulation, which prolongs their half-life 70-90 fold. The 
resulting pool of circulating IGFs is thought to be a reservoir for times of stress 
(Guler et al., 1989, Hodgkinson et al., 1989).  
 
1.6.1.3 IGF1R and IGF2R 
The IGF1R is a heterotetrameric glycoprotein. It is made up of paired, di-sulfide 
linked α and β  subunits. The α -subunits are located in the extracellular space and 
bind to the IGFs, while the β-subunits have a long intra-cytoplasmic domain, which 
contains intrinsic tyrosine kinase activity, as well as critical sites for tyrosine and 
serine phosphorylation (O'Kusky and Ye, 2012). The IGF1R shares around 46% 
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homology with the Insulin Receptor (InR). Both receptors can form heterodimeric 
hybrid receptors. Although their exact physiological function is not fully understood, 
the hybrid receptors may play a role in certain forms of cancer (Belfiore et al., 2009, 
Kim et al., 2012). IGF1 binds with high affinity to IGF1R. IGF2 and insulin also 
bind, but with a 10-fold and 100-fold lower affinity, respectively (O'Kusky and Ye, 
2012). The IGF1R seems to be expressed in neural stem cells and all other neural 
cells evaluated (Baron-Van Evercooren et al., 1991). Once IGFs bind to the α -
subunit of the IGF1R, a conformational change takes place, which results in auto-
phosphorylation of the β -subunit. This activates a series of intracellular substrate 
proteins, which will be explained in more detail later (O'Kusky and Ye, 2012).  
 
The largest abundance of the InR and IGF1R is found in Hensen’s node, neural fold, 
neural tube and the developing eyes (Girbau et al., 1989). IGF1R is ubiquitously 
expressed in all neural cell types. High abundance of this receptor seems to coincide 
with high rates of cell proliferation and growth (Popken et al., 2005). Furthermore, 
the IGFs and IGF1R often seem to be expressed in close proximity of one another, 
which may suggest that IGFs act locally in an autocrine or paracrine fashion. 
However, IGF1 can cross the blood brain barrier, suggesting that circulating IGF1 
must also be able to influence signalling in the brain (Aberg et al., 2007). IGF1 and 
IGF1R are expressed during early development, before the establishment of neural 
tissues (Ayaso et al., 2002, O'Kusky and Ye, 2012). IGF1 seems to be more 
abundantly expressed in anterior/head regions during late neurulation and 
organogenesis. In the developing eyes, IGF1 was detected in the epithelial cells (de 
Pablo et al., 1993). 
 
The IGF2R is a single chain transmembrane protein, which is identical to the cation-
independent mannose-6-phosphate receptor. It translocates IGF2 and proteins 
containing mannose-6-phosphate units to lysosomes for degradation. The global 
ablation of IGF2R has been shown to lead to overgrowth, due to the subsequent 
accumulation of IGF2 and signalling through the IGF1R (Efstratiadis, 1998, 
Eggenschwiler et al., 1997, O'Kusky and Ye, 2012). 
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1.6.1.4 IGF signalling through the IGF1R 
Most of the IGF signals affecting growth are mediated via the IGF1R. Binding of 
IGF1 or IGF2 to the IGF1R leads to the activation of the tyrosine kinase in the 
receptor’s β -subunit. The subsequent auto-phosphorylation of the tyrosine residues 
recruits docking proteins (LeRoith et al., 1995), such as insulin receptor substrates 
IRS-1, IRS-2, IRS-3, IRS-4, Grb2-associated binder-1 (Gab-1), Ras and Src 
homology containing proteins. The group of IRS molecules are involved in insulin 
signalling and are widely expressed throughout the CNS. IRS-1, -2, -4 and Gab-1 
exhibit spatial/temporal expression patterns (Fantin et al., 1999, Folli et al., 1994, 
Numan and Russell, 1999, Sciacchitano and Taylor, 1997, Ye et al., 2002b), while 
only low levels of IRS-3 can be detected in the brain. Knockout studies in mice, 
suggest that IRS-1 is not essential in IGF neural signalling. These results may be due 
to other IRS members (IRS-2 and -4) compensating for the lack of IRS-1 (Ye et al., 
2002b). IRS-2 seems to be more important for the IGF and insulin mediated 
signalling in the CNS (Schubert et al., 2003). The phosphorylated docking proteins 
then recruit down-stream signalling molecules to transduce the IGF signal. The Ras-
Raf-MAP (mitogen-activated protein) kinase and Phosphoinositide-3 (PI3)-AKT 
kinase pathways are known to play crucial roles in IGF signalling (O'Kusky and Ye, 
2012). 
 
Furthermore, in vitro studies in non-neural cells have shown that the IGF1R can be 
modified by SUMO-1 (small ubiquitin-like modifier protein-1) and translocate into 
the cell nucleus, where it acts as a transcription factor to regulate its own expression 
(Sehat et al., 2010). Since neural cells are able to internalise the IGF1R, it is possible 
that IGF1R can act as a transcription factor in neural tissues too (Romanelli et al., 
2007). There is some evidence that G-protein mediates some of IGF’s neural actions 
(Kuemmerle and Murthy, 2001). 
 
IGF treatment of cells leads to an increase in AKT phosphorylation and activation, 
which is sustained for a minimum of 24 hours (unlike the transient activation, that 
takes place with the Raf-ERK pathway) (O'Kusky and Ye, 2012, Romanelli et al., 
2007). The PI3K-Akt pathway plays a key role in the survival of neural cells and it is 
also important for neural and IGF stimulated proliferation (Johnson-Farley et al., 
2007). Its critical downstream effectors are glycogen synthase kinase 3β (GSK3β) 
	 66	
and β-catenin, which is a common mediator of IGF-I and Wnt signalling to promote 
neural cell proliferation and survival. Another downstream effector is mammalian 
target of rampamycin (mTOR), which is involved in signals relating to cell 
maturation and function (Guardiola-Diaz et al., 2012). 
 
IGF signalling through the MAP pathway (Ras-Raf MAP kinase pathway) has been 
well studied. MAP kinase signalling is organised in three tiers of signalling cascades 
(Ye et al., 2010). Based on in vitro studies with pharmacological inhibitors, it is 
known that the Raf-Erk pathway seems to be key to IGF stimulated cell proliferation 
(D'Ercole et al., 1996). In neural IGF signalling, the MAP kinase pathway seems to 
be mainly involved in cell maturation and survival (O'Kusky and Ye, 2012). 
 
1.6.1.5 IGF signalling through the IGF2R 
There is little evidence to suggest that the IGF2R mediates the growth actions of both 
IGF1 and IGF2. Studies suggest that it may mediate some IGF actions, such as 
acetylcholine release from cultured neurons (Hawkes et al., 2006), and facilitate 
memory improvement in rodents (Chen et al., 2011). No enzymatic activity has been 
observed at IGF2R’s intracellular domain and potential associated intracellular 
pathways are still unclear. G-protein has been identified as a key molecule for IGF2-
IGF2R actions in neuronal cells (Hawkes et al., 2006). Other molecules such as 
protein kinase C (Hawkes et al., 2006), MAP kinase (McKinnon et al., 2001) and 
GSK3 (Chen et al., 2011) are also likely to participate. 
 
1.6.2 IGF signalling in eye development 
Pera et al. (2001) were the first to present evidence that IGF signalling is involved in 
the anterior neural development in X.laevis. They found that IGF1, IGF2, IGF3 
(particular to X.laevis) and IGFBP-5 promote anterior development, and when 
overexpressed, expand the head region at the expense of trunk tissue in the frog 
embryos.  
 
The overexpression of both IGF1 and IGF2 (in the 4 to 8 cell embryo) resulted in 
expanded head structures and ectopic eyes (IGF1 induced ectopic eyes: 66%; IGF2 
induced ectopic eyes: 29%). In the animal cap, forced overexpression of IGFs 
increased the expression of anterior neural and some eye specific markers (Pera et 
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al., 2001). A dominant negative form of IGF1R (DN-IGF1R) had the opposite effect, 
whereby head tissue was drastically supressed and eye development was inhibited. 
The presence of DN-IGF1R inhibited Chordin mediated neural induction. Forced 
overexpression of IGF2 in the ventral marginal zone, resulted in embryos with 
ectopic heads and cement glands reminiscent of the Cerberus overexpression 
phenotype (Pera et al., 2001). 
 
Overall, Pera and colleagues found that IGF mRNA injection in the neural plate 
region caused embryos to develop ectopic eyes, while injection in the prospective 
ventral mesoderm resulted in ectopic head formation. IGF signalling may regulate 
how much tissue is allocated to both head and trunk portions of the embryo. Not only 
is an inhibition of BMP, Wnt and Nodal necessary for head induction, but it seems 
also an active IGF signal (Pera et al., 2001). 
 
The study by Pera and colleagues (2001) was closely followed by Richard-Parpaillon 
et al. (2002), who also confirmed a crucial role for IGF signalling in head formation 
in Xenopus laevis. Their study focussed more on the effects of IGF1. Much like Pera 
et al., they found that IGF1 overexpression expanded head, eye and cement gland 
tissue, while depletion of the IGF1R lead to drastic reduction in the aforementioned 
tissues. They found that IGF1 elicits its effect through inhibiting Wnt signalling in 
the early embryo at β-catenin level (Richard-Parpaillon et al., 2002). 
 
In Xenopus, IGF1 is expressed maternally, and after midblastula transition both IGF1 
and IGF2 are expressed in the embryo. By in situ hybridisation, the IGF1R can be 
detected after the end of gastrulation and in higher amounts in anterior and dorsal 
regions (Richard-Parpaillon et al., 2002). IGF1 did not cause generalised hyperplasia, 
but did cause different phenotypes depending on the site of mRNA injection. Dorsal 
injections caused enlarged head structures, whereby mid and hindbrain was regularly 
expanded, while the forebrain and neural tube structure remained unchanged. IGF1 
was also shown to expand the expression of Otx2, NCAM and Pax6, with a strong 
induction of cement gland marker XAG. A morpholino targeted at the IGF1R caused 
microcephaly, as well as small or no eyes (Richard-Parpaillon et al., 2002). 
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Richard-Parpaillon et al. (2002), also found that IGF1 overexpression affects 
convergent extension movements in the developing embryos. Dorsal injections often 
resulted in gastrulation defects with delayed mesoderm involution and open 
blastopores. The IGF1 overexpression phenotype (with the dorsally curved embryos 
and a shortened anterior-posterior axis) seemed overall very similar to that of Wnt 
inhibitors such as Cerberus and Dickkopf. This prompted Richard-Parpaillon et al. 
(2002) to examine if IGF1 acts by inhibiting Wnt signalling. They found that IGF1 
inhibits Wnt target genes siamois, xnr-1, wnt-8, DN-GSKb and β-catenin. The 
hypothesized IGF1 induced eye induction via Wnt inhibition is also in keeping with a 
study in an eyeless phenotype in Zebrafish, which showed that suppression of Wnt is 
required for both eyes and the telencephalon to develop properly (Richard-Parpaillon 
et al., 2002, van de Water et al., 2001). 
 
1.6.3 Factors thought to play a role in IGF mediated eye development 
Since the original studies by Pera et al. (2001) and Richard-Parpaillon et al. (2002), 
more work has been carried out which further confirms the important role of IGF 
signalling in eye development and introduced other key players in more detail. With 
IGF being quite broadly expressed throughout the embryo during development, the 
question remains - how can it propagate eye development in a specific spatial and 
temporal fashion?  
 
1.6.3.1 Kermit2/XGIPC is important for eye development 
Kermit2 (also known as XGIPC) is an IGF receptor interacting protein, which acts 
downstream of the IGF1R. It is required for the maintenance of IGF induced AKT 
activation. There is a long list of identified binding partners for Kermit2, including 
several membrane proteins, but their importance and biological functions are not 
well understood. Kermit2 binds to the intracellular domain of the IGR1R in Xenopus 
(Wu et al., 2006) and the human equivalent ‘GIPC’ has also been shown to bind the 
human IGF1R (Ligensa et al., 2001). Furthermore, the expression of Kermit2 is very 
similar to that of the IGF1R (Wu et al., 2006). 
  
Kermit2 has been shown to be required for IGF mediated eye development. A 
knockout of Kermit2 results in embryos with inhibited development of the anterior 
structures, particularly the eyes. Kermit2 is apparently needed to maintain the IGF 
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induced AKT activation, which plays an important role in eye development (Wu et 
al., 2006). 
 
Previously, it had been shown that the inhibition of IGF signalling leads to severe 
disruption of all anterior development in the Xenopus embryos. However, Kermit2 
loss-of-function experiments only affected the eyes. A possible explanation is that 
Kermit2 acts only through the AKT signalling pathway, which has been shown to be 
particularly important for eye development. Another explanation might be that eye 
development requires specific temporal IGF signals. The induction of anterior 
structures may only require an early IGF signal, whereas proper eye development 
calls for a maintained IGF signal. As Kermit2 is required for prolonged maintenance 
of the IGF-AKT signal, its knockdown therefore only affects eye development (Wu 
et al., 2006). Kermit2 might also regulate the subcellular location of IGF1R. 
Mammalian GIPC is known to be involved in the regulation of endocytic trafficking, 
which raises the possibility that the Xenopus orthologue has similar abilities (Wu et 
al., 2006). 
 
A study by La Torre et al. (2015) investigated whether mammalian GIPC has the 
same role in eye development, as Kermit2 has in frog. They found that GIPC binds 
and interacts with the IGF1R and activates Akt1. A DN-GIPC1 causes an inhibition 
of eye field cells with a down regulation of endogenous GIPC1. Pharmacological 
inhibition of Akt1 phosphorylation mimicked the DN-GIPC1 phenotype. Their 
results indicate that GIPC1 is important to separate eye field fate from telencephalic 
fate and it is likely to act through the IGF1R via the Akt1 pathway (La Torre et al., 
2015). 
 
1.6.3.2 The translational initiation factor eif6 affects eye development in 
Xenopus 
Eif6 (eukaryotic initiation factor 6) is a highly conserved translational initiation 
factor, which regulates ribosome assembly and mediates both selective mRNA 
translation and apoptosis. It is thought to act as part of the ‘RNA-induced silencing 
complex’ (RISC) and many of its functions have been traced back to the 
phosphorylation of its serine 235 by protein kinase C (De Marco et al., 2011). In the 
developing embryo, Eif6 is expressed in abundance in the dorsal mesoderm, 
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presumptive eye field and the mid-hindbrain border. When overexpressed in X. laevis 
embryos, a disrupted eye development was observed. This phenotype was shown to 
be only temporary however and, by stage 42, eye development had recovered. Other 
anterior structures remained unaffected by eif6 overexpression. While morpholino 
application had no effect on the embryo, already small amounts of eif6 mRNA 
caused transient eye defects. It can be concluded, that for normal eye development, 
no eif6 must be present (De Marco et al., 2011). 
 
Eif6 is regulated by extracellular signals such as IGF (Gandin et al., 2008, Tussellino 
et al., 2012). Eif6 has been shown to interact with the IGF1R and Kermit2 in the 
kidney, where eif6 seems to down regulate Kermit2 levels. It is also plausible that in 
eye development eif6 interacts with Kermit2. Looking at expression patterns in 
development - eif6 and Kermit co-localise. More work is required to establish 
whether eif6 and Kermit2 are required for the eye inducing IGF signal. It may be 
possible that eif6 regulates Kermit2 levels, which then influences IGF mediated 
downstream AKT signalling (Tussellino et al., 2012).  
 
1.6.3.3 IRS-1 is important for eye development 
IRS-1 belongs to the family of insulin receptor substrates (IRS). IRS-1 mediated 
receptor phosphorylation can activate two branches of the so-called canonical IRS 
pathway. The first one is the Ras/MAPK pathway, which is important for cell 
growth, division and differentiation. The second is the PI3/AKT (Ras independent) 
pathway, which is involved in mitogenesis, cell motility, metabolism, cytoskeleton 
organization, cell survival and differentiation. It has also been directly linked with 
IGF mediated eye induction and development (Bugner et al., 2011). IRS-1 is a major 
substrate for both the IGF1R and the InR and links both receptors to common 
downstream signalling pathways, such as the PI3K and MAPK pathways. IRS-1 
seems to preferentially activate the PI3K/AKT kinase pathway (Bugner et al., 2011). 
 
IRS-1 is already present in the oocyte and is further expressed throughout all of 
embryogenesis with increased expression levels in the developing eye and brain, 
branchial arches, otic vesicles and pronephrons (Bugner et al., 2011). The IRS-1 
expression levels coincide with expression for IGF-1, which is mainly observed in 
anterior and dorsal tissues of the developing embryo. The expression pattern of IRS-
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1 suggests that it plays a role in neural induction and eye development. Since the 
IGF1R is present at higher levels during X. laevis embryo development than the 
insulin receptor (InR), it is likely that IRS-1 mainly mediates IGF1R signalling 
(Bugner et al., 2011). An IRS-1 morpholino strongly decreased the expression of 
EFTFs Rx1, Pax6 and Otx2. Since blocking of IGF1R signal transduction leads to a 
reduction of anterior/head structures, one might expect the same phenotype with the 
IRS-1 loss-of-function experiment. This was however not the case. There is 
potentially a redundancy between different members of the IRS family (e.g. between 
IRS-1 and IRS-2). Furthermore, overexpression of IRS-1 did again not induce the 
expected expansion of head, eye and cement gland (Bugner et al., 2011).  
 
 
1.7 Thesis Aims 
How eyes are formed has been a longstanding research interest from both the 
scientific and clinical points of view. Recent outstanding technological progress has 
made molecular-based therapies a realistic prospect. In contrast, the whole molecular 
picture from naïve neuroectoderm to retinal precursor cells, still remains to be fully 
elucidated. Compared to the extensively characterised eye-field specific transcription 
factors, there are still a number of questions left unanswered with regards to the 
inductive signals that initiate the expression of these transcription factors, and thus 
specify the eye field.  
 
The SLRP family of proteins is involved in a large number of biological events, and 
Prof. Ohnuma’s group is particularly interested in their functions during neural 
development. During a systematic functional screening in Xenopus embryos, the 
SLRP ASPN showed a strong eye-inducing activity when overexpressed and I 
became interested in the molecular function of this protein. 
 
The work presented in this thesis aims to investigate the role of ASPN in early 
embryonic eye development, in the Xenopus laevis embryo. To this end, ASPN’s 
temporal and spatial expression patterns during frog development will be 
investigated and the induced overexpression eye phenotype analysed in more detail 
(Chapter 3). Chapter 4 employs a morpholino based loss-of-function approach to 
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verify that ASPN is indeed essential for eye development. Chapter 4 also explores 
whether ASPN is unique amongst SRLPs in affecting eye development and what 
effect ASPN has in the developing zebrafish embryo. Finally, the molecular 
mechanisms underlying the actions of ASPN will be investigated in Chapter 5.  
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2 CHAPTER 2: MATERIALS AND 
METHODS 
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2.1 Materials 
2.1.1 Standard solutions 
 
Table 2.1: Composition of standard solution used in this project 
Solution Composition 
100 x Denhardt's solution 
10 g Ficoll 400 (GE Healthcare), 10 g 
Polyvinylpyrrolidone (Sigma), 10 g Bovine Serum 
Albumin. Dissolved in 500 ml double distilled water 
(ddH2O), filter sterilised and stored at -20°C. 
 6 x DNA loading dye 10 mM Tris-HCl (pH 7.6), 0.15 % Orange G, 60 % Glycerol, 60 mM EDTA. Made up in ddH2O. 
 8 x ELS (egg laying solution) 
For 4 liters (L): 205.71 g NaCl, 4.77 g KCl, 2.72 g 
Na2HPO4.2H2O, 5.815 g Tris Base, 5.38 g NaH CO3, 
16.149 g MgSO4x7H2O dissolved in 4 litres of 
ddH2O and pH adjusted to 7.6 with glacial acetic 
acid.  
 4 % Ficoll 
20 g Ficoll (GE Healthcare) dissolved in 500 ml of 
0.2 x MBS; 500 μl Gentamicin. Solution filter 
sterilised and stored at 4°C 
10 x MEM 
209.2 g MOPS (1 M), 7.6 g EGTA (20 mM), 2.47 g 
MgSO4.7H20 (10 mM) in 1 L ddH2O and adjust pH 
to 7.4. Filter sterilise and store protected from light. 
10 x PBS 
For 1 L: 80 g NaCl, 2 g KCl, 18.1 g Na2HPO4.2H2O, 
2.4 g KH2PO4; pH adjusted to 7.4 with NaOH or HCl 
and autoclaved. 
4 % PFA 32 % PFA stock (Electron Microscopy Sciences) was diluted in 1 x PBS to a 4 % solution. 
 20 x SSC 
175.3 g NaCl, 88.2 g Sodium citrate. Made up to 1 L 
ddH2O and pH adjusted to 7.0 with 1 M HCl, 
autoclaved and stored at RT. 
 50 x TAE 242 g Tris base, 57.1 ml Glacial acetic acid, 100 ml 0.5 M EDTA. Make up to 1 L with ddH2O. 
 1 x Transfer buffer 1 g SDS, 14.4 g Glycin, 3 g Tris was dissolved in 800 ml ddH20 and 200 ml MeOH 
5 x Tris-glycine running buffer 15.1 g Tris base, 94 g Glycine, 5 ml 20 % SDS. Dissolved and made up to 1 L of ddH2O. 
Alkaline Phosphatase (AP) -
buffer 
15 ml 1 M Tris-HCl pH 9.5, 3 ml 5 M NaCl, 7.5 ml 
1 M MgCl2, 1.5 ml 10 % Tween 20. Dissolved in 
150 ml ddH2O. 
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Bleaching solution 
42.5 ml ddH2O, 2.5 ml Formamide, 2.5 μl 20 x SSC, 
5 ml H2O2 (30 % solution). Made fresh before use 
and kept on ice. 
Blocking buffer 
(immunohistochemistry) 
10 % Goat serum (Sigma), 0.3 % Triton-X 100 
(Sigma), 0.1 % Sodium azide (Sigma) in 1 x PBS, 
filter sterilized and stored at 4°C. 
Blocking buffer (Western Blot) 5 % non-fat milk, 0.1 % Triton-X 100 in 1 x PBS. 
Blocking solution (whole mount 
in situ) 
MAB containing 2 % blocking agent (Roche) was 
heated in the microwave until fully dissolved with 
milky appearance.  Once solution had cooled on ice,  
20 % heat treated lamb serum (Invitrogen) was 
added. 
2 % cysteine 4 g cysteine (Sigma) in 200 ml ddH2O water and pH adjusted to 7.8 with NaOH. 
Hybridisation buffer 
500 ml Formamide, 250 ml 20 x SSC, 10 ml 100 x 
Denhardt's solution, 10 ml 10 % Tween-20, 1 g 
CHAPS (Sigma), 2 ml 0.5 M EDTA, 1 g Torula 
RNA (Sigma), 100 mg Heparin sodium salt (Sigma). 
Made up to 1 L with ddH2O and stored at -20°C in a 
glass bottle. 
Luria-Bertani (LB) agar 40 g LB-agar powder (Fisher Scientific) in 1 L ddH2O, autoclaved. 
 LB-Broth 25 g LB Broth powder (Fisher Scientific) in 1 L ddH2O, autoclaved. 
Lysis buffer 
200 μl 1 M TrisHCl pH 8.0, 300 μl 5 M NaCl, 40 μl 
500 mM EDTA, 100 μl NP40. Made up 10 ml with 
ddH2O. 
MAB 
Dissolve 11.61 g Maleic acid, 8.77 g NaCl, 7.8 g 
NaOH in 1 L ddH2O and adjust to pH 7.5 with 10 N 
NaOH. 
10 x MBS 
102.6 g NaCl, 1.5 g KCl, 4 g NaHCO3, 47.6 g 
Hepes, 4 g MgSO4 7H2O, 1.56 g Ca(NO3)2 4H2O, 
1.18 g CaCl2 2H2O in 2 L of ddH2O and pH adjusted 
to 7.5. Autoclaved and stored at 4°C.       
10 x MEMFA For 50 ml: 5 ml 10 x MEM solution, 5 ml 37 % formaldehyde, 40 ml ddH2O 
10 x MOPS 
83.7 g MOPS, 13.6 g Sodium Acetate, 3.7 g EDTA, 
dissolved in 1 L of nuclease free distilled water, pH 
adjusted to 7 with NaOH. 
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10 x MOPS-EDTA buffer 
41.86 g MOPS, 4.102 g Sodium Acetate anhydrous, 
20 ml 0.5 M EDTA (pH 8). Fill to 800 ml with 
DEPC.H2O and pH to 7.0 using 10 M NaOH. 
Finally fill to 1000 ml with DEPC.H2O and add 200 
μl DEPC. Solution was mixed, left to stand over 
night prior to autoclaving. The buffer was then 
stored at 4 °C in the dark. 
RNA Gel Loading Buffer 
750 μl deionised Formamide, 250 μl 37 % 
Formaldehyde, 150 μ l 10 x MOPS-EDTA buffer, 
360 μl 6 x DNA loading dye, 6 μl Ethidium 
Bromide (10 mg/ml).  
Steinberg's Solution 
For 1 L: 3.4 g NaCl, 0.05 g KCl, 0.08 g 
Ca(NO3)2•4H2O, 0.205 g MgSO4•7H2O, 0.56 g Tris. 
Add ddH2O up to 1 L and adjust pH to 7.4 with HCl.   
TN-buffer 150 mM NaCl, 5 mM KCl, 0.5 % NP-40 detergent, 10 mM Tris-HCl (pH 7.8) 
TNEB-buffer 150 mM NaCl, 5 mM MgCl2, 0.5 % NP-40 detergent, 10 mM Tris-HCl (pH 7.8) 
Wash buffer (Western Blot) 1 L PBS with 0.1 % Triton-X 100. 
X-gal (stock solution) 
Dissolve 0.1 g of X-gal (Melford, UK) in 5 ml 
dimethylformamide-DMF (Sigma, UK), store in the 
dark, -20°C 
X-gal staining solution 
0.15 g K3Fe(CN)6, 0.2 g K4Fe(CN)6·3H2O, 0.024 g 
MgCl2.6H2O, 0.01 g Sodium deoxycholate, 20 μl 
NP40 (IGEPAL), 100 ml 1 x PBS, store protected 
from light at RT. 
 
 
2.2 Methods 
2.2.1 Xenopus laevis embryo handling and techniques 
2.2.1.1 Xenopus housing 
Xenopus laevis pigmented frogs were purchased from Nasco (US) and housed in the 
UCL Institute of Ophthalmology biological resource unit according to UK Home 
office regulations. 
 
Xenopus frogs were housed in opaque tanks at a density of 10 females or males per 
27 L (same sex tanks), supplied with tank enrichments including 20 cm long dark 
coloured plastic tubes. Frog water was filtered and re-circulated through the 
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Tecniplast (Italy) system. Housing conditions were carefully controlled and closely 
monitored. The temperature was kept between 17°C and 19°C degrees, and frog 
water at pH 8. Xenopus frogs were kept on a 12/12-hour light-dark cycle and fed 
twice a week with Xenopus Diet Pellets (Scientific Animal Food and Engineering, 
France). Each frog was identified by the unique pigmentation pattern on its back, 
which was photographed and made into an identity card. All injections were 
carefully recorded on the identity card and in log-books for regulated procedures, as 
required by the Home Office. 
 
2.2.1.2 Induction of superovulation in Xenopus females 
The minimum age of female X.laevis used for superovulation is two years old. By 
law, females can be used no more than four times a year, which equates to a resting 
period of at least 12 weeks between induced superovulation.  
 
The veterinary grade hormones used to induce egg laying were PMSG-Intervet® 
(PMSG = Pregnant Mare Serum Gonadotropin) and CHORULON® (HCG = Human 
Gonadotropin hormone; both purchased from Intervet, UK). The 5000 IU vial of 
PMSG powder was reconstituted in the 25 ml of provided solvent (final 
concentration 200 IU/ml), subsequently aliquotted and stored at -20°C. Aliquots 
were only thawed once and unused hormone was discarded. Female X.laevis were 
injected with 50 IU of PMSG (i.e. 250 μl of reconstituted hormone) into the dorsal 
lymph sac, at least three days (usually a week) prior to HCG injections. 
 
HCG hormone was freshly prepared on the day, just before use. Chorulon vials 
containing 1500 IU powder were resuspended in 1.5 ml of the solvent provided 
(remaining solvent was discarded if not used within 24 hours) giving a final 
concentration of 1000 IU/ml. Around 12-14 hours before the planned egg-laying, 
females were injected with between 200 - 400 μl (200-400 IU) subcutaneously into 
the lymph sac, depending on size of the animal. After the HCG injection, the female 
frogs were transferred to tanks containing egg filters overnight. 
 
2.2.1.3 Testis isolation 
Sexually mature X.laevis males were injected subcutaneously with the anaesthetic 
MS-222 (also known as ethyl 3-aminobenzoate methanesulfonate or Tricaine 
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methanesulfonate; Sigma, UK). After ensuring the animal had lost consciousness 
(i.e. with toe-pinch and testing for gag-reflex), the abdomen was opened, the testis 
isolated and then the heart and major blood vessels were cut. After removing all 
excess blood, testis were kept in a vial with 1 x Modified Barth’s Solution (MBS; see 
Table 2.1) at 4°C and used within 7 days. 
 
2.2.1.4 Egg collection and in vitro fertilisation 
The next morning, females were transferred to the lab and kept at 18 °C room 
temperature in individual tanks with 1 x Egg-Laying-Solution (ELS; see Table 2.1). 
With its high salt content, the ELS preserves oocyte quality until fertilisation.  
 
Eggs were collected and washed three times in 1 x MBS. A small piece of testis was 
cut and crushed in a 1.5 ml microfuge tube containing 1 x MBS. As much liquid as 
possible was removed from the dish containing the eggs, before applying the crushed 
testis solution. The egg and testis solution were gently mixed with a plastic stirrer 
and left covered for five minutes before being flushed with 0.1 x MBS. Lowering the 
salt concentration from 1 x MBS to 0.1 x MBS induces sperm motility and aids 
fertilisation. After circa 20 minutes, successfully fertilised eggs undergo cortical 
rotation, which is visible by the dark animal poles facing upwards. Female frogs 
were returned to the animal house and kept overnight in egg-filter containing tanks, 
before being returned to their holding tanks the following day. 
 
2.2.1.5 De-jellying of embryos 
Approximately one hour post-fertilisation (or when the first signs of cell division 
became visible), eggs were de-jellied with 2% cysteine solution (see Table 2.1). For 
this, 0.1 x MBS was removed from the embryos and replaced with cysteine solution. 
The dish was then gently swirled until embryos started to detach from the dish and 
floated freely. The cysteine solution was left for no longer than four minutes, before 
embryos were thoroughly and repeatedly washed in 0.1 x MBS (ca. seven to 10 
washes).  
 
2.2.1.6 Rearing and staging embryos 
Xenopus embryos were staged according to Nieuwkoop and Faber (Nieuwkoop and 
Faber, 1994). Xenopus embryos were maintained in 0.1 x MBS solution, which was 
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regularly replaced with fresh solution, while the animals grew to the desired stage. 
Before developmental stage 13, embryos were kept below 16°C to minimise 
spontaneous gastrulation defects. After stage 13, the embryos were kept at 
temperatures between 14°C and 20°C, according to the requirement of the 
experiment - the higher the incubation temperature, the faster the embryos’ 
development progressed.  
 
2.2.1.7 Microinjection of Xenopus embryos 
Microinjection is a powerful technique to reliably deliver an accurate amount of 
substance, such as messenger RNA, DNA or morpholinos, into early stage Xenopus 
embryos. Microinjection was carried out using a PLI-100 Pico-Injector (Harvard 
Apparatus, US). Microinjection needles were pulled from borosilicate capillary glass 
(Harvard Apparatus) using a P-97 Flaming/Brown micropipette puller (Sutter 
Instrument, US). The injection dishes were prepared using 49-well silicone moulds, 
which were placed on molten 1% agarose solution in small petri dishes and left to set 
at room temperature (RT). 4% Ficoll solution was prepared (see Table 2.1). 
 
On the injection day, the workstation and tools were wiped down with RNase Zap™ 
(RNase removing agent, Sigma) and the needle calibrated using sharp forceps to give 
an injection volume of 10 nl. Embryos were de-jellied at the first sign of cleavage 
and then transferred into the injection dishes containing 4% Ficoll solution. Injection 
solution (e.g. mRNA, morpholinos) was prepared and kept on ice. The needle was 
then filled and embryos injected at the desired site and stage. Injected embryos were 
kept in the injection moulds with 4% Ficoll solution overnight and then transferred 
into petri dishes containing 0.1 x MBS the following day. 
 
2.2.1.8 Animal Cap assay 
Following fertilisation, embryos were kept at 14 °C over night in 0.1 x MBS until 
they reached stage 8 to 9 (usually the morning following fertilization). The embryos 
were then transferred to 1% agarose (in water) injection dishes, filled with 
Steinberg’s Solution (see Table 2.1). Covering the dissecting dishes with 1 % 
agarose is necessary to protect the dissected and rather sticky animal caps from 
attaching to the plastic dish. Using sharp forceps, the vitelline membrane of the 
embryos was carefully removed, without damaging the animal hemisphere and the 
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embryo carefully pushed back into shape. Using two very sharp forceps the animal 
cap was cut out, taking extra care not to excise any marginal zone cells (white fluffy 
appearance), and placed with the inner side facing up. After 30 minutes to one hour 
the animal caps formed spheres and were then cultured at 20 °C alongside control 
whole embryos to the desired stage for further analysis. 
 
2.2.1.9 Fixing Xenopus embryos 
Once Xenopus embryos reached the required stage, they were anaesthetised in a 0.1 x 
MBS solution containing 0.2 mg/ml MS-222. After being anaesthetised, embryos 
were transferred to 4 ml borosilicate glass vials (Fisher Scientific, UK) and fixed in 
either 4% paraformaldehyde (PFA; Table 2.1) or MEMFA (Table 2.1) solution for 
one hour at RT on a rocking platform or at 4°C overnight. Injected MEMFA-fixed 
embryos were either processed for β-Galactosidase (β-gal) staining or else washed in 
1x phosphate buffered saline (PBS; Table 2.1) three times and then stored in 
methanol at -20°C, until further use. 
 
2.2.1.10 β-gal staining 
MEMFA fixed embryos were washed three times with 1x PBS and then incubated in 
1x PBS with 2 mM MgCl2 for 15 minutes at RT. Then PBS was replaced with 500 μl 
X-Gal mixer with 25 μl of 20 mg/ml X-gal solution (X-gal purchased from Melford, 
for both solutions’ composition see Table 2.1) in each vial, and all samples were 
incubated at 37°C, protected from light, until staining was satisfactory. Embryos 
were then washed in PBS three times and stored in methanol at -20°C. 
 
2.2.1.11 DiI Staining of neural retina and optic nerve 
DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; Sigma) is a 
lipophilic non-toxic fluorescent dye, which inserts into cell membranes. It can be 
used in both live or aldehyde fixed tissue to label neuronal processes and somata. 
Fixed tissue labels through dye diffusion along the cell membranes while staining in 
live cells seems to be mainly localised to intracellular vesicles. In this experiment, 
DiI was used to stain potential nerve projections from the ectopic eye structures 
towards the brain or spinal cord. The precise administration of the dye is very 
important to limit its spread. Post-injection incubation conditions and time frames are 
also important as too little incubation may result in incomplete labelling, while too 
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lengthy incubation tends to increase non-specific labelling. 
 
Tadpoles were anaesthetized in 0.2 mg/ml MS-222 and then fixed in 4% PFA for one 
to two hours at RT or at 4°C overnight. Glutaraldehyde fixed tissue is not suitable for 
analysis in whole-mounts, because it produces intense background fluorescence. 4% 
PFA fixed embryos were then immobilized in a dish with 1 x PBS on plasticine with 
micro-pins. Using sharp forceps, the skin overlying the eye was carefully removed 
and a small cut made into the sclera. The lens and vitreous were removed without 
damaging the rest of the eye and retina. Solution was removed from the dish, so that 
the eye was buffer-free but still moist. Using a micro-pin probe, DiI crystals were 
pushed into the eyecup. The labeled tadpoles were then put back into fixative and 
cultured in the dark at RT, until optimal fluorescent labeling of the tissue was 
achieved. Depending on age and size of the tadpole, incubation time ranged between 
three days and two weeks. 
 
2.2.1.12 Luciferase assay in Xenopus embryos 
The reporter constructs of ARE-luc (Activin-Responsive Element; (Chen et al., 
1997)), TOPFLASH (the TCF/LEF Optimal Promoter monitoring the WNT activity; 
Upstate) and BRE-luc (BMP responsive element; (Tozer et al., 2013)) were used. 
pRL-CMV (Promega, Madison, USA) was used as a normalization control, and 
luciferase assays were performed by a dual-luciferase assay system (Promega). 
Embryos were harvested in triplicates at stage 10.5 by freezing on dry ice. Luciferase 
assays were performed using Dual-Luciferase® Reporter Assay System (Promega) 
according to the manufacturer’s protocol. The luminescence levels were measured 
using a FLUOstar OPTIMA plate reader (BMG LABTECH, Ortenberg, Germany). 
The Relative Luciferase Unit (RLU) was calculated as the ratio of firefly luciferase 
against Renilla luciferase. 
 
2.2.2 Xenopus tissue processing and sectioning 
2.2.2.1 Embedding and cryo-sectioning of Xenopus embryos 
Embryos were fixed in 4% PFA for one to two hours at RT (or at 4°C overnight). 
Embryos were then placed in 30% sucrose (in 1 x PBS) in embedding moulds 
(Sigma) for one to two hours on a rocker at room temperature or until embryos were 
saturated and sank to the bottom. All sucrose solution was then removed from the 
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mould and the embryos covered in liquid Tissue-Tek® O.C.T. compound (Sakura 
Finetek, USA) and properly orientated using forceps. The moulds containing 
embryos in O.C.T. compound were then placed onto a pre-chilled metal plate, sitting 
on dry ice. Once the O.C.T. compound was completely set, the blocks were stored in 
a tissue paper padded box at -80 degrees. Cryosections were cut at 10 microns 
thickness using a cryostat-microtome (Leica, Wetzlar, Germany) and collected on 
Superfrost™ Plus microscope slides (Fisher Scientific). Before sectioning, embryo 
containing O.C.T. blocks were stored inside cryostat chamber at -20 °C for 10 
minutes. Cut sections were left at RT until O.C.T. compound had melted and dried. 
All slides were then stored at -80 °C until further processing.  
 
2.2.2.2 Embedding and paraffin sectioning of Xenopus embryos 
Embryos were fixed in 4% PFA as described in previous section 2.1.8. The embryos 
were then placed in labelled cassettes. Using a tissue processor in the Institute of 
Ophthalmology Pathology department, the cassettes were then taken through a series 
of graded ethanol washes to dehydrate the tissue and were finally bathed in Xylene 
and hot paraffin wax. After tissue processing, the embryos were embedded in 
paraffin wax and once hardened sectioned on a manual rotary microtome (Leica RM 
2235). Tissue sections were cut at 5-7 micron thickness and collected on 
Superfrost™Plus slides (Fisher Scientific) and stored at RT.  For de-waxing, slides 
were washed three times with xylene for five minutes each, and then rehydrated by 
passing through decreasing gradients of ethanol: 100%, 95%, 75%, 40% for five 
minutes each, followed by double distilled water (ddH2O). 
 
2.2.2.3 Hematoxylin and Eosin (H&E) staining of paraffin sections 
H&E staining was performed in an automated system (Leica ASP300S) in the 
Pathology department. Every wash lasted around 10 seconds. Briefly, paraffin 
sections were de-waxed in xylene and passed through two washes of absolute 
alcohol, two washes in 90% alcohol, one wash in distilled water and were then 
stained in Harris hematoxylin for five washes. Then, sections were washed in 
running tap water, differentiated in 1% acid alcohol for 10 seconds and washed once 
again in tap water. Afterwards, they were passed through two washes of 90% 
alcohol, counterstained with eosin for three washes, dehydrated in 95% alcohol for 
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two washed and finally cleared with xylene, before being mounted using DPX 
mounting medium (Fisher Scientific).  
 
2.2.3 DNA Techniques 
2.2.3.1 Transformation of plasmids into bacterial cells 
The E.coli bacterial strain used in this study was XL1-Blue competent cells 
(Stratagene, US). Prior to transformation, 100 μl XL1-Blue aliquots were thawed on 
ice. Then 50 ng of DNA was added to each aliquot, mixed gently and incubated on 
ice for 30 minutes. Then the tubes were placed in a 42°C water bath for exactly 45 
seconds, followed by immediate incubation on ice for 2 minutes. The brief heat-
shock treatment facilitates the entry of the DNA plasmids into the bacterial cells. 900 
μl pre-warmed S.O.C. medium (Invitrogen, US) was added to each tube and the 
bacterial samples were further incubated at 37°C for one hour with shaking at 225-
250 rpm for the antibiotic resistant gene to be expressed. 100 μl of each 
transformation mixture was plated onto a pre-warmed LB agar plate (see Table 2.1), 
containing 50 μg/ml ampicillin, using aseptic techniques. The plates were inverted 
and incubated at 37°C overnight for the bacterial colonies to form. 
 
2.2.3.2 Preparation of liquid bacterial cultures for midi prep 
Individual bacterial colonies were picked up from the LB plates using sterile 
toothpicks and placed into snap-cap (BD-Falcon) tubes, containing 3 ml of LB broth 
(see Table 2.1) with 100 μg/ml ampicillin (or if required other selection antibiotics). 
The cultures were incubated for eight hours at 37°C shaking at 225 rpm.  250 μl of 
the bacterial culture was then added to 100 ml of LB broth (+ ampicillin) in an 
autoclaved beaker and incubated overnight at 37°C shaking at 225 rpm. 
 
2.2.3.3 Midi prep – harvesting DNA plasmids from bacterial cultures 
For the plasmid harvest, the Qiagen Plasmid Midi Prep kit (Qiagen, Germany) was 
used and all procedures carried out according to manufacturer’s protocol. For the 
final elution step, DNA plasmids were eluted in 50-100 μl ddH2O instead of the 
buffer supplied by Qiagen, to avoid adverse cross reactions in subsequent analysis. 
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2.2.3.4 Restriction enzyme digest 
Enzymes were chosen according to known restriction sites on the plasmids used and 
were purchased from New England Biolabs UK (NEB, UK). Reaction buffers were 
supplied alongside the enzymes. Usually 10 μg of the circular plasmid was digested 
with 3 μl of the enzyme in a total volume of 100 μl. Samples were incubated at 37°C 
for three hours. Once successful digestion was confirmed by running a small amount 
of sample on a 1% argarose gel, the rest of the sample was cleaned using the 
GeneJET PCR purification kit (Fermentas, US) and the clean linearized plasmid re-
suspended in 30 μl RNase free water. 
 
2.2.3.5 Agarose gel electrophoresis 
To analyse quality, size and linearization, samples were run at 100 Volts on an 
agarose gel. The gel percentage was chosen according to sample molecule sizes. To 
make the gel, agarose powder was added to an appropriate amount of 1x Tris-
acetate-EDTA (TAE, see Table 2.1) buffer and the mixture heated in the microwave 
to boil. Once all the agarose was dissolved, SYBR® Safe DNA Gel stain 
(Invitrogen) was added at a ratio of 1 in 10,000 and the liquid poured into a gel cast 
and left to set. The set gel was then transferred into a running tank and submerged in 
TAE buffer. DNA samples and 1 Kb Plus DNA ladder (Invitrogen) was mixed with 
6x loading dye and loaded into gel wells. The tank was closed and connected to a 
power source and left to run at 80 – 100V. Gels were visualised using an ultraviolet 
trans-illuminator (Gene Flash, Syngene Bio imaging). 
 
2.2.4 RNA techniques 
2.2.4.1 In vitro synthesis of capped mRNA  
The mMessage mMachine kit (Ambion, UK) was used for the transcription reaction 
(either SP6, T3 or T7 RNA polymerase depending on the plasmid and promoter used, 
see Table 2.1). For the transcription reaction 1 μl to 1.5 μl of DNA/linearized 
plasmid, 2 μl of 10 x transcription buffer, 10 μl 2 x ribonucleotide mix, 2 μl 10 x 
enzyme mix was made up to a total volume of 20 μl with ddH2O. Samples were then 
incubated for three hours at 37°C. Finally 1 μl of Turbo DNase (included in the kit) 
was added to each sample and incubated for a further 15 minutes at 37°C. To stop the 
reaction 115 μl nuclease free water and 15 μl ammonium acetate were added. 
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Table 2.2: Plasmids used for mRNA production 
 
 
 
2.2.4.2 Extraction and cleaning of capped mRNA 
Following the mRNA in vitro synthesis, equal volumes of phenol (150 μl) were 
added to each mRNA sample, mixed well and centrifuged at maximum speed of 
13,300 rpm (Heraeus Fresco 17 centrifuge, Thermo Fisher) for two minutes at 4°C. 
The aqueous top layer was then transferred into a separate microfuge tube. The 
phenol extraction step was repeated once more. In the fumehood, an equal amount of 
chloroform was added to the collected aqueous solution, mixed by inverting and 
tapping the microfuge tube and centrifuged for two minutes at full speed (13,300 
rpm). Again as much of the aqueous layer as possible was collected in a fresh 
microfuge tube, while not touching the walls of the tubes to avoid contamination. An 
equal volume of ice-cold iso-propanol (stored at -20 °C) was added to the collected 
solution, gently mixed by tapping the microfuge tube and stored at -20 °C over night.  
 
The next day, the samples were centrifuged for 30 minutes at 4°C at 13,300 rpm. The 
supernatant was carefully discarded without disturbing the mRNA pellet and then re-
suspended in 200 μl of ice-cold 75% ethanol. The sample was centrifuged for a 
further 20 minutes at 13,300 rpm and the supernatant again very carefully removed. 
The pellet is not sticky at this point and can easily be lost. The microfuge tube 
containing the pellet was air dried in the fume hood for ca. 5-10 minutes on ice, 
before re-suspending in 10 μl of RNase free water (Qiagen) and determining the 
concentration using a NanoDrop™2000 (Thermo Scientific). Samples were diluted 
in RNase free water to a concentration of 1 μg/μl and then store at -80°C. 
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2.2.4.3 Preparation of RNA-gel 
To assess the quality of RNA, samples were run at 80 - 100 V on a RNA gel. The 
following steps were carried out in a laminar fume hood due to the use of 
formaldehyde. For a 30 ml solution, 0.3 g of agarose was added to 21.6 ml of ddH2O 
water and boiled in the microwave. In the fume hood, 3 ml of 10 x MOPS (see Table 
2.1) and 5.4 ml of 12.3 M formaldehyde were added to the agarose mix. 2 μl of RNA 
constructs, including RNA ladder, were mixed with 8 μl of RNA Gel loading buffer 
(see Table 2.1) and the samples incubated at 65-70 °C for 10 minutes, placed on ice 
for two minutes and then loaded into the gel pockets. The gel was run in a 1 x MOPS 
solution for 10 minutes and then checked in a UV transilluminator for distinct bands 
representing the RNA samples.  
 
2.2.4.4 Synthesis of DIG-labelled riboprobes 
The plasmids used for riboprobe synthesis are shown in Table 2.3. Pax6- and Rx1-
plasmids were kindly provided by Dr. Michael Zuber. 1 μg of linearised template 
plasmid was added to a reaction mixture containing 2 μl transcription buffer (Roche), 
2 μl RNA/DIG labelling mix (Roche; 10 mM ATP, 10 mM CTP, 10 mM GTP, 6.5 
mM UTP, 3.5 mM DIG-11-UTP), 2 μl of the appropriate enzyme (Roche; e.g. SP6) 
and nuclease-free water to a total volume of 20 μl. The solution was incubated at 
37°C for two hours. 2 μl of DNase1 (equals 2 units) was then added to remove 
template DNA and incubated at 37°C for a further 15 minutes. To stop the reaction 
0.8 μl of 0.5 M EDTA was added and the probe precipitated with 1.25 μl of 8 M LiCl 
and 75 μl of 100% EtOH. Contents were mixed well and left overnight at -20 °C. 
 
The following day, the mixture was centrifuged at 13,000 rpm for 30 minutes at 4 
°C. The supernatant was carefully removed and the pellet re-suspended in 200 μl of 
75% ice-cold ethanol. The mixture was centrifuged for another 20 minutes and again 
the supernatant was removed with out disturbing the pellet. After air-drying for 5-10 
minutes, the pellet was re-suspended in 10 μl of RNase free water and then added to 
5 ml of Hybridisation buffer (see Table 2.1) to be stored at -20 °C. The probes could 
be reused for at least a year, without significant reduction in signal strength. 
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Table 2.3: Plasmids used for riboprobe synthesis 
 
 
 
2.2.4.5 Whole mount in situ hybridization of Xenopus embryos 
Xenopus embryos which had been fixed and stored in methanol at -20°C were first 
allowed to warm to room temperature, and then rehydrated by washing for 10 
minutes each in 75%, 50% and 25% methanol, followed by three washes of 5 
minutes each in PBST (0.1% Tween-20 in 1x PBS). The embryos were then treated 
with ice-cold proteinase K solution (Roche, use at 2 μg/ml in PBST) for two minutes, 
followed by one wash in 0.1 M triethanolamine for five minutes and one wash in 0.1 
M triethanolamine with 0.5% acetic anhydride for 10 minutes. Subsequently, two 
five-minute washes in PBST were performed, followed by a 20-minute fixation in 
4% formaldehyde in PBST and six five-minute washes in PBST again. Then the 
embryos were washed once in hybridization buffer that was pre-warmed to 60°C and 
incubated in fresh hybridization buffer for two hours at 60°C. This pre-hybridisation 
step, helps to decrease non-specific binding. For hybridization, embryos were 
incubated with DIG-labeled riboprobes at 60°C overnight. 
 
On the second day, the embryos were removed from the riboprobe solutions and 
washed in 2 x saline sodium citrate (SSC) four times, 20 minutes each time at 60°C, 
followed by two 20-minute washes in 0.2 x SSC at 60 °C and two 5-minute washes 
in maleic acid buffer (MAB) at RT (Table 2.1). In the meanwhile, blocking solution 
(Table 2.1) was prepared and the mixture was allowed to cool on ice before use. 
Blocking was performed for one hour at RT and blocking solution was replaced with 
anti-dig alkaline phosphatase (AP) Fab fragments antibody (Roche), diluted 1 in 
5000 in fresh blocking solution. The embryos were incubated with antibody at 4° C 
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overnight on a rocking platform.  
 
On the third day, embryos were washed once in alkaline phosphatase (AP) buffer 
(see Table 2.1) first and then twice for 5 minutes each time in AP buffer containing 2 
mM levamisole (Sigma), which helps inhibit endogenous alkaline phosphatase 
activity and hence lowers the background signal. The colour reaction was developed 
using the chromogenic AP substrate BM Purple (Roche) with 2 mM levamisole 
protected from light. When the colouration was complete, embryos were washed in 
100% methanol for 30 minutes to stop the reaction and fixed in MEMFA overnight 
at RT. 
 
2.2.4.6 Depigmentation of Xenopus embryos 
After two five-minute washes in 1 x PBS, embryos were incubated in bleaching 
solution (see Table 2.1) on a light box in a laminar flow hood. When bleaching was 
complete, embryos were again washed in 1 x PBS and stored at RT in MEMFA. 
 
2.2.4.7 RNA extraction and reverse transcription 
RNA used for PCR (polymerase chain reaction) was extracted using the RNeasy® 
RNA extraction kit (Qiagen). The complementary DNAs (cDNAs) were synthesised 
with the reverse transcription enzyme SupersScript™ II and Random Hexamers 
(both Life Technologies), which are random sequences of short 
oligodeoxyribonucleotides. 11 μl of the extracted RNA and 1 μl of random hexamers 
was incubated for 10 minutes at 70°C and then immediately put on ice. Then, 4 μl of 
5 x First Strand Buffer (250 mM Tris-HCL, pH 8.3 at RT, 375 mM KCL, 15 mM 
MgCl2), 2 μl 0.1 M DTT, 1 μl 10 mM dNTP and 1 μl of Superscript II enzyme 
(Thermo Fisher) was added and incubated for one hour at 42°C. After the incubation, 
20 μl of ddH2O was added and samples stored at -20°C. 
 
2.2.4.8 Semi-quantitative RT-PCR 
For semi-quantitative reverse transcription (RT) PCR, Platinum® Pfx DNA 
polymerase (Life Technologies) was used. The primer sequences were taken from 
previous reports (Mizuseki et al., 1998; Shimizu et al., 2013) and the De Robertis 
group laboratory web page and can be seen in Table 2.4 (website address: 
http://www.hhmi.ucla.edu/derobertis/protocol_page/Pdfs/Frog%20protocols/Primers
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%20for%20RT-PCR.pdf). For the PCR reaction 0.5 μl of Platinum Pfx enzyme, 5 μl 
10x Pfx Amp Buffer, 1.5 μl dNTP (10mM), 0.5 μl of each forward and reverse 
primer (100 μM), 1 μl cDNA and 40.5 μl ddH2O was mixed per sample. As a 
standard protocol the following cycle parameters were used in the PCR machine: 
94°C for 5 minutes, and then 35 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 
30 seconds at 72°C, followed by 5 minutes at 72°C. 
 
2.2.4.9 Quantitative RT-PCR 
Quantitative RT-PCR (qRT-PCR) was performed using the 7900 HT Fast Real-Time 
PCR machine (Applied Biosystems) with the SYBR Green detection system 
(Applied Biosystems). Each gene expression level was normalised to that of ODC 
(ornithine decarboxylase). In detail, 10 μl of 2 x Q-PCR enzyme mix SYBR green 
(ABI), 9 μl of ddH2O, 1 μl cDNA and 0.2 μl of primers (100 μM each) was mixed 
for each sample. A relative quantification of the target genes was achieved by 
comparing it to a reference gene transcript, such as ODC (or Histone 4). For this the 
Ct data was first linearised, normalised to ODC. The means of each set of technical 
duplicates were calculated and then the means and standard deviations of each set of 
biological triplicates determined. The data analysis followed the Pfaffl method 
(Pfaffl, 2001), whereby the relative expression ratio is calculated from the real-time 
PCR efficiencies and the crossing point deviation of an unknown sample versus a 
control. The primers used for qRT-PCR are shown in Table 2.4. 
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Table 2.4: Primers used in semi-quantitative PCR and qRT-PCR 
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2.2.5 Protein techniques 
2.2.5.1 Immunohistochemistry on sectioned frog tissue 
Cryo-sections were removed from - 80 °C, defrosted and then re-fixed with 4% PFA 
for 10-15 minutes, before commencing the immunohistochemistry protocol. The 
antibodies used in this study are shown in Table 2.5. 
 
After three 10-minute washes in 1 x PBS, sections were blocked in blocking buffer 
(see Table 2.1) for 30 minutes at RT. In the meanwhile, primary antibodies were 
diluted in blocking buffer to the appropriate concentrations (Table 2.5). Sections 
were incubated with the primary antibody in a humidity chamber at 4°C overnight.  
 
On the second day, sections were washed three times in 1 x PBS for 15-minutes each 
time and then incubated with secondary antibody diluted in blocking buffer (Table 
2.5) at RT for 60 minutes, protected from light. Three 15 minute washes in 1 x PBS 
were performed to remove the unbound antibodies and sections were mounted using 
ProLong® Gold anti-fade mountant with DAPI (Life Technologies). Slides were 
stored at 4°C in darkness until images were captured using a fluorescent microscope 
(Carl Zeiss Axioskop 2 Plus) with a QICAM 12-bit Color Fast 1394 (Qimaging) and 
the Openlab software. Images were processed using Adobe Photoshop CS4 (Adobe 
Systems, US). 
 
Table 2.5: Antibodies used for cytochemistry 
 
 
 
2.2.5.2 Western Blot 
2.2.5.2.1 Protein extraction from Xenopus embryos 
Lysis buffer (Table 2.1) was prepared, protease inhibitor cocktail (Roche) was added 
according to manufacturer’s protocol and the solution kept at 4°C. Xenopus embryos 
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or animal caps were collected in centrifuge tubes and any medium carefully 
removed. 5 μl of lysis buffer per whole embryo or 3 μl per animal cap, was added 
and the animal tissues lysed on ice by pipetting up and down. The homogenised 
samples were centrifuged at 13,000 rpm for five minutes at 4°C. The clear 
supernatant was collected and either used immediately or stored at -80°C.  
 
2.2.5.2.2 Whole cell extracts of HEK293 
Media was removed and cells washed once in 1 x PBS. 900 μl of 1 x PBS was added 
to each 30 mm dish of cells and, using a scraper, cells were detached and then 
collected in a centrifuge tube and briefly centrifuged for 1-2 minutes at a very low 
speed (500-1000 rpm). Excess PBS was removed and cells then briefly snap frozen 
in liquid nitrogen and defrosted on ice. Next, 500 μl of RIPA (50mM Tris-HCl, pH 
8.0, 150mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, Sigma, UK), 
supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitors 
(Roche), was added to the samples. Cells were lysed, by pipetting the solution up and 
down. The lysed cell solution was then centrifuged at a high speed of 13,300 rpm for 
five minutes and the extract collected for further use in SDS-PAGE gel analysis. 
 
2.2.5.2.3 SDS-PAGE 
The amount of protein in each sample was determined using a BCA assay kit 
(Thermo scientific). 2 x Laemmli sample buffer (62.5 mM Tris, pH 6.8, 20% 
glycerol, 2% SDS, 0.01% bromophenol blue, Biorad, UK), supplemented with 1% 2-
mercaptoethanol, was added in a 1:1 buffer to sample ratio, and then heated to 95 ºC 
for five minutes in a heat block for the purpose of protein denaturation. For the SDS-
PAGE analysis, 4-15 % Mini PROTEAN® TGX™ gels were purchased (Biorad). 30 
μg of each protein sample was run out on the gel, alongside the Precision Plus 
Protein™All Blue protein standard (Bio-Rad, UK). Electrophoresis was performed 
with the Mini-Protean III system (Bio-Rad), at 70 - 100V, in 1 x running buffer 
(Table 2.1).  
 
2.2.5.2.4 Western blot transfer, immunoblotting and development 
Proteins were transferred onto PVDF nitrocellulose membranes (GE healthcare), 
which had been activated in methanol for 1 minute. The Bio-Rad wet transfer 
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chamber system was used, which was performed at 60 V for two hours.  
 
Protein integrity was checked using Ponceau stain (Sigma, UK). Membranes were 
then blocked in blocking buffer (see Table 2.1) for 30 minutes at RT, and incubated 
overnight with the primary antibody (diluted in blocking buffer) according to the 
manufacturer’s instructions (Table 2.6). The following day, membranes were washed 
in PBS containing 0.1% Triton-X, for three 10-minute washes, and incubated with 
appropriately diluted secondary HRP-conjugated antibody (Table 2.6) blocking 
buffer, for one hour at RT.  
 
Membranes were washed thrice in PBS containing 0.1% Triton-X, for 10 minutes per 
wash. ECL reagents (GE Healthcare) were applied according to manufacturer’s 
protocol for 5 minutes and membranes then wrapped in cling film and exposed to 
autoradiography film (Kodak, UK). When required, membranes were stripped in 
stripping buffer (Bio-Rad, UK) for 15 minutes, and were subsequently washed thrice 
in PBS with 0.1% Triton-X, for 10 minutes per wash, before staining with a different 
antibody. This was particularly useful to detect levels of the protein of interest in 
relation to the loading control. The antibodies used in the western blots are 
summarised in the Table 2.6, below. 
 
Table 2.6: Antibodies used for Western blotting 
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2.2.6 Tissue culture techniques 
2.2.6.1 Cell culture 
Human embryonic kidney cell line HEK 293 (ATCC number CRL-1753) was 
maintained in Dulbecco’s Modified Eagle’s medium (DMEM + Gluta Max, Gibco) 
supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml 
penicillin/streptomycin (Life Technologies). Cells were cultured in tissue culture 
dishes of 60 mm diameter. Cell passaging was carried out in sterile conditions using 
a hood (Microflow II Biological cabinet). Cell medium was removed and cells gently 
washed in 1 x PBS (PAA, UK) prior to adding 1.5 ml of 0.25% Trypsin (PAA, UK) 
in PBS. Cells were briefly incubated at 37°C in the incubator to promote the cells 
detaching. After around two to three minutes, 5 ml of fresh pre-warmed media was 
added to the cells and everything was transferred into 10 ml falcon tubes and briefly 
centrifuged. The supernatant was discarded without disturbing the cell pellet. Cells 
were re-suspended in fresh medium and plated out into fresh cell culture dishes. 
HEK 293 cells were cultured in a 37°C incubator with 5% CO2 supply (Sanyo, 
MCO-18AIC, Japan). 
 
2.2.6.2 Transfection and conditioned media 
For transfection, cells at 70-80% confluency were used, usually in 30mm diameter 
culture dishes. 2.5 μg of the expression vector, 5 μl of Lipofectamine 2000 (Thermo 
Fisher) and 100 μl of Opti-MEM (Life Technologies) was incubated for 10 minutes 
at RT, before being added to the cell dish. 
 
For the preparation of conditioned media, HEK293 cells were transfected with the 
chosen expression vectors and were incubated for three days in Opti-MEM (Life 
Technologies). Cells that had been separately cultured in serum-free conditions, were 
then treated with the conditioned media. 
 
Cell extracts were prepared using TN-buffer (150 mM NaCl, 5 mM KCl, 0.5% NP-
40 detergent, 10 mM Tris-HCl [pH 7.8]), supplemented with protease inhibitor 
cocktail (Roche) according to the manufacturer’s protocol. For the analysis of 
phosphorylated proteins, 5 mM NaF and 1 mM Na3VO4 were added to inhibit 
dephosphorylation. 
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2.2.6.3 Immunoprecipitation 
Immunoprecipitation (IP) was performed using Protein G Sepharose 4 Fast Flow (GE 
Healthcare). Cells were transfected with vectors separately and the cell populations 
then mixed on the following day. This was done to avoid non-specific intracellular 
binding of the secreted proteins analysed. Cell extracts of previously transfected cells 
with the appropriate expression vectors (each containing either a -myc, -HA or –
FLAG tag) were prepared using TNEB-buffer (150 mM NaCl, 5 mM MgCl2, 0.5% 
NP-40 detergent, 10 mM Tris-HCl [pH 7.8]), supplemented with protease inhibitor 
cocktail (Roche) (according to the manufacturer’s protocol), 5 mM NaF and 1 mM 
Na3VO4. 25 μl of each sample was retained at this point for later western blot 
analysis.  The remaining cell extracts were used for IP: 20 μl of TNEB cell extract 
was incubated with 20 μl of Protein G Sepharose beads and 2 μl of the chosen 
antibody for IP on a shaker, at 4°C over night. The next day, the IP samples were 
centrifuged at 13,000 rpm, the supernatant removed and beads washed in fresh 
TNEB buffer several times. IP samples were then prepared for direct use in SDS-
PAGE gel analysis, along side the earlier retained control samples. 
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3 CHAPTER 3: ASPN INDUCES ECTOPIC 
EYES IN XENOPUS LAEVIS EMBRYOS  
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3.1 Introduction 
Vision is certainly one of our most treasured senses and loss of sight is associated 
with a greatly reduced quality of life (Langelaan et al., 2007). So it is of no great 
surprise that the areas of eye induction, and growing eyes in vitro, are of great 
interest to the science and clinical community. So far, there have been great advances 
with growing differentiated eye and retinal tissues artificially (Eiraku et al., 2011, 
Gonzalez-Cordero et al., 2013, Nakano et al., 2012), but science is not yet capable of 
producing a full size human eye, ready for implantation into a human patient. 
 
The “eye-maker” gene Pax6 has long been known to be by it self sufficient to induce 
eye development. When the Pax6 homolog eyeless was identified in Drosophila 
(Quiring et al., 1994), it was shown that the ectopic expression of ey in the imaginal 
discs of the fly resulted in the formation of ectopic eyes on wings, legs and antennae 
(Halder et al., 1995a, Nornes et al., 1998). Soon after, other groups showed that Pax6 
homologs from ribbonworm, squid and ascidians are also capable of inducing ectopic 
eye structures in Drosophila (Glardon et al., 1997, Kozmik et al., 2003, Loosli et al., 
1996, Suga et al., 2010, Tomarev et al., 1997). This proved that a highly conserved 
group of genes must regulate eye development across both vertebrates and 
invertebrates. The tightly regulated signalling network, which regulates eye 
development in the fly, has since also been identified in vertebrates, where they are 
referred to as the ‘eye field transcription factors’ (as introduced in detail in chapter 
1.4).  
 
The frog model Xenopus laevis played a crucial role in this discovery. In response to 
overexpression of various EFTFs, frog can also display ectopic eye tissue (Zuber et 
al., 2003). Various overexpression studies, dating back to the 1990s, have been 
carried out in Xenopus, which show that several EFTFs are by themselves sufficient 
to expand endogenous eyes or induce ectopic eye tissue (Andreazzoli et al., 1999, 
Bernier et al., 2000, Chow et al., 1999b, Mathers et al., 1997a, Zuber et al., 1999). In 
more recent years, signals other than the EFTFs have been identified, which can also 
induce these ectopic-eye phenotypes in Xenopus, such as Frizzled 3 (fz3) 
(Rasmussen et al., 2001), purine signalling molecule E-NTPDase2 (Masse et al., 
2007) and changes in transmembrane voltage (achieved through EXP1 and GlyR 
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overexpression) (Pai et al., 2012). These signals may be involved in the upstream 
regulation of the EFTFs during early development. 
 
The family of SLRPs have become a popular research topic, as they have been 
shown to be involved in a range of important biological events such as development, 
growth and cancer. While they were once thought so be solely involved in collagen 
fibril organisation (Iozzo, 1999, Kalamajski and Oldberg, 2009, Keene et al., 2000, 
Kresse et al., 1997, Neame et al., 2000, Reinboth et al., 2006), the SLRP family of 
proteins are now well known for their ability to modulate many important 
intracellular signalling pathways. Most members of the SLRP family are expressed 
during the development of neural tissue (Le Goff and Bishop, 2007, Ohta et al., 
2006). During embryogenesis, SLRPs have been shown to play important roles in a 
number of developmental processes such as germ layer specification, patterning and 
morphogenesis (Dellett et al., 2012, Moreno et al., 2005b, Morris et al., 2007, Ohta et 
al., 2004, Zagris et al., 2011). The overall expression patterns of SLRP family 
members throughout early development, and aforementioned findings from recent 
studies, certainly suggests a possible role in neural development and maintenance. 
SLRP family members are highly expressed in ocular tissues and mutations in many 
SLRPs are associated with eye malformations (Dellett et al., 2012, Lin et al., 2010, 
Majava et al., 2007, Singla et al., 2011, Wang et al., 2011). 
 
Asporin  (ASPN) is a relatively novel member of the SLRP family. To reiterate - 
ASPN was first identified in mice (Henry et al., 2001, Lorenzo et al., 2001), where it 
is mainly expressed in cartilage and bone during development. Like many other 
SLRPs, ASPN binds collagen and inhibits TGF-β signalling (Ikegawa, 2008, Kou et 
al., 2010, Nakajima et al., 2007) and it was found to play an important role in 
cartilage homeostasis (Torres et al., 2007). An aspartic acid repeat polymorphism in 
the N-terminal of the ASPN protein has been linked to osteoarthritis in humans 
(Kizawa et al., 2005). More recently, ASPN has become the focus of cancer research, 
where - depending on the type of cancer – it can have both a pro-invasive or tumour 
supressing effect (Maris et al., 2015, Satoyoshi et al., 2015).  ASPN’s role in early 
embryogenesis is however, still elusive.  
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During a functional screening of SLRP family members in Xenopus laevis, 
overexpression of ASPN mRNA caused a striking eye phenotype in the injected 
embryos. The embryos had developed enlarged and often ectopic eye-like tissue. 
ASPN’s ability to induce this ectopic eye phenotype, prompted me to analyse the 
function of ASPN in more detail. The findings from the overexpression experiments, 
suggested that ASPN might play a crucial role in eye induction and possibly neural 
induction – at least in frog.  
 
As a starting point for this project, it was important to get a better understanding of 
the Xenopus ASPN protein (e.g. sequence, special features and structure), as well as 
homologies and variations compared to other species, including humans. For this I 
carried out an in silico analysis, using the BLAST and Clustal Omega tools, to 
analyse and compare sequences. 
 
Secondly, ASPN expression levels throughout early development, as well as 
expression patterns, needed to be investigated. Knowing where and when ASPN is 
expressed during Xenopus embryo development might already indicate potential 
roles and mechanisms through which ASPN elicits its actions. I initially used semi-
quantitative PCR and qRT-PCR to determine ASPN expression levels at different 
developmental stages, as well as in different parts of the embryo. To visualise the 
patterns of expression throughout embryogenesis, I designed whole-mount in situ 
hybridisation ribo-probes for ASPN. 
 
After establishing that ASPN is indeed expressed in the eye field region and at the 
time of eye induction, confidence grew, that this is indeed a novel and important 
factor for eye development. I proceeded to perform a detailed analysis of the eye 
phenotype observed upon ASPN overexpression, which will be covered in the 
second part of this chapter. Morphology of the expanded and ectopic eye-like tissue 
was examined, as well as antibody staining for eye specific cell types. Also, an 
attempt was made to visualise potential optic nerves extending from these ectopic 
eyes towards the brain. Finally, the effect of ASPN overexpression on several eye-
field transcription factors and other developmental markers was investigated. 
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3.2 Structure and expression of Xenopus Asporin 
3.2.1 In silico analysis 
During a systematic investigation of SLRP family functions, we found that one of the 
clones demonstrated a strong ectopic eye formation activity upon forced expression 
and I became interested in its detailed molecular function. This clone encoded a 
polypeptide sequence similar to human ASPN belonging to the class 1 SLRP and 
drawing a phylogenic tree using the Clustal Omega phylogeny tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) showed that this clone contained a 
Xenopus orthologue of the ASPN gene (Lorenzo et al., 2001, Henry et al., 2001) 
(Figure 3.1). 
 
In detail, using protein BLAST (http://blast.ncbi.nlm.nih.gov) and based on the 
human amino acid sequences of various SLRP members, Xenopus laevis homologous 
genes were previously identified. IMAGE (Integrated Molecular Analysis of 
Genomes and their Expression; http://www.imageconsortium.org) clones were 
purchased from Source Biosciences and the produced clone mRNA injected into 
Xenopus embryos. The IMAGE clone #6931202 encoding Xenopus Asporin (NCBI 
Gene ID 495030) showed a strong eye inducing activity. In this study a very similar 
gene, which we termed asporin-b, was identified (registered in GenBank accession 
no.: LC056842). Its existence is probably due to the aforementioned allotetraploidy 
of Xenopus laevis. However, in this study ‘Asporin’ will refer to asporin-a, unless 
otherwise stated. 
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Figure 3.1: Phylogenic tree of SLRP family members and evolutionary relationship of 
ASPN orthologs in different vertebrate species. (A) The phylogenic tree shows the SLRP 
family members, which are divided into classes I-V. Asporin belongs to canonical class I, 
alongside Decorin and Biglycan (adapted from Dellet et al. 2012). (B) An evolutionary tree 
of ASPN orthologs from different vertebrate species, was created using the Clustal W2 
Phylogeny tool (http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/). The branch 
lengths are proportional to the amount of inferred evolutionary change. The length of the 
branch represents the amount of genetic change (line segment = genetic change of 0.05) and 
is represented in nucleotide substitutions per site (i.e. number of substitutions divided by the 
length of the sequence). 
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Sequence alignment using the Clustal Omega tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) of ASPN in different species further 
revealed that Xenopus ASPN has some typically conserved characteristics. Xenopus 
ASPN has a signal peptide and a 13 amino acid stretch comprising aspartic acid and 
asparagine (Figure 3.2, B, red) in its amino-terminal region, which is how ASPN was 
named (Henry et al., 2001, Lorenzo et al., 2001). This stretch is followed by a 
cysteine cluster with the C-X3-C-X-C-X6-C pattern, which is conserved among the 
class I SLRPs ASPN, Biglycan and Decorin, where the second cysteine is replaced 
by arginine in Xenopus (Dellett et al., 2012). The characteristic stretch of eight 
leucine-rich repeats was also found to be conserved among vertebrate species (Figure 
3.2, blue). mRNA similar to ASPN has been found in many vertebrate species such 
as zebrafish, which also contains stretches of aspartate residues. In mouse and fish 
poly-aspartate stretches are interrupted by other amino acids, but the domain is still 
conserved across species. This suggests that the aspartates are important to the 
function of ASPN (Lorenzo et al., 2001). 
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Figure 3.2: Alignment and comparison of ASPN amino-acid sequences in different 
species. The leucine-rich repeat domains (blue rectangles) and aspartic-acid rich repeat 
domain (red rectangle) seems to be conserved across vertebrate species, as evidenced in this 
sequence alignment of ASPN protein sequences of frog, chick, mouse, fish and human. 
Asterisks: isoleucine, leucine and valine, Black disc: cysteine (in the cysteine rich domain), 
I-VIII: leucine rich repeat, as predicted by a database search via LRR finder 
(http://www.lrrfinder.com).  
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3.2.2 Expression levels of ASPN during early development in Xenopus 
To investigate the expression profile of ASPN during Xenopus laevis embryogenesis, 
I initially performed semi-quantitative PCR on whole embryos at different 
developmental stages (Figure 3.3, A). ASPN expression was already apparent in the 
unfertilized egg, but expression levels gradually increased during embryogenesis 
with higher levels being detected around stage 10, 13, 17 and then again at stage 28 
(Figure 3.3, A).  
 
In order to supplement this initial semi-quantitative PCR data, the expression of 
ASPN in different areas of the embryos was investigated. For this, explants of 
microinjected animal caps, dorsal marginal zone (DMZ) and ventral marginal zone 
(VMZ) were prepared and assayed for ASPN expression by means of qRT-PCR 
(Figure 3.3, B). To mimic the forebrain, embryos were injected with Chordin (Chd) 
mRNA (Sasai et al., 1995) into the animal blastomeres and animal cap explants cut 
(Figure 3.3, B (iii)). In addition, Chd and Wnt8 mRNA was co-injected and animal 
cap explants cut, which were to mimic more posterior neural domains (Figure 3.3, B 
(iv)) (Takai et al., 2010). Both Chd and Chd + Wnt8 injected animal caps showed 
enhanced ASPN expression compared to animal caps from un-injected control 
embryos (Figure 3.3, B (i)). ASPN expression in explants from DMZ (Figure 3.3, B 
(v)) and VMZ (Figure 3.3 (vi)), mimicking dorsal and ventral mesoderm 
respectively, showed low ASPN expression similar to that seen in the control animal 
cap. The DMZ and VMZ explants were cut at stage 10.5 and then cultured until stage 
18 before they were assayed. The character of the explants was confirmed by long 
culture (see Figure 3.4) and Otx2 (Chow et al., 1999a) and Krox20 expression (Nieto 
et al., 1991) (Figure 3.3, C, D), where Otx2 expression was elevated in both IGF2 
(Figure 3.3, C (ii)) and Chd (Figure 3.3, C (iii)) injected animal cap, as well as in the 
DMZ (Figure 3.3, C (v)). Krox20 was up regulated in animal caps injected with Chd 
and Wnt8 (Figure 3.3, D (iv)), including some expression in DMZ tissue (Figure 3.3, 
D (v)). 
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Figure 3.3: Expression of ASPN and other related genes in various explants. (A) Semi-
quantitative RT-PCR of ASPN and Histone4 expression levels. Whole embryos were 
analysed by RT-PCR at various developmental stages. Low levels of ASPN expression can 
be detected already in the unfertilised egg. A marked increase in ASPN levels seems to occur 
at around stage 10, which continues through to later developmental stages. Expression levels 
of ASPN (B), Otx2 (C) and Krox20 (D) in various types of explants are shown, as assayed 
by qRT-PCR. Animal caps (control (i) or injected with mRNAs of 500 pg IGF2 (ii), 500 pg 
Chd (iii) or 500pg Chd + 100 pg Wnt8 (iv)) and dorsal marginal zone (DMZ; (v)) and 
ventral marginal zone (VMZ; (vi)) were prepared at stages 9 (animal caps) and 10.5 (DMZ, 
VMZ) and assayed at stage 18. 
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Figure 3.4: Cultured explants of injected animal caps, dorsal marginal zone (DMZ) and 
ventral marginal zone (VMZ). (A, B) Un-injected control animal cap explants formed the 
expected round ball shape of epidermal tissue, while Chordin (Chd) and Wnt8 injected 
animal caps (C, D) elongated in keeping with posterior neural domains. Chd injected (E, F) 
and IGF2 injected (I, J) animal explants show a spherical shape mimicking forebrain regions. 
DMZ (G, H) and VMZ (K, L) explants mimic dorsal and ventral mesoderm respectively.  
 
 
3.2.3 Expression pattern of ASPN during early development in Xenopus 
After establishing, that ASPN is indeed expressed during early Xenopus 
development, with increased levels in the forebrain region of the embryo, in the next 
step I wanted to visualise the expression patterns of ASPN in more detail.  
 
For this I designed in situ ribonucleotide probes, which I synthesised via the PCR 
method based on a technique published by David and Wedlich (2001). Primer pairs 
for Xenopus ASPN, which result in products larger than 600 base pairs (bp), were 
selected using Primer Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Care 
was taken to choose primer pairs that targeted different parts of the ASPN gene, to 
increase the chances for producing a working ribo probe. The targeted areas on the 
ASPN gene of the three chosen primer pairs 1, 2 and 7 are shown in Figure 3.5. The 
sequence for the T3 promoter was then added to the forward primers, and in the case 
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of reverse primer, the T7 promoter sequence was added (Figure 3.5). Using this 
approach the PCR product could be directly used for ribo probe synthesis, without 
the need to first subclone into a T3 and T7 promoter containing expression vector. As 
template for the PCR reaction, the ASPNa sequence was used. Lastly, an ASPN 
antisense probe was directly produced from the template ASPN plasmid (termed 
“ASPN 3”) using the SP6 promoter. 
 
 
Figure 3.5: Method and design of whole-mount in situ probe for ASPN with PCR. (A) 
Primer pairs resulting in products larger than 600 bp were selected, using Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Care was taken to choose primer pairs 
that targeted different parts of the ASPN gene, to increase the chances for producing a 
working riboprobe. The target areas on the ASPN gene of the three chosen primer pairs 1, 2 
and 7 are shown in (B). To the forward primer the sequence for the T3 promoter was added 
and in the case of reverse primer, the T7 promoter sequence was added (C). As template for 
the PCR reaction, the ASPNa plasmid sequence was used, which is integrated in a pCS2+ 
vector. Lastly, a fourth ASPN probe was directly produced from the ASPN plasmid using 
SP6 promoter and polymerase. 
 
 
Many different primer combinations and resulting probes were tested on the 
embryos, but only the three most promising shall be introduced in the following 
section. These three most efficient ribo probes will be referred to as ‘ASPN 1’, 
‘ASPN 2’ (derived from primer pairs 1 and 2 respectively; Figure 3.5) and ‘ASPN 3’ 
(produced from ASPNa sequence containing plasmid).  
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The whole-mount in situ hybridization was carried out on embryos of stages between 
13 and 42, to map the expression pattern throughout development. In the case of all 
three probes tested, embryos younger than stage 13 showed a uniform staining. It 
would be easy to assume that ASPN is ubiquitously expressed throughout the 
embryo at those very early developmental stages. But more likely when taking PCR 
results into account is that the in situ probes are not sensitive enough to detect ASPN 
expression at very low levels (Figure 3.6, A). 
 
Overall probe ASPN 1 showed the best staining results (Figure 3.6, A-G), however 
only ubiquitous staining could be observed of embryos of stage 13 or younger 
(Figure 3.6, A). During neurula stages, ASPN was still rather ubiquitously expressed, 
however, there seems to be a little more abundance at the neural plate (Figure 3.6, 
B), including the presumptive eye field. This becomes more obvious when directly 
compared to the expression pattern of eye field transcription factor Pax6, as shown in 
Figure 3.6, C. The expression of ASPN is more evident around the presumptive eye 
field at the tailbud stage (Figure 3.6, D, E). At stage 35, strong expression can be 
observed in the whole head region (Fig. 3.6, F), while stage 42 sees expression only 
in selected head tissues (Figure 3.6, G). For the control sense probe no specific 
staining was found in embryos up to stage 28 (Figure 3.6, H). However, in older 
embryos such as shown in Figure 3.6, I at stage 42, some staining could be observed. 
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Figure 3.6: Whole-mount in situ hybridisation with probe ASPN 1. Antisense probe 
staining is shown in embryos from stages 13 – 41 (A, B, D-G) and sense probe control 
staining is shown (H, I).  Specific staining can be observed from stage 18, where ASPN 
seems to be expressed around the neural plate and presumptive eye field (B). As a frame of 
reference, the Pax6 expression pattern at st18 is shown in (C) which shows some overlap 
with ASPN (B). From stage 22 (E) ASPN signal seems to be more condensed around 
presumptive eye field, while the whole head region is signal positive at higher stages (F, G).  
 
 
Both probes ASPN 2 (Figure 3.7) and ASPN 3 (Figure 3.8) show very similar 
staining profiles compared to ASPN 1 probe (Figure 3.6). For both probes, again no 
staining patterns were observed in gastrula stage embryos. Late neurula stage 
embryos show a more focussed ASPN signal around neural plate and the 
presumptive eye field area (Figure 3.7, A, B; Fig. 3.8 A, B, C). At late tailbud stages, 
both ASPN 2 and ASPN 3 result in localised ASPN staining in the head region 
(Figure 3.7, C, D; Fig. 3.8, D, E). ASPN 2 sense probe gave some staining at late 
tailbud stages in the head region (Figure 3.7, F), which may just be a result on non-
specific background staining.  
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Figure 3.7: Whole-mount in situ hybridisation with probe ASPN 2. ASPN in situ 
staining is shown in embryos from stage 18-42. In embryos younger than stage 18, no 
specific areas of staining could be found. From stage 18 (A) to stage 20 (B), staining can be 
found in dorsal and anterior tissues. At later stages 35 (C) staining is mainly restricted to the 
head region and stage 42 (D) shows weak staining in certain head and proctodeum regions. 
Sense probe staining is shown in (E) and (F). 
 
Figure 3.8: Whole-mount in situ hybridisation with probe ASPN 3. ASPN in situ 
hybridisation results are shown from stage 18-42 embryos. Again, embryos younger than 
stage 18 exhibited no specific areas of expression, but a more ubiquitous expression. Around 
stage 18 (A), 20 (B) and 22 (C) specific ASPN expression can be seen around the 
presumptive eye field and neural tube. At stage 35 (D), expression is found in the whole 
head region, while stage 42 exhibits staining in some head regions and the presumptive 
protodeum (E).  
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3.3 ASPN induces ectopic eyes in Xenopus embryos 
3.3.1 ASPN overexpression phenotype  
Gain-of-function experiments in Xenopus laevis embryos - achieved by injecting 
artificially high amounts of the protein’s mRNA and subsequent phenotype analysis - 
can often give a good first indication of the protein’s function during development. 
To find out more about ASPN’s potential role in early frog development, varying 
concentrations of ASPN mRNA were injected into a dorsal or ventral animal 
blastomere at the four to eight cell stage. At the four to eight-cell stage, dorsal and 
ventral blastomeres in the animal pole of the embryo can be distinguished according 
to pigmentation (see Figure 3.9). Depending on where in the embryo ASPN mRNA 
was overexpressed i.e. in a dorsal or ventral, animal or vegetal blastomere, very 
different phenotypes could be observed. Dorsal animal injections of ASPN mRNA 
lead to striking eye phenotypes, while ventral animal overexpression resulted in 
extremely shortened and anteriorised embryos. These different ASPN induced 
phenotypes, shall be introduced and examined in the following section. 
 
 
 
Figure 3.9: Schematic diagram of the four-cell stage Xenopus laevis embryo. (A) Shown 
is the animal pole of a four-cell frog embryo. The two dorsal blastomers show lighter 
pigmentation, while ventral blastomers are darker in colour. (B) The four-cell embryo is 
shown from a lateral view with the animal pole at the top and vegetal pole at the bottom. The 
lighter pigmented dorsal animal poles were the targets of ASPN mRNA injection for the 
purpose of ectopic eye induction. Pictures were adapted from Nieuwkoop and Faber (1994).  
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3.3.1.1 Dorsal Animal injections 
For targeted ASPN overexpression in the dorsal animal blastomers of the embryo, 
increasing amounts of mRNA (0.5, 1 and 3ng) were microinjected at the four to eight 
cell stage of the embryo. The embryos were cultured until they reached 
developmental stage 42 and their phenotype then assessed. Control injections were 
carried out using β -gal mRNA. The resulting variety of mostly eye-related 
phenotypes, are represented in Figure 3.10. 
 
There is a large variety in eye related phenotypes, following ASPN overexpression. 
The phenotypes can be broadly sub-divided into embryos displaying: a) ectopic eye-
like tissue, which could include ectopic RPE, retina with lens; b) enlarged or 
expanded endogenous eyes and c) various defects of the endogenous eye, including 
missing eye structures, misshaped eyes, wrong eye location and very rarely ectopic 
heads.  
 
The ectopic eye-like structures were of varying size from very small retina/RPE-like 
spots to ones of enormous size, which trumped the endogenous eye (Figure 3.10, C, 
C’). These ectopic structures were mostly observed in the midline of the head region, 
with some rarely occurring in posterior tail tissues (Figure 3.10, D, D’) or the flank 
of the tadpole. Embryos displaying ectopic eye-like structures had an otherwise 
normal body, with no shortened or twisted body axes.  
 
The enlarged eye phenotype was often uneven so that the concerned eye looked 
disproportionate and pulled out of shape (Figure 3.10, E, E’). In this category I count 
what others have referred to as proximal eye defects, i.e. a thin elongation of the 
retinal/RPE tissue towards the neural tube (Figure 3.10, F, F’). 
 
The most varied phenotype-subgroup, were the various eye defects that occurred 
upon forced overexpression of ASPN. In these embryos parts of the eye were 
missing (Figure 3.10, H, H’), thereby rendering the endogenous eye misshaped. As 
seen in Figure 10 (I, I’) eyes also developed in the wrong place, such as more 
medially. The embryo in Figure 3.10, J, J’ was a very rare find: it had an ectopic 
head structure including a pair of eyes and a cement gland, while the ‘original’ head 
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exhibited one large fused eye in the front of the head where the eye-field had failed 
to separate. 
 
 
Figure 3.10: Phenotypes observed following ASPN mRNA injection into the developing 
X.laevis embryo. There is a great variety of different eye related phenotypes, which can be 
observed following an injection of 3ng of ASPN mRNA into one of the dorsal animal 
blastomeres at 4 or 8 cell stage, compared to control (A, A’). Ectopic eyes could be found in 
the head region (B, B’, C, C’) and sometimes also in tail and flank regions (D, D’). 
Expanded endogenous eye and ectopic retina was observed (E, E’, F, F’, G, G’). 
Additionally there were many eye related defects such as missing retina (H, H’), multiple 
eyes, which failed to divide (I, I’) and very rarely ectopic heads with a set of eyes and 
cement gland (J, J’). 
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Figure 3.11: Quantification of the ASPN induced phenotypes. Following the injection of 
0.5 ng, 1 ng or 3 ng of ASPN mRNA into a dorsal animal blastomere, phenotypes were 
quantified at developmental stage 42. The phenotypes were divided into four categories; 
embryos with normal eyes (black), with enlarged eyes (green), with ectopic eyes (red) and 
short axis (white). The number of ectopic eyes increased with increasing ASPN mRNA 
concentration injected. 
 
 
Figure 3.11 shows the quantitative phenotype distribution following the ASPN 
mRNA injections with 0.5, 1 and 3ng. As expected, control injections with β -gal 
mRNA had no significant effect on Xenopus development (Figure 3.11). Incidences 
of tadpoles developing ectopic eye-like tissue increased with augmenting ASPN 
concentrations; from only 4% at 0.5ng ASPN to 15% at 1ng and finally 32% at the 
highest concentration tested of 3ng of ASPN mRNA. At the same time, the number 
of embryos with enlarged and expanded eyes was highest at the lowest ASPN 
concentration (60%), while slightly lower percentages of embryos were affected 
when 2 or 3ng mRNA was injected (47% and 53% respectively). The number of 
unaffected normal looking tadpoles decreased with increasing ASPN concentrations 
(14% for 0.5ng, 1% for 1ng and 6% for 3ng).  
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3.3.1.2 Ventral animal injections 
Results of the ASPN overexpression experiment in dorsal animal blastomeres seem 
to suggest a role in eye development. The dorsal animal blastomeres have been 
shown to majorly contribute to eye and also lens tissue (Figure 1.5) and certain 
factors such as IGFs, purine-signalling molecule E-NTPDase2 and Frizzled3 have 
been shown to affect eye development when overexpressed in these tissues (Masse et 
al., 2007, Pera et al., 2001, Rasmussen et al., 2001, Richard-Parpaillon et al., 2002). 
IGFs also had a posteriorising effect on Xenopus embryos when injected in ventral 
animal blastomeres, which was determined to be due to the inhibition of Wnt 
signalling pathway. So in the next step, I wanted to explore if ASPN has a similar 
effect when overexpressed in the ventral blastomeres. In comparison to dorsal animal 
injection phenotype, when the ASPN mRNA was injected into one of the ventral 
animal blastomeres of the embryo, a very different phenotype could be observed. 
The embryos had an extremely shortened body (Figure 3.12, B, C, D) compared to 
the un-injected control (Figure 3.12, A). Posterior development seems to have been 
extremely inhibited, following ASPN injection, which might be due to Wnt-signal 
inhibition. Besides the dramatic shortening of the body, two-tails could often be 
observed, which might be a gastrulation defect due to general developmental toxicity 
caused by the high mRNA amount injected. Sometimes the tadpoles exhibited 
expanded eye-like tissue, reminiscent of the phenotype seen with dorsal animal 
injections (Figure 3.12, D). 
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Figure 3.12: Phenotypes observed following ASPN overexpression in a dorsal vegetal 
blastomere. Compared to the un-injected control (A), embryos injected with ASPN mRNA 
in one of their dorsal vegetal blastomeres at the 4 or 8 cell stage exhibited a dramatically 
shortened body phenotype (B, C, D). This was sometimes accompanied by a double-tail and 
expanded eye-pigment (C, D). 
 
 
3.3.2 Histological examination of ectopic tissue reveals eye-like structure 
To further characterise the eye related phenotypes, tadpoles were embedded and 
sectioned in paraffin wax and then stained with Hematoxylin and Eosin (H & E 
staining) for histological analysis. Sectioned embryos displaying an expanded eye or 
ectopic eye phenotype can be seen in Figure 3.13, E and F, respectively. The 
extending endogenous retina and RPE seen in Figure 3.13, E, seems to merge with 
the neural tube, which itself is oddly shaped and shows signs of hyper-proliferation. 
It should be noted that no expansion of the cement gland was observed (Figure 3.13, 
A-C), which is the anterior-most structure in the embryo, suggesting that ASPN 
function is not entirely the same as IGF signalling (Pera et al., 2001), and thereby 
also differs from the effects of Cerberus (Bouwmeester et al., 1996). 
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Figure 3.13: Paraffin sections of ASPN induced expanded eye and ectopic eye. Tadpoles 
with an enlarged endogenous eye (B, B’, B’’) and an ectopic eye (C, C’, C’’) were paraffin 
sectioned, followed by H&E staining (E, F). Control embryo and section are shown in A, A’, 
A’’ and D. 
 
The presumed ectopic eye tissue shows a layered neural retina structure, with 
occasionally duplicated retinas and additional layering (Figure 3.14, C-H). The RPE 
found on the injected side (Figure 3.14, D, F, H) is thicker than on the un-injected 
side (Figure 3.14, B). Two cases of embryos with ectopic eye-like structures are 
shown in Figure 3.14, C, D and E, F. One of the ectopic structures is embedded in 
the neural tube (Figure 3.14, C, D), while the other induced ectopic tissue is adjacent, 
yet separate to, the neural tube (Figure 3.14, E, F). In both cases, the pigment can 
only be seen on the outside of the structure, which is presumably RPE, and the 
induced tissue has an overall epithelial character. Again, the presumed RPE is thicker 
than in the endogenous eye (Figure 3.14, B). Based on these observations from the 
histological data, I assumed that the condensed pigment structure surrounding the 
ectopic tissue is a pigmented epithelium of the retina (RPE), and the retinal structure 
was induced by the forced expression of ASPN. The enlarged endogenous eyes and 
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ectopically induced eyes show all the specific layers of the retina, which suggests the 
presence of all retinal cell types. The expansion and ectopic location of the induced 
eye tissue could be due to ASPN expanding the eye field at very early stages, 
through up-regulated EFTFs expression outside the normal eye field boundaries. The 
disorganisation of the ectopically induced and expanded retinas could be a result of 
the mRNA injection technique in Xenopus itself. Injected mRNA does not diffuse 
widely and evenly within the targeted embryo blastomere due to the inherent high 
lipid content of the embryonic tissue (lack of diffusion of injected material has been 
shown repeatedly with injection tracing agents such as β-gal). This could result in a 
mosaic cell population, where cells have different amounts of ASPN mRNA, which 
could then cause an uneven eye induction and explain faulty and disorganized 
layering and structure of the ectopic eye tissue. 
 
 
Figure 3.14: H & E stained paraffin sections of expanded and ectopic eye tissue. 
Sectioning plane is shown (A) and an un-injected control eye section (B). Also shown is an 
ectopic eye-like tissue, which developed within the neural tube (C, D) and thereby distorts 
the structure/appearance of the neural tube. Another ectopic eye is shown, which was found 
adjacent to the neural tube (E, F). Lastly, an expanded endogenous eye is shown in (G, H). 
The endogenous eye is fused with ectopic eye tissue and the neural tube.  
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3.3.3 Histological examination of brain reveals abnormal and enlarged CNS 
Even without a fully developed ectopic eye structure being embedded or fused with 
the neural tube, ASPN injected embryos develop abnormal looking neural tubes, as 
seen in Figure 3.15, C, D. In these injected animals, the neural tube often shows 
signs of hyperplasia and is therefore often distorted with abnormal tissue layering 
and distribution. Often spots or circular inclusions of pigment could be found on top 
of the neural tube tissue and underlying the epidermis (Figure 3.15, C). This 
phenotype could be a result of ASPN’s eye inducing activity and the expansion of 
eye field transcription factor expression domains, such as Rx1, which has previously 
been shown to modulate proliferation in the anterior neural plate (Andreazzoli et al., 
1999, Zuber, 2010, Zuber et al., 2003). Also, overexpression of EFTFs Six3 and Six6 
has been shown to affect the entire head region and leads to abnormal neural tissue 
structures. They also control eye precursor proliferation and are capable of 
converting midbrain cells to retinal progenitor cells (Bernier et al., 2000, Zuber, 
2010). 
 
 
Figure 3.15: ASPN affects the development of the neural tube. Stage 42 tadpoles injected 
with ASPN (C, D) exhibit an abnormal neural tube structure compared to un-injected control 
embryo (B). Sectioning plane is shown in (A).  
 
 
3.3.4 ASPN induced ectopic tissue is composed of eye specific cell types 
The histological data suggested that the induced ectopic structures had an eye-like 
character. To further verify this hypothesis, I performed immunohistochemistry 
staining on cryo-sectioned ectopic and endogenous eyes (Figure 3.16). The 
antibodies used targeted eye specific cell types in Xenopus: β -crystallin for lens 
(Figure 3.16, B, C), glutamine synthetase for Müller glia (Figure 3.16, D, E), Hu-
C/Hu-D for retinal ganglion and amacrine cells (Figure 3.16, F, G), and calbindin for 
cone photoreceptors (Figure 3.16, H, I). The ectopic structures stained positive for all 
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retinal specific antibodies tested. While β -crystallin positive lens was not always 
present, all ectopic structures examined tested positive for Müller glia, retinal 
ganglion and amacrine cells, as well as the cone photoreceptors (Figure 3.16, E, G, 
I). Where lens tissue was found, it was always correctly positioned on the epidermis 
facing side of the ectopic tissue (Figure 3.16, C). As previously mentioned, ectopic 
tissue often displayed layered, yet often unnaturally folded, retinal tissue. The Müller 
glia cells found in those induced structures still spanned the depths of the retina 
(Figure 3.16, E). However, due to the irregular overall layering, there is no parallel 
spatial pattern of Müller glia cells, as is the case in the endogenous eye (Figure 3.16, 
D). Layering can be observed for the population of Hu-C/Hu-D positive amacrine, 
the retinal ganglion cells, and also calbindin positive cone photoreceptors, but again 
due to folding of the ectopic tissue, the end location of the stained cells is not the 
same as in the endogenous eye (Figure 3.16, F-I). 
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Figure 3.16: ASPN induced ectopic eye-like structures contain retina specific cell types. 
Tadpoles were injected with 3ng of ASPN mRNA and grown to stage 42. Ectopic eye-like 
structures (C, E, G, I) and control normal eyes (B, D, F, H) were cryo-sectioned and stained 
with β-crystallin antibody (lens; B, C), glutamine synthetase (Mueller glia; D, E), Hu-C/Hu-
D (horizontal and amacrine cells; F, G) and calbindin (cone photoreceptors; H, I). Sectioning 
plane is shown in (A). 
 
 
3.3.5 DiI staining cannot verify the existence of an optic nerve in ectopic eye 
structures 
After histological and immunohistochemical data confirmed eye character for the 
ASPN induced structures, I wanted to find out if and how they might be innervated. 
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In vertebrates, axons often have to travel long distances to their final site of 
innervation. In the eye, the retinal ganglion axons from the retina normally grow 
along the well-defined optic tract, towards the tectum (Harris, 1986). In previous 
studies (Harris, 1986, Koo and Graziadei, 1995, Sedohara et al., 2003), it was shown 
that transplanted eyes in the cranial region, extend ‘cellular bridges’ and axons 
towards the optic tecta in the brain. These are maintained through metamorphosis 
and into adulthood. Also, transplanted eyes located in the area behind the head along 
the dorsal midline appear to extend axons, which enter the spinal cord (Giorgi and 
Van der Loos, 1978, Katz and Lasek, 1978). 
 
To visualise the nerves, DiI (1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine 
Perchlorate) crystals where placed in the optic cup onto the retinas of 4 % PFA fixed 
embryos and then incubated in fixative for several days, before analysing. In Figure 
3.17 (A-F) DiI staining of an endogenous eye of an un-injected embryo is shown. 
The retina stained strongly (Figure 3.17, B), as did the optic nerve leaving the retina 
(Figure 3.17, B, C, D). When dissected out of the tadpole and visualised by itself, the 
embryo’s brain appeared to have also been stained (Figure 3.17, E). However, it was 
not possible for me to image the optic nerve extending and joining the tectum in the 
brain whilst keeping the embryo intact (Figure 3.16, F). 
 
 
Figure 3.17: DiI staining of retina and optic nerve in control and ectopic eye tissue. (A-
F) The lens of the endogenous eye was removed, and DiI crystals placed inside the optic cup 
of a 4% PFA fixed embryo at stage 42. The embryo was then incubated in fixative in the 
dark for 48 hours and the resulting staining analysed. (G-L) DiI crystals were also used to 
stain ectopic eye-like tissue. While no single optic nerve could be found, many smaller axons 
could be found, extending away from the ectopic eye tissue (I, J, K, L).  
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While the labelling of the endogenous eye and its optic nerve appeared to have 
worked, the labelling of ectopic structures turned out to be more difficult (Figure 
3.17, G-L). Since the ectopic structures often did not display a cupped structure, 
placement and retaining of the DiI crystal for prolonged incubation and staining 
turned out to be tricky. Stained ectopic retina and RPE can be seen in Figure 3.17, H. 
While no single large optic nerve could be found leaving the ectopic structures, it 
does seem to be well innervated, with several axons extending away from it (Figure 
3.17, I-L). 
 
3.3.6 ASPN induces eye-field specific transcription factors (EFTFs) both in 
vivo and in vitro. 
As previously described, the EFTFs play a crucial role in eye induction and their 
expression patterns have been well documented and characterized. The 
overexpression of several EFTFs causes the formation of ectopic eyes in Xenopus. It 
seemed therefore likely that overexpression of ASPN mRNA affects the expression 
of EFTFs. However, at what point in early development ASPN elicits its action and 
which EFTF members might be affected, remained to be seen. 
 
In order to address the earlier effects of ASPN overexpression, I analysed gene 
expression patterns by whole-mount in situ hybridisation in embryos at stage 17 and 
22.  ASPN mRNA was injected into a single dorsal animal blastomere at the 4-cell 
stage and the embryos were cultured until the early tailbud stage 17. For EFTFs Rx1 
and Pax6, embryos at stage 22 were also analysed.  
 
At stage 17, the expression of Rx1 (Mathers et al., 1997b) (Figure 3.18, A, B; 90%, 
n=11) and Pax6 (Chow et al., 1999a) (Figure 3.18, E, F; 100%, n=11) was clearly 
expanded or appeared ectopically in the ASPN overexpressing side of the embryo, 
while the Otx2 expression pattern remained unchanged (Figure 3.18, I, J; 100%, 
n=11) (Blitz and Cho, 1995). In contrast, the telenchephalon marker XBF1 (FoxG1; 
telencephalon; (Bourguignon et al., 1998)) (Figure 3.18, K, L; 50%; n=20), En-2 (the 
midbrain-hindbrain junction; (Hemmati-Brivanlou et al., 1990)) (Figure 3.18, M, N; 
81.5%, n=27) and Krox20 (hindbrain/rhombomere3 and 5; (Nieto et al., 1991)) 
(Figure 3.18, O, P; 100%, n=12) were down regulated. At stage 22, the ectopic and 
expanded expression of Rx1 (Figure 3.18, C, D; 93%, n=15) and Pax6 (Figure 3.18, 
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G, H; 78%, n=14) is still maintained. These observations suggest that ASPN 
specifically encourages retinal development in vivo. 
 
Next, the function of ASPN in vitro was investigated. For this purpose, animal cap 
explants were prepared from embryos injected with the ASPN mRNA, and their gene 
expression analysed when the sibling whole embryos reached stage 22. ASPN 
increased the expression levels of Sox2 and NCAM (general neural), XAG1 (cement 
gland), XBF1 (telencephalon), Pax6 and Rx1 (forebrain and eye regions), Otx2 
(forebrain and midbrain), while En-2 (midbrain and hindbrain junction), Krox-20 
(hindbrain), Slug (neural crest) and cardiac Actin (mesoderm) were not affected by 
ASPN (Figure 3.18, Q). This suggests that ASPN can induce eye development on its 
own. 
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Figure 3.18: ASPN induces forebrain marker genes both in vivo and in vitro. (A-Q) 
Forebrain marker genes were increased at the expense of posterior markers in vivo, 
following unilateral ASPN mRNA injection. The tracer β-Galactosidase (light blue staining) 
was injected without (A, C, E, G, I, K, M, O) or with (B, D, F, H, J, L, N, P) ASPN mRNA 
(3ng). Embryos were analysed by in situ hybridisation with Rx (A-D), Pax6 (E-H), Otx2 (I, 
J), XBF1 (K, L), En2 (M, N) and Krox20 (O, P) probes at stages 17 and 22 (for Rx, Pax6). 
Affected areas are indicated with yellow arrowheads. (Q) Control (lane 2) or ASPN-injected 
(lane 3) animal cap explants were analysed by semi-quantitative RT-PCR. Whole embryos 
(lane 1) were used as positive control for the PCR. 
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3.4 Discussion 
3.4.1 A Xenopus ortholog of ASPN plays an important role in eye development 
The eye-inducing polypeptide of interest in this study, turned out to be a Xenopus 
laevis ortholog of ASPN. Multiple sequence alignment of ASPN in different 
vertebrate species, further revealed that it possesses many conserved features, such as 
the aspartic acid rich repeat and the number of leucine-rich-repeat domains (Figure 
3.2). This suggests that these protein-features are important for its function. It is 
interesting that no ASPN ortholog could be found in Drosophila – its expression 
might be restricted to vertebrate species. 
 
Until now, ASPN has been mostly associated with bone related disease, such as 
osteoarthritis, cartilage homeostasis and more recently with cancer (Kizawa et al., 
2005, Satoyoshi et al., 2015, Torres et al., 2007, Maris et al., 2015). It is now 
recognized that SLRPs are not merely involved in the upkeep of the extra-cellular 
matrix and offering of structural support.  This class of proteoglycans has been found 
to be involved in crucial cell signalling events, which direct developmental events 
such as migration, growth and development.  
 
Most members of the SLRP family are well known to inhibit TGF-β and BMP 
signalling by directly binding to their respective molecules and thereby inhibiting 
receptor binding and cell-signal pathway activation. To demonstrate this point: 
Decorin, a class I SLRP, is known to bind to EGFR, IGF1R, WISP-1, LRP-1, c-
MET, TFG-b and BMP4. It can regulate the downstream signalling of their 
associated signalling pathways (Brandan et al., 2006, Dellett et al., 2012, Desnoyers 
et al., 2001, Iozzo, 1999, Kolb et al., 2001, Schaefer et al., 2007) and is thought to be 
essential for convergent extension movements (Zoeller et al., 2009). Fellow class I 
SLRP biglycan regulates dorsal-ventral axis formation and has the ability to induce 
secondary axes in frog embryos, by modulating chordin mediated BMP4 inhibition 
(Dellett et al., 2012, Moreno et al., 2005b). Tsukushi (TSK) binds to and regulates 
the associated signalling pathways of at least nodal/Vg1, BMP4/chordin, FGF8, 
Frizzled4 and delta (Morris et al., 2007, Ohta et al., 2011). In Xenopus TSK is 
involved in germ layer specification and patterning events (Dellett et al., 2012, 
Morris et al., 2007) and in chick it was found to act as a neural inducer and modulate 
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organizer formation and neural induction (Ohta et al., 2004). Xenopus TSK further 
controls ectodermal patterning and neural crest specification, by modulating BMP 
and Notch/Delta signals (Dellett et al., 2012, Kuriyama et al., 2006).  
 
SLRPs defects have long been known to cause various eye diseases (Bech-Hansen et 
al., 2000, Bredrup et al., 2005, Lin et al., 2010, Majava et al., 2007, Pellegata et al., 
2000). The discovery that SLRP family member ASPN may play a crucial role in eye 
development is therefore not too surprising. Yet, so far, there have been no reports on 
ASPN’s role in a developmental biology context. 
 
Despite its wide popularity as a model organism, the genome of Xenopus laevis is 
still poorly understood. Genetic studies in X.laevis are challenging, as it is 
allotetraploid (also referred to as pseudotetraploid) with a large genome size of 3.1 
Gbp (Pollet and Mazabraud, 2006). The allotetraploidy is thought to be due to a 
whole-genome duplication event after interspecific hybridisation of diploid species, 
which took place between 30-55 million years ago (Pollet and Mazabraud, 2006, 
Uno et al., 2013). While some genes are present in the frog in a diploid state, other 
genes were conserved as duplicated ‘allogenes’. These can show different degrees of 
divergence (usually lower than 10%) (Pollet and Mazabraud, 2006). 
 
Each animal model offers particular technical advantages and limitations (Harland 
and Grainger, 2011). Based on these, the researcher has to decide which model is 
best suited to investigate the scientific problem in question. The frog Xenopus laevis 
offers many advantages compared to other amphibian models (e.g. inducible egg 
laying, large robust eggs, etc.) and definitely has the jump on many other vertebrate 
models, especially mammalian models. Since there is a high conservation of many 
important developmental and cellular processes, as well as a high degree of genomic 
synteny with mammals, insights gained from work in Xenopus can be used to better 
understand development and disease in humans. The syntenic regions between 
Xenopus (tropicalis and laevis) with human are often 100 genes or more (Harland 
and Grainger, 2011). Hopefully, the insights gained from investigating the role of 
Xenopus ASPN are therefore transferable to mammalian models. 
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3.4.2 ASPN is expressed in the presumptive eye field of frog embryos around 
the time of eye induction 
Since this study is based on an eye phenotype that was discovered following forced 
overexpression, the initial question that poses itself is whether ASPN plays a direct 
role in early eye induction? If this was the case, ASPN expression should be present 
around the time of eye induction and in the right tissues - i.e. anterior neuroectoderm 
and more specifically the presumptive eye field. 
 
In human and mouse at adult stages, ASPN was found to be expressed in a variety of 
tissues via Northern blot analysis, however in varying amounts: high expression 
levels were found in the liver, heart, aorta and uterus, while only low levels of ASPN 
were detected in lung, bone marrow, trachea and no apparent ASPN expression in the 
human CNS, spleen and thymus (Henry et al., 2001, Lorenzo et al., 2001). The 
highest concentrations of ASPN mRNA were found in articular cartilage, as well as 
in aorta and uterus. This suggests that ASPN expression takes place in smooth 
muscle cells. Intermediate levels of mRNA were also found in other tissues, 
containing smooth muscle cells (Lorenzo et al., 2001). In developing mouse 
embryos, ASPN expression analysed by whole-mount in situ hybridisation, showed 
high expression levels in the developing skeleton (particularly in perichondrium and 
periosteum of cartilage and bone), as well as specialised connective tissues such as 
tendon and sclera (Henry et al., 2001). However, Henry et al. (2001) did not find 
ASPN expression at early developmental stages in the presumptive eye field region. 
 
Since the 1960s it has been known that the eye anlagen are already specified at the 
neural plate stage, as shown in the salamander experiments by Lopashov and Stroeva 
(1964). As mentioned in the general introduction, EFTFs such as ET, Rx1, Pax6, 
Six3, Six6 and Lhx2 are expressed in a specific timed manner and pattern to 
eventually lead to the development of the eye. In Xenopus laevis, Six3 is the only 
EFTF that can be detected at egg stage, although this early expression seems to be 
only transient and disappears again by stage 10.5 (Zuber et al., 2003). ET, Pax6 and 
Rx1 are firstly detectable around stages 10, 10.5 and 11 respectively. A strong 
expression of most EFTFs can be seen to start nearly simultaneously around stage 12 
to 12.5. While Zuber et al. (2003) found variability between samples, the relative 
time frame remained the same. Otx2 is required for the establishment of the 
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presumptive forebrain and midbrain region. It is therefore expressed in the entire 
presumptive neuroectoderm during gastrula stages. At the beginning of neurulation, 
Otx2 expression is down regulated in the central part to form an expression gap. This 
gap is the location of the presumptive eye field and shortly after EFTFs start to be 
expressed in partly overlapping patterns within this Otx2 free area (Pannese et al., 
1995, Zuber et al., 2003). 
 
In my PCR analysis of ASPN expression levels throughout early development of X. 
laevis, ASPN was already detected in the egg with weak expression prior to stage 10, 
at which point a marked increase took place (Figure 3.3, A). As mentioned 
previously, this is also the time at which the first eye field transcription factors ET, 
Rx1 and Pax6 start to be expressed. Therefore, the timing of this increased ASPN 
expression coincides nicely with the beginning of eye induction.  
 
Since ASPN seems to be expressed at the correct time for eye induction, the question 
remained; whether spatial expression patterns further confirmed a potential role for 
ASPN in eye development? The qRT-PCR results performed on animal caps 
mimicking forebrain (Chordin induced), and other slightly more posterior neural 
domains (Chordin and Wnt8 induced) (Figure 3.3, B (iii), (iv)), clearly indicate that 
ASPN is expressed in anterior neuroectoderm and either directly or indirectly 
induced by Chordin. Since no ASPN expression could be detected in VMZ and DMZ 
(representing ventral and dorsal mesodermal tissue, respectively) the expression of 
ASPN in the broad anterior neuroectoderm seems to be specific, i.e. ASPN is not 
simply ubiquitously expressed throughout the embryo at the same level (Figure 3.3, 
B (v), (vi)). 
 
In the hope of elucidating the exact expression pattern of ASPN during early X. laevis 
development, I set out to design and produce whole-mount in situ hybridisation 
probes. While ASPN 3 was directly synthesised from the ASPNa sequence in a 
pCS2+ plasmid, ASPN 1 and ASPN 2 were produced via a PCR method. 
Unfortunately, none of the in situ probes showed specific staining of ASPN 
expression patterns around the beginning of eye induction (i.e. stages 10-12). The 
absence of a visible ASPN in situ signal at the time of eye induction, stands in 
contrast to the detected ASPN qPCR signal. Since the gain-of-function experiments 
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suggest an early role for ASPN in eye development, this discrepancy in detected 
ASPN could be due to technical limitations of WISH. It is possible, that ASPN 
expression levels are simply too low to produce a visible signal in the in situ 
experimental setting around the time of eye induction. It is only from around stage 18 
that specific areas of ASPN expression become visible around the neural plate and 
anterior regions. Particularly when compared to the expression pattern of EFTF Pax6 
(Figure 3.6, B, C), it becomes apparent that the ASPN expression pattern shares 
some overlapping expression areas with Pax6. At later stages, specific ASPN 
expression in the eye region becomes apparent (Figure 3.6, D, E).  
 
Together these observations revealed that ASPN is expressed during early 
embryogenesis around the time of eye induction. The detected ASPN expression 
levels throughout early frog development and specific expression patterns in the 
anterior neuroectodem, make it highly likely that ASPN plays a role in neural and 
more specifically eye development.  
 
3.4.3 ASPN induced ectopic structures have eye character 
The histological and immunohistochemical analyses showed that the ASPN induced 
ectopic structures have indeed eye character. Injected ASPN mRNA can either 
expand the endogenous eye on the injected side of the embryo, or even induce the 
formation of ectopic eye structures - mostly in the head region and occasionally in 
posterior tissues such as the tail or along the flank of the embryo (Figure 3.10).  
 
While these ASPN induced structures, are definitely of an eye nature, they are 
abnormal in many ways: The retinal pigment epithelium, which surrounds the 
induced tissue, is thicker than normal (Figure 3.14, B, D, F). While the neural retina 
has a layered appearance and contains eye specific cell types (such as Mueller glia, 
horizontal and amacrine cells, cone photoreceptors and sometimes also lens) the 
layering is in parts doubled and inverted (Figure 3.14, D).  The overall size of 
induced ectopic eyes was impressive and often outsized the endogenous eye (Figure 
3.10, C, C’).  With over 30% of embryos injected with 3 ng of ASPN mRNA, 
exhibiting ectopic eyes, ASPN is a very potent eye inducer (Figure 3.11). 
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It is still unclear if ectopic sensory organs, such as eyes, can connect to the CNS and 
become functional. It is possible that due to CNS plasticity, the brain can adapt and 
ectopic eyes may be able to function through novel pathways (Blackiston and Levin, 
2013). In previous experiments, it was shown that transplanted ectopic eyes in the 
head region form ‘cellular bridges’ to connect with the optic tecta (Koo and 
Graziadei, 1995), while ectopic eyes transplanted in posterior tissues along the dorsal 
midline, also extend axons that seem to enter the spinal cord (Katz and Lasek, 1978, 
Giorgi and Van der Loos, 1978, Sedohara et al., 2003). In the case of ASPN induced 
ectopic eyes, it is not possible to draw conclusion as to their functionality. With DiI 
staining it could only be ascertained that the induced eye-structures are innervated 
and extend axons into the surrounding tissue. It was technically not possible to 
establish, if and where these axons found their postsynaptic partners (Figure 3.16, H-
L). But attractants may be expressed and the presumptive retinal cells (either 
endogenous or ectopically induced) may be guided by those attractants. 
 
Beyond establishing whether the right nerve connections are present, assessing the 
functionality of ectopic eyes in Xenopus laevis is generally very challenging. Frogs 
are notoriously difficult to use in cognitive studies and learning assays. In previous 
aversive training studies, frogs would rather die than adapt to avoid repeated 
exposure to electric shocks (Blackiston and Levin, 2012). Recently Blackiston and 
Levin (2012) developed a protocol for visual conditioning, which they used to assess 
the functionality of transplanted ectopic eyes. 
 
3.4.4 ASPN induces eye field transcription factors (EFTFs) both in vivo and in 
vitro 
When ASPN was overexpressed in a dorsal animal blastomere a spectrum of eye 
phenotypes could be observed as a result, ranging from enlarged endogenous eyes, to 
ectopic eye-like structures and various eye defects (Figure 3.10). The expanded or 
ectopic eye-like tissues were often connected with the animal’s neural tube, which 
itself often showed signs of hyperplasia (Figure 3.14, G, H; Figure 3.15 C, D).  
 
The observed phenotypes are reminiscent of those found upon overexpression of 
various EFTFs: Rx1 overexpression, for example, expands endogenous eye tissue 
and induces ectopic retina and RPE, while also leading to the expansion and 
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duplication of the neural tube (Andreazzoli et al., 1999, Mathers et al., 1997a). 
Depending on the injection site, Pax6 overexpression lead to ectopic eyes, lenses and 
RPE, as well as eye defects proximal to the neural tube (Chow et al., 1999b). 
Overexpressing Six3 in frog also lead to expanded endogenous eye and head tissues, 
and ectopic eyes, which seems to originate from transformed midbrain tissue. At 
very high concentrations Six3 disrupted eye morphology and lead to CNS 
hyperplasia (Bernier et al., 2000). When closely related Six6 is overexpressed in 
Xenopus, a dramatic increase in eye size at the expense of midbrain could be 
observed, along with retinas that are fused with the forebrain (Bernier et al., 2000, 
Zuber et al., 1999).  
 
Based on these earlier studies, the working hypothesis was that ASPN is likely to 
directly affect the eye field transcription factors and elicit its effect by inducing their 
expression. This theory could be confirmed by the whole mount in situ hybridisation 
experiments, which showed an expansion of the expression domains of EFTFs Rx1 
and Pax6 (Figure 3.18, B, D, F, H), following ASPN overexpression. Posterior 
markers FoxG1, En2 and Krox20 in contrast were down regulated (Figure 3.18, L, N, 
P). PCR analyses in animal cap, further confirmed that ASPN seems to induce 
forebrain specific marker genes both in vivo and in vitro (Figure 3.18, Q). ASPN did 
not expand the Otx2 expression domain (Figure 3.18, I, J), even though in animal cap 
explants increased levels could be detected (Figure 3.18, Q). Otx2 is thought to 
‘prime’ the anterior part of the embryo for the subsequent expression of eye specific 
genes (Zuber et al., 2003). There is a possibility that ASPN may not induce Otx2 in 
vivo, or it may potentially increase the intensity of Otx2 expression, while not 
expanding the area in which it can be detected. More likely though is that stage 17 
and stage 22 are too late to detect any possible ASPN-induced changes in Otx2 
expression patterns. While Otx2 is initially broadly expressed from the very anterior 
presumptive cement gland to the region of the midbrain, already by stage 12/13 Otx2 
can no longer be detected in the eye field. In fact, in order for the eye to develop, 
Otx2 needs to be supressed within the eye field so that EFTFs can be expressed 
(Pannese et al., 1995, Zuber, 2010). 
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3.4.5 The ASPN induced phenotype in Xenopus, closely resembles the IGF 
overexpression phenotype but is not identical 
Overexpression studies dating back to the 1990s, showed that several EFTFs are by 
themselves sufficient to expand endogenous eye tissue or induce ectopic eyes. Pera et 
al (2001) and Richard-Parpaillon et al. (2002) showed that IGF signalling plays an 
important role in anterior head and also eye development. Overexpression of IGFs 
resulted in expanded expression domains for various EFTFs and lead to ectopic eye 
phenotypes. The ASPN induced phenotypes are very reminiscent of the IGF induced 
eye phenotypes described by Pera et al. (2001) and Richard-Parpaillon et al. (2002), 
which raised the possibility of ASPN – an extracellular protein – conveying at least 
some of its eye inducing effects through the IGF signalling pathway. 
 
However, there are also some differences. Pera and colleagues (2001) observed a 
drastic expansion of cement gland tissue upon overexpression of IGF1 and IGF2 in 
the embryos, and also Richard-Parpaillon et al. (2002) found ectopic cement glands 
when IGF1 was overexpressed in ventral animal blastomeres. While there was some 
induction of cement gland marker XAG in injected animal cap transplants (Figure 
3.18, Q), no expanded or even ectopic cement glands could be observed in the whole 
embryos upon forced overexpression of ASPN (Figure 3.13, A’’, B’’, C’’).  
 
Richard-Parpaillon and colleagues observed ectopic eye like structures and 
hyperplasia of the anterior part of the neural tube, when IGF1 mRNA was injected 
into a dorsal animal blastomere (4-cell stage). The same is found following ASPN 
overexpression. However, in their study, forced expression of IGF1 in dorsal animal 
blastomeres resulted in a high number of embryos with severely truncated body 
phenotypes; a consequence of inhibited convergent-extension movements. While 
truncated embryos were also observed following ASPN overexpression, this 
phenotype was mainly observed when injections occurred in the ventral animal 
blastomeres (Figure 3.12). Richard-Parpaillon et al. (2002) observed expanded and 
ectopic Otx2 expression in the IGF1 injected side of the embryos. As previously 
described, in the ASPN overexpressing embryos no such ectopic Otx2 expression 
could be found (Figure 3.18, K, L). However in animal cap explants, ASPN was 
capable of inducing Otx2 expression (Figure 3.18, S). The comparison of IGF and 
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ASPN induced phenotypes suggests, that ASPN may transduce some of its actions 
through the IGF signalling pathway.  
 
 
3.5 Summary 
In this chapter, I show that the SLRP family member ASPN plays a role in early 
Xenopus eye development. It is expressed at the time and place of eye induction and 
has the ability to up-regulate the expression of eye field transcription factors Rx1 and 
Pax6, both in vivo and in vitro, at the expense of posterior neural markers. Forced 
overexpression of ASPN leads to the induction of ectopic tissue, which could be 
shown to have eye character, including eye specific cell types. While functionality of 
these induced ectopic eyes could not be confirmed due to technical challenges, 
ASPN certainly seems to play an important role in eye development.  
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4 CHAPTER 4: ASPN IS ESSENTIAL FOR 
EYE DEVELOPMENT AND UNIQUE 
AMONGST SLRPs 
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4.1 Introduction 
While gain-of-function experiments are easily carried out in Xenopus laevis, thanks 
to the very accessible, large and robust embryos, loss-of-function studies are trickier. 
Due to the allotetraploid genome of X.laevis, loss-of-function can only be achieved 
through manipulation of expression and transient loss-of-function, by using 
dominant-negative constructs, antisense RNA and morpholinos (antisense-
oligonucleotides). To address X.laevis’s allotetraploidy, two morpholinos can be co-
injected, each targeting one of the duplicated genes (allogenes). These may have 
slightly different sequences, but have a conserved function. True loss-of-function 
could not be accomplished until the use of the diploid relative Xenopus tropicalis 
(Harland and Grainger, 2011, Henry et al., 2008). 
 
Morpholinos are synthetic oligonucleotides, which are complementary to, and 
therefore target, specific sequences like the 5’UTR (5’ untranslated region) to 
prevent the initiation of mRNA translation. Morpholino antisense oligos (Gene 
Tools, 2016) bind complementary RNA and, depending on where they are targeted 
to, can block gene expression, modify RNA splicing or inhibit miRNA (micro RNA) 
activity. Morpholinos (MO) are short chains of typically 25 subunits, which each 
comprise of a nucleic acid base (i.e. A, C, G or T), a morpholine ring in the backbone 
(which replaces the ribose/deoxyribose) and a non-ionic phosphorodiamidate 
intersubunit linkage. MOs do not degrade the RNAs but act via an RNAse H-
independent steric blocking mechanism. Because of their high target specificity, 
MOs are supposedly free of any off-target expression modulation. To better 
understand ASPN’s role in early embryogenesis and eye development, I performed 
loss-of-function analysis by using morpholino oligonucleotides for ASPN, which is 
presented in this chapter. For this purpose morpholinos were designed, which block 
the translation initiation by targeting the 5’UTR sequence through the first 25 bases 
of the coding sequence.  
 
The family of SLRPs share a lot of functions such as the binding to collagen and 
members of the TGF-β and BMP family of proteins (Iozzo and Schaefer, 2015, Iozzo 
and Schaefer, 2010). It is thought that class I-III arose due to chromosomal 
duplication, which may account for functional redundancy. Probably the most 
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thoroughly researched SLRPs are ASPN’s fellow Class I members - Decorin and 
Biglycan. A lot of research had been carried out to find out more about their 
functions in cancer, angiogenesis and inflammation (Hsieh et al., 2014, Jarvinen and 
Prince, 2015, Neill et al., 2012, Sofeu Feugaing et al., 2013). A question posed itself 
as to whether ASPN is unique amongst SLRPs in its ability to induce the striking 
ectopic eye formation, or if it is a shared characteristic amongst this proteoglycan 
family? To investigate this further, I injected Xenopus Decorin, Lumican, Epiphycan 
and Chondroadherin mRNA into the developing embryos and analysed the 
phenotypes. The results are presented in the second half of this chapter. 
 
As previously mentioned, the frog Xenopus is a good model to investigate eye 
development due to both practical reasons and a vertebrate species wide conserved 
gene network, which governs eye development/induction. The hope is that results 
obtained in frog are mostly transferable to human. While testing the transferability 
hypothesis in a mammalian model was beyond the scope of this study, I did test the 
frog ASPN mRNA for eye inducing effects in Zebrafish embryos, which will be 
described at the end of this chapter. 
 
 
4.2 ASPN loss-of-function analysis 
Morpholino ASPN-MO1 was designed to target the translational inititation site of 
both ASPNa and ASPNb (Figure 4.1). To confirm the specificity of ASPN-MO1, 
another set of morpholinos termed ASPNa-MO2 and ASPNb-MO2 were designed to 
be co-injected to ensure the duplicated genes translation was thoroughly blocked 
(Figure 4.1). 
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Figure 4.1: Design and target regions of morpholino oligonucleotides against ASPN. 
The nucleotide sequences (black characters) around the start codon (in rectangle) of Xenopus 
ASPN are shown. In addition to ASPNa, which this study is based on, we found another 
genome sequence (probably due to the pseudotetraploidity), and termed it ASPNb. The 
sequences and target regions for morpholinos ASPN-MO1 (red), ASPNa-MO2 (blue) and 
ASPNb-MO2 (purple) are also displayed. 		
4.2.1 ASPN Morpholino induced Phenotype 
The ASPN morpholino (ASPN-MO1) was injected into one dorsal animal blastomere 
at 4-cell stage of the embryos, at concentrations of 10ng, 20ng and 40ng. The 
resulting phenotypes were analysed at developmental stage 42. As a control, I used a 
scramble morpholino, referred to as control-MO (sequence: 
CCTCTTACCTCAGTTACAATTTATA).  
 
The injected tadpoles displayed a variety of eye defects on the injected side, ranging 
from partly missing eye structures and very reduced sized eyes, to a complete lack of 
eye development (Figure 4.2, C, E). While on the un-injected side, the endogenous 
eye developed normally. The control-MO injected embryos showed no phenotype 
(Figure 4.2, A). Paraffin sectioning and H & E staining of injected tadpoles further 
confirmed that ASPN-MO1 injection inhibited eye development compared to the 
control-MO (Figure 4.2, B, D, F). The majority of tadpoles injected with ASPN-
MO1 that exhibited the small eye phenotype, had otherwise normal body length 
(Figure 4.2, H). The morpholino-induced small eyes exhibited – despite the overall 
size – normal retinal layering with RPE and lens. This suggests that ASPN may only 
be involved in the early stages of eye induction and may not play a role in later 
stages of retinal cell type specification. 
 
The phenotype distribution at concentrations of 10ng, 20ng and 40ng is shown in 
Figure 4.3 (A, B, C). Inhibition of eye development increased, with increasing 
amounts of ASPN-MO1 injected. At a concentration of 10ng, 75% of injected 
tadpoles showed no phenotype, 19.4% of tadpoles displayed a slightly reduced eye 
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size and 5.6% had a very small or missing eye. At twice the injected ASPN-MO1 
concentration (20ng, Figure 4.3, B) - only 1.8% of tadpoles remained completely 
unaffected, while the majority of injected tadpoles showed an extremely reduced eye 
size. At very high concentrations of 40 ng of ASPN-MO1, nearly all embryos 
showed severe eye phenotypes, with 89.4% of injected embryos showcasing the very 
small eye phenotype and 9% missing eyes (Figure 4.3, A-C). At 10 ng of ASPN-
MO1 the overall embryo body length and shape was not affected, while 22% of 
embryos injected with 20 ng ASPN-MO1, and 79% of embryos injected with 40 ng 
of ASPN-MO1, had severely truncated body shape (Figure 4.4). 
 
 
Figure 4.2: The ASPN-MO1 induced eye phenotype. (A) Shown are a control-MO 
injected tadpole with normal eyes, (C) a tadpole injected with 20ng of ASPN-MO1 with a 
reduced eye size on the injected side and (E) an embryo injected with 40ng of ASPN-MO1 
with no eye on the injected side and severely truncated body. H & H stained paraffin 
sections of these embryos (B, D, F respectively) further confirmed the disrupted eye 
development. The majority of embryos displaying a ‘small-eye’ phenotype, showed normal 
body length (H) compared to control (G). 
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Figure 4.3: Eye phenotypes found, following ASPN-MO1 injections at different 
concentrations. Shown are the phenotype distributions amongst tadpoles injected with 10ng 
(A; n=36), 20ng (B; n=55) or 40ng (C; n=47) of ASPN-MO1 into one dorsal animal 
blastomere at the 4-cell stage. Embryos were analysed at stage 42.  
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Figure 4.4: High doses of ASPN MO1 lead to embryos with shortened bodies. While 
embryos were unaffected at injections of 10 ng ASPN-MO1 (n=36), at higher concentrations 
of 20 ng (n=55) or 40 ng (n=47) of ASPN-MO1 increasing numbers of embryos with the 
‘small-eye’ phenotype also displayed a severe truncation of their anterior-posterior body 
axis. 
 
 
4.2.2 The ASPN-MO1 phenotype can be rescued 
To confirm the specificity of ASPN-MO1 and show that the phenotype was not due 
to off-target effects, a rescue experiment was performed. For this experimental set-up 
mRNA, which is immune to the morpholino’s effect, is used to ‘rescue’ the MO-
induced phenotype. The eye defects induced by ASPN-MO1 could be rescued by co-
injection of ASPN mRNA containing only the coding region (ASPNCDR), further 
verifying the specificity of ASPN-MO1 (Figure 4.5). 20 ng of ASPN-MO1 was co-
injected with either 1 ng or 3 ng of ASPNCDR mRNA and the resulting phenotypes 
analysed. With increasing ASPNCDR concentration, the frequency of ASPN-MO1 
related phenotypes (small eye, missing eye) decreased, while ASPN overexpression 
related phenotypes (enlarged and ectopic eyes) increased (Figure 4.5, D). 
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Figure 4.5: ASPN-MO1 effects can be rescued by addition of ASPN mRNA. (A-C) 
Representative images from the injection of control-MO (A; n=59), ASPN-MO1 (B, n=55) 
and ASPN-MO1 together with the coding region of ASPN (ASPNCDR) mRNA (C). (D) 
Quantification of the phenotypes. For the rescue experiment, embryos were injected with 
either 20 ng ASPN-MO1 and 1 ng ASPNCDR (n=42), or 20 ng ASPN-MO1 and 3 ng 
ASPNCDR (n=47), and the phenotypes analysed at stage 41.  
 
 
4.2.3 ASPN-MO2 confirms specificity 
To further verify the specificity of ASPN-MO1, another set of ASPN morpholinos, 
termed ASPNa-MO2 and ASPNb-MO2 (Figure 4.1) was injected. To address the 
allotetrapleudity of Xenopus laevis, these two ASPN-MO2s were co-injected into the 
embryos, each targeting one of the duplicated genes (i.e. the allogenes). The ASPN-
MO2s were further designed to target different areas of the mRNA compared to 
ASPN-MO1 (Figure 4.1). 
 
ASPNa-MO2 and ASPNb-MO2 (referred to as ASPN-MO2) were co-injected into 
one animal blastomere of a 4-cell embryo at concentration of 10ng each, and the 
phenotype analysed at stage 42. ASPN-MO2 induced a very similar phenotype 
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compared to ASPN-MO1 injected embryos, such as inhibited eye development 
(Figure 4.6, B, C), but with overall less efficacy (Figure 4.6, D; Figure 4.3, B). 
Again, the phenotype induced by ASPN-MO2 could be rescued through co-injection 
of ASPNCDR  as shown in Figure 4.7. 
 
 
Figure 4.6: Eye phenotype observed following ASPN-MO2. (A-C) Representative images 
of an embryo injected with control-MO (A) or 20ng of ASPN-MO2 (10ng ASPNa-MO2 and 
10ng ASPNb-MO2) (B, C). Following the injections of 20ng of ASPN-MO2, 28% of 
embryos developed a small eye on the injected side (D) (n=78). 
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Figure 4.7: Effects of ASPN-MO2 can be rescued with co-injection of ASPN mRNA. (A-
C) Representative images from the injection of 20ng control-MO (A, n=62), 20ng ASPN-
MO2 (B, n=78) and 20ng ASPN-MO2 together with 1ng of the coding region of ASPN 
(ASPNCDR) mRNA (C). (D) Quantification of the phenotypes. For the rescue experiment 
embryos were injected with either 20ng ASPN-MO2 and 1ng ASPNCDR (n=87) or 20ng 
ASPN-MO2 and 3ng ASPNCDR (n=47), and the phenotypes analysed at stage 42. 
 
 
4.2.4 ASPN-MO1 changes expression of EFTFs 
As I had determined that ASPN mRNA injection affects the expression of several 
eye field transcription factors (Chapter 3), I wanted to examine if the same holds true 
for ASPN-MO. So to describe the phenotype induced by ASPN-MO on a molecular 
level, I performed in situ hybridisation with probes for eye and other regional genes. 
For this either ASPN-MO1 or control-MO was injected (alongside β -gal tracing 
mRNA) into an animal blastomere at 4-cell stage and the expression patterns 
analysed at developmental stages 18 and 22. 
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ASPN-MO1 significantly affected the expression of the early eye-field transcription 
factors Rx (80%, n=10; Figure 4.8, B) and Pax6 (89%, n=11; Figure 4.8, F), while 
Otx2, En2 and Krox20 were unaffected at neurula stages (n=20 each; Figure 4.8, J, 
N, R). This tendency was maintained at early tailbud stages (stage 22) on the injected 
side of the embryos, as shown by the reduced expression of the second-stage eye-
field transcription factors Six3 (67%, n=12; Figure 4.8, D) and Optx2/Six6 (56%, 
n=16; Figure 4.8, H) (Zuber et al., 2003), while other regional markers remained 
unaffected (n=20 each; Figure 4.8, L, P, T). In all cases, the control-MO injected 
embryos were completely unaffected and showed normal expression patterns (n=10 
each; Figure 4.8, A, C, E, G, I, K, M, O, Q, S). These results suggest that ASPN is 
required for eye-field specification and eye development. 
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Figure 4.8: ASPN-MO1 affects the expression of EFTFs. Either control-MO (A, C, E, G, 
I, K, M, O, Q, S) or ASPN-MO (B, D, F, H, J, L, N, P, R, T) was injected together with β-
Galactosidase mRNA as a tracer (light blue product) and embryos were analysed at stage 18 
(A, B, E, F, I, J, M, N, Q, R) or stage 22 (C, D, G, H, K, L, O, P, S, T) by in situ 
hybridization with the probes of Rx (A, B), Six3 (C, D), Pax6 (E, F), Six6 (G, H), Otx2 (I-
L), En2 (M-P) and Krox20 (Q-T). Arrowheads in B, F, D and H indicate affected areas.  
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4.2.5 ASPN and Chordin relationship 
As shown earlier in Chapter 3 (Figure 3.3, B), animal caps injected with neural 
inducer Chordin showed elevated ASPN levels in vitro. As a further attempt to 
unveil the relationship between Chordin and ASPN, animal caps injected with 
Chordin (Sasai et al., 1994) were prepared, which showed the expected elevation in 
forebrain and eye gene Rx2a and Pax6 expression (Figure 4.9 (ii)). In contrast, when 
ASPN-MO1 was co-injected with Chordin mRNA, the expression of these early eye 
marker genes was significantly down-regulated (Figure 4.9 (iii)), suggesting that 
ASPN acts downstream of the neural inducer Chordin. ASPN seems to be required 
for eye development, especially during the initial stages of the entire developmental 
process. 
 
 
Figure 4.9: ASPN is essential for the induction of EFTFs by Chordin (Chd). Animal 
caps of control (i; black bars), Chd-injected (ii; blue bars) and Chd+ASPN-MO-injected (iii; 
red bars) embryos were prepared and the animal caps were analysed at stage 22 by qRT-PCR 
(*P<0.01; Student’s t-test). Error bars represent s.e.m. 
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4.3 The ASPN induced eye phenotype is unique amongst SLRP 
members 
To find out whether ASPN’s ability to induce ectopic eyes is unique amongst the 
SLRP family of proteins, I overexpressed a selection of SLRPs and examined them 
with respect to eye forming activities.  Representative proteoglycans from each of the 
first four SLRP classes were chosen: Decorin (class I), Lumican (class II), Epiphycan 
(class III) and Chondroadherin (class IV). 
 
The mRNAs of these four SLRPs were then injected at a concentration of 3ng into a 
dorsal animal blastomere of a 4-cell embryo and the resulting phenotypes categorised 
at stage 42. In Figure 4.10 the phenotype distribution can be seen. We know that 
ASPN has the ability to induce ectopic eyes. This ability is not shared with the other 
tested SLRPs. Neither Decorin nor Chondroadherin overexpression induced an eye 
phenotype, but instead strongly truncated embryos. Lumican overexpression and 
Epiphycan overexpression lead to mild extension or enlargement of the endogenous 
eye (Figure 4.10).  
 
 
Figure 4.10: ASPN’s ability to induce ectopic eyes is unique amongst SLRPs. The 
mRNA of SLRP family members ASPN, Lumican, Decorin, Epiphycan and Chondroadherin 
were injected at 3ng into a dorsal animal blastomere at the 4-cell stage and the phenotypes 
analysed at stage 42. Only ASPN overexpression resulted in embryos with ectopic eyes.  
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When 3ng of X. laevis Lumican was injected in a dorsal animal blastomere at 4-cell 
stage, some embryos developed a mild eye phenotype, which is shown in more detail 
in Figure 4.11. The endogenous eye on the injected side was enlarged, with either 
little wisps of retinal tissue extending away from the eye (Figure 4.11, A, C, D) or 
little spheres of retinal tissue developed adjacent to the eye (Figure 4.11, B). When 
the affected embryos were paraffin sectioned, the retina-like histology of the ectopic 
tissue confirmed eye character (Figure 4.11, E, H). Of course, to have certainty about 
what type of retinal cells are present in the Lumican-induced tissue, further 
immunohistochemical analysis would have to be carried out. The retina of the 
endogenous eye on the injected side of the embryo was sometimes found to show 
irregularities in layering, as seen in Figure 4.11, F. The neural tube section of a 
Lumican injected embryo, shown in Figure 4.11, G, also shows signs of hyperplasia 
and abnormal structure, which is reminiscent of the effect ASPN has on neural tube 
development. 
 
 
Figure 4.11: Lumican induces a mild eye phenotype. When 3ng of Lumican mRNA was 
injected into a dorsal animal blastomere at the 4-cell stage, some embryos exhibited an eye 
phenotype where retina was expanded or small spheres of ectopic retina developed adjacent 
to the endogenous eye (A-D). The retinal character of the extra tissue was confirmed in 
paraffin-sectioned samples (E, H). Endogenous retina on the injected side also appeared 
irregular (F). In some embryos, the neural tube had an abnormal structure (G). 
 
 
In Figure 4.12 the overexpression phenotypes, following the injection of 3ng 
Epiphycan, 3ng Decorin and 3ng Chondroadherin, are characterised. Epiphycan 
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induces a very subtle enlargement of the endogenous eye on the injected side (Figure 
4.12, B, C) in about a quarter of all injected embryos (Figure 4.10). No ectopic eye 
tissue was found in the Epiphycan injected embryos. The overall body length and 
shape was also not affected. No abnormalities were observed in the layering and 
morphology of both the embryo’s neural tube or retina (Figure 4.12, D). When 3ng 
of Decorin was overexpressed in the animal blastomere of the frog embryos - 86% of 
embryos showed a shortened body, and were overall smaller in size, than un-injected 
controls (Figure 4.10; Figure 4.12, E). No eye related phenotype could be observed. 
Furthermore, the structure of the neural tube also seemed unaffected by Decorin 
overexpression (Figure 4.12, F). The overexpression of 3ng Chondroadherin resulted 
in 82% of embryos having severely truncated and twisted bodies (Figure 4.10; Figure 
4.12, G, H). No ectopic eye tissue or eye enlargement could be observed in these 
embryos. 
 
 
Figure 4.12: Overexpression phenotype of Epiphycan, Decorin and Chondroadherin. 3 
ng of Epiphycan (A-D), Decorin (E, F) and Chondroadherin (G, H) was injected into a dorsal 
animal blastomere of the 4-cell embryo, and the phenotype categorised at stage 42.  
Epiphycan overexpression sometimes induced a very subtle enlargement of the endogenous 
eye on the injected side (B, C). Decorin overexpression did not result in eye phenotypes, but 
in overall shortened embryo bodies (E, F). Overexpression of Chondroadherin led to 
severely truncated and malformed embryos (G, H). 
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ASPN’s striking eye phenotype is mediated through the IGF signalling pathway, as 
will be shown in Chapter 5. I was interested to see whether fellow class I SLRP 
Decorin shares this ability to activate the IGF downstream signalling. Moreover, the 
question posed itself whether class II SLRP Lumican induces its mild eye phenotype 
– like ASPN – through the IGF signalling pathway. For this, HEK 293 cells were 
transfected with ASPN-myc, Lumican-myc or Decorin-myc constructs, and the 
conditioned expression media applied to another set of HEK 293 cells for 20 
minutes. Western blotting analysis was then performed with antibodies for 
phosphorylated ERK (p-ERK), ERK, phosphorylated AKT (p-AKT) and AKT 
(Figure 4.13, D). Based on these results, it seems that Decorin does not activate ERK 
or AKT phosphorylation. Lumican seems to induce AKT phosphorylation and, 
potentially to a much lesser extent, ERK phosphorylation. Since ASPN seems to 
activate ERK more strongly than Lumican, it could be assumed that p-ERK plays a 
more important role for ASPN’s eye inducing effects, while p-AKT may play a more 
minor role. AKT and ERK signalling have both been previously shown to be 
important for eye development (Bugner et al., 2011, Li et al., 2013, Wu et al., 2006). 
 
 
Figure 4.13: Characterisation of Lumican and Decorin. (A-C) Representative images of 
the embryos injected with 3ng ASPN (A), 3ng Lumican (B) and 3ng Decorin (C) mRNAs. 
(D) Differential activation of ERK and AKT by SLRP proteins. Control (i), ASPN-myc (ii), 
Lumican-myc (iii) or Decorin-myc (iv) expression media were prepared and applied onto 
HEK293 cells. 
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4.4 ASPN overexpression in Zebrafish 
ASPN is an important factor in early eye development and it seems to be unique 
amongst SLRPs in its ability to induce large ectopic eyes in Xenopus laevis. But the 
question remains, whether ASPN fulfils the same role in other vertebrate species. 
Amphibians, such as the African clawed frog Xenopus, have some unique features 
that are not shared by other vertebrate classes, such as the ability to regenerate 
various body parts, including the eye, following injury (Vergara and Del Rio-Tsonis, 
2009, Lee et al., 2013). So the ability to grow extra eyes may be a Xenopus specific 
trait. In fact, ectopic eyes and ectopic lenses in Zebrafish embryos have very rarely 
been reported (Cavodeassi et al., 2005, Kondoh et al., 2000), compared to those in 
Xenopus (Andreazzoli et al., 1999, Bernier et al., 2000, Chow et al., 1999b, Masse et 
al., 2007, Mathers et al., 1997a, Pai et al., 2012, Rasmussen et al., 2001, Zuber et al., 
1999). To illustrate: while shown to play an important role in Zebrafish head and eye 
development, IGF overexpression did not result in an ectopic eye phenotype in the 
fish embryos (as found in frog). However, the gene network, which regulates early 
eye induction is known to be highly conserved amongst vertebrates. Unfortunately, 
testing ASPN on a mammalian model was beyond the scope of this current study. So 
in a first attempt to investigate the role of ASPN in another class or vertebrates, I 
analysed the effect of X. laevis mRNA on Zebrafish embryo development.  
 
100pg, 200pg or 300pg of X. laevis ASPN mRNA was injected into Zebrafish 
embryos at 1-cell stage and the phenotypes then analysed 72 hours post fertilisation 
(hpf). At 100pg, ASPN injected fish embryos appeared largely unaffected, with 
around 94% of embryos showing no phenotype and 4.6% of embryos displayed an 
overall shortened body (Figure 4.14, C, D, E). Extraordinarily, one embryo was 
found to have developed, what appears to be a third eye in the middle of its head 
(Figure 4.14, A, B). Unfortunately, due to time constraints, it was not possible to 
investigate the potential eye character any further. 
 
At 200pg of ASPN mRNA, half of the injected Zebrafish embryos showed various 
developmental defects, such as an overall shortened body and several eye 
malformations (Figure 4.15, D). Nearly a third of injected embryos displayed 
cyclopia with a single eye in the middle of their head (Figure 4.15, A, A’, D). 
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Smaller proportions of embryos showed diminished eye size (Figure 4.15, B, B’, D) 
or fused retinas (Figure 4.15, C, C’, D). At the highest concentration tested (300pg 
ASPN mRNA), embryos increasingly showed a shortened body phenotype, with 
either cyclopia, small eyes or no eyes (Figure 4.16, A-E). 
 
 
 
Figure 4.14: Phenotype in Zebrafish after injection of 100pg ASPN mRNA. Zebrafish 
embryos were injected with 100pg of Xenopus ASPN mRNA at the 1-cell stage and the 
phenotype analysed 72 hours post fertilisation. While the majority of embryos seemed 
unaffected by the injection (E), around 5 % had a truncated body often with reduced head 
size (C, D). Very rarely an embryo developed with what looked like a third eye located in 
the centre of the forehead (A, B, E) (n=66). 
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Figure 4.15: Phenotype in Zebrafish after injection of 200pg ASPN mRNA. Zebrafish 
embryos were injected with 200pg of Xenopus ASPN mRNA at the 1-cell stage and the 
phenotype analysed 72 hours post fertilisation. Half of the injected embryos exhibited a 
phenotype following injection (D). These ranged from cyclopia (A, A’), to decreased eye 
size (B, B’) and fused retinas (C, C’) (n=28). 	
 
 
Figure 4.16: Phenotype in Zebrafish after injection of 300pg ASPN mRNA. Zebrafish 
embryos were injected with 300pg of Xenopus ASPN mRNA at the 1-cell stage and the 
phenotype analysed 72 hours post fertilisation. Nearly half of the embryos injected exhibited 
a phenotype (E). A high proportion showed cyclopia (C, D), with other embryos showing 
reduced eye size (B) compared to control (A) (n=30). 	
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4.5 Discussion 
4.5.1 ASPN is an important factor in Xenopus eye development 
Following the gain-of-function study (Chapter 3), which indicated a role for ASPN in 
early eye development, I now wanted to test this hypothesis from a different angle. 
Through a transient loss-of-function, by use of specific morpholinos, I wanted to 
analyse what happens in eye development when ASPN is not present. 
 
In keeping with the earlier overexpression experiment, the transient loss of ASPN 
activity through morpholinos ASPN-MO1 and ASPN-MO2 induced disrupted eye 
development in the injected embryos. The affected eyes were strongly diminished in 
size or even completely absent, as can be seen in the paraffin section where no eye 
rudiments are present (Figure 4.2, E, F; Figure 4.6). As expected from the 
aforementioned phenotype, ASPN-MO1 injections resulted in a down regulation of 
the eye specific genes Rx1 and Pax6 at stage 18. Second stage EFTFs - Six3 and 
Six6 - can also be seen to be down regulated on the morpholino injected side of the 
embryos at stage 22 (Figure 4.8).  
 
While widely used in frog and Zebrafish, the reliability of morpholino-induced 
phenotypes has recently come under scrutiny (Eisen and Smith, 2008, Kok et al., 
2015, Stainier et al., 2015) and many researchers have started to question the 
reliability of morpholino oligos as a loss-of-function system. Antisense strategies 
normally lead to some off-target effects. These can make it very difficult to assess 
whether the resulting phenotype is due to gene knockdown or these off-target effects. 
It is therefore extremely important to use proper controls to try and prove the 
specificity of the morpholino (Eisen and Smith, 2008). Morpholino oligos are still 
widely used in the Xenopus research community as a reasonable gene knockdown 
(gene function interfering) system, where genetic methods (such as gene knockout) 
have not yet been established as a common method. The recently developed 
CRISPR/Cas9 system may provide a powerful tool for achieving loss-of-function in 
the future (Ma et al., 2014, Wang et al., 2015). But as long as materials are 
overexpressed in the embryos, off-target problems cannot be completely resolved, 
whichever other methods we may use. 
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Nevertheless, there is an obvious need to ensure the specificity of the morpholinos 
used in this study. Therefore, as well as ASPN-MO1, an additional set of morpholino 
oligos was designed, which target independent areas of the ASPN mRNA (Figure 
4.1), and it was confirmed they provided essentially the same phenotypes (i.e. the 
disruption of frog eye formation). Designing the second morpholino oligos 
necessitated us to isolate ASPN-b, the allogene of ASPN-a. The cDNA sequence of 
ASPN-b has been registered in GenBank (LC056842). 
 
The two different ASPN morphlinos (ASPN-MO1 and ASPN-MO2) were shown to 
induce the same type of eye phenotype, albeit with different efficacies. To further 
validate their specificity, rescue experiments were carried out. These experiments are 
generally accepted as one of the means to show morpholino specificity (Eisen and 
Smith, 2008). For this experimental set up the morpholino phenotype is “rescued” by 
adding back mRNA, which is immune to the morpholino. This immunity was 
achieved by using ASPN mRNA, which only contained the coding region (and not 
the translational start site). For both ASPN-MO1 and ASPN-MO2 the rescue 
experiments showed that the induced phenotype can be rescued by co-injection of the 
ASPN mRNA (Figure 4.5; Figure 4.7). 
To further verify morpholino activity, the reduced levels of the protein of interest 
should also be shown via Western Blotting. Unfortunately we could not find any 
commercially available antibodies, which gave a signal for Xenopus ASPN. While 
not ideal, by using two different morpholinos whose very similar phenotypes can be 
rescued by adding ASPN mRNA, I have hopefully convincingly proven the 
specificity of the morpholinos’ actions. 
 
Another interesting aspect is ASPN’s relationship with the neural inducer Chordin. 
As shown in Chapter 3, Chordin injected in animal cap leads to increased levels of 
ASPN. When ASPN-MO1 was co-injected with Chordin, the expression levels of 
EFTFs Rx1 and Pax6 were down regulated compared to the strong induction 
observed upon Chordin injection (Figure 4.9). This might suggest that ASPN acts 
downstream of Chordin, but upstream of the EFTFs. When ASPN is transiently 
inhibited by ASPN-MO1 in the developing embryo, the EFTFs (at least Rx1 and 
Pax6) are not induced, which leads to disturbed eye development. In summary, 
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ASPN is required for frog eye formation, especially in the early stages of eye 
development. 
 
4.5.2 ASPN’s ability to induce ectopic eyes is unique amongst other SLRP 
family members 
Class I ASPN, Decorin and Biglycan share similarities in terms of structure and 
amino acid sequences (Chapter 3, Figure 3.1). Whilst they also share certain 
properties that are mediated via their core proteins, such as the ability to bind to 
collagen, TGF-β and BMP family members, their biochemical characteristics differ 
from each other. Different binding affinities and binding partners result in a 
functional diversity (Kou et al., 2010). ASPN can bind type 1 collagen and competes 
with Decorin (but not Biglycan) for the collagen-binding site (Kalamajski et al., 
2009). Furthermore, ASPN has been shown to bind directly to TGF-β and BMP-2 
and inhibits them from binding to their respective receptors (Yamada et al., 2007, 
Nakajima et al., 2007, Tomoeda et al., 2008). Decorin interacts with the TGFβ1 and 
EGF receptors and either enhances or diminishes their signal intensities (Iozzo and 
Schaefer, 2010). Likewise, Biglycan binds to BMP4 and regulates early 
embryogenesis or osteoblast differentiation (Moreno et al., 2005a, Chen et al., 2004). 
This diversity is also reflected in the embryonic activities of each protein. The 
ASPN-induced strong eye phenotype could not be found when injecting other class I 
SLRPs in Xenopus embryos (Figure 4.10) (Kalamajski et al., 2009, Kizawa et al., 
2005). SLRP members of other classes also did not elicit the ectopic eye phenotype 
when they were overexpressed – the exceptions being the class II SLRP Lumican and 
class III SLRP Epiphycan, which occasionally induced a subtle eye phenotype 
(Figure 4.11, Figure 4.12) (Kuriyama et al., 2006).  
 
Due to the known importance of IGF signalling in the development of the anterior 
head and eye structures, as well as similarity in overexpression phenotype (Pera et 
al., 2001, Richard-Parpaillon et al., 2002), it was likely that ASPN elicits its effect 
through IGF signalling pathway (as indeed I will prove in Chapter 5). IGF is known 
to induce ERK and AKT phosphorylation in vitro. None of the SLRPs tested induced 
the ectopic eye phenotype observed upon ASPN overexpression. This is consistent 
with the fact that the levels of ERK and AKT activation by Lumican and Decorin are 
different (Figure 4.13, D). Therefore, each SLRP seems to have its own unique 
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functions and is not redundant with others. This demonstrates, that ASPN is unique 
amongst SLRPs in its role during frog eye development. 
 
4.5.3 ASPN may play a role in Zebrafish eye development 
The family of SLRPs seems to be conserved across vertebrate species, with ASPN 
orthologues identified in several species (Chapter 3, Figure 3.1, B). From an 
evolutionary point of view, the Zebrafish Danio rerio is the furthest relative to 
mammals. A close evolutionary ASPN orthologue to Zebrafish is the Xenopus 
version. The Zebrafish is a very popular model organism. Much like the frog, they 
are easy to keep and embryos are easily harvested and used for injections of mRNA 
or morpholinos (Chhetri et al., 2014, Glass and Dahm, 2004).  
 
Since the techniques used in Zebrafish are very similar to those employed in Xenopus 
work, it seemed like a straightforward approach to test the effects of ASPN during 
early development in this vertebrate organism. For the injections, I used Xenopus 
ASPN mRNA, which may not be ideal. However, as previously mentioned, studies, 
which investigated the conserved function of Pax6 amongst vertebrate species 
initially used the Pax6 homologues of other species (e.g. ribbonworm and squid), and 
overexpressed them in Drosophila to assess their function (Glardon et al., 1997, 
Loosli et al., 1996, Tomarev et al., 1997). Also, the mRNA was injected into the fish 
embryos at the one cell stage, which results in a global up-regulated expression of 
ASPN, as opposed to the more targeted approach in frog. 
 
At the lowest concentration tested of 100pg, one of the embryos displayed what 
looked like an ectopic third eye (Figure 4.14, A, B). In published literature ectopic 
eyes in Zebrafish embryos (Cavodeassi et al., 2005) or ectopic lenses (Kondoh et al., 
2000) are rarely reported, compared to those in Xenopus (Andreazzoli et al., 1999, 
Bernier et al., 2000, Chow et al., 1999b, Masse et al., 2007, Mathers et al., 1997a, Pai 
et al., 2012, Rasmussen et al., 2001, Zuber et al., 1999). However, the Zebrafish 
embryo is very sensitive to injected material – a reason why it is increasingly used 
for toxicity testing (McCollum et al., 2011). Too much injected material can quickly 
lead to general toxicity in the embryos. This makes it often difficult to discern 
between specific phenotypes induced by the the material injected (e.g. mRNA or 
morpholino) and those induced by general toxicity (Rosen et al., 2009).  
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It is possible that ASPN plays a role in Zebrafish eye development. As will be shown 
in detail in Chapter 5, ASPN elicits its effect through the IGF signalling pathway. 
IGF signalling has also been shown to play an important role in Zebrafish 
development. A DN-IGF1R causes loss of head and eyes, as well as an absence of 
the notochord. Overexpressing IGF1 dorsalises the Zebrafish embryos with an 
expansion of the forebrain and a reduction of trunk and tail. In severe cases the 
embryos exhibited a complete lack of posterior and ventral tissues (Eivers et al., 
2004). Regarding IGF overexpression, the Zebrafish phenotype is therefore very 
similar to that found in Xenopus, (Pera et al., 2001, Richard-Parpaillon et al., 2002).  
 
Intended as a preliminary screen, I am aware that much more work needs to be 
carried out to say with certainty whether ASPN fulfils the same role in Zebrafish as it 
does in frog eye development. But it is a first step to showing a potentially conserved 
role for ASPN across other vertebrate species and is worth investigating further. To 
take this research forward, the endogenous Zebrafish ASPN should be used and 
overexpression analysis carried out on a larger number of embryos, with an 
optimisation of mRNA concentrations to exclude off-target effects. Again, the 
possible effects on eye field transcription factors in fish could be assessed using 
whole mount in situ hybridisation techniques. For loss-of-function studies, the 
CRISPR technique could possibly be employed, which has been shown to work well 
in Zebrafish (preferable to morpholino use, due to the range of off-target side effects 
that can occur).   
 
4.6 Summary 
Results presented in this chapter showed that ASPN is an essential factor in Xenopus 
eye development. The knockdown of ASPN by means of morpholino injections 
inhibited the expression of eye specific genes and resulted in a small eye or complete 
loss of eye development. Furthermore, ASPN appears to be unique amongst other 
SLRPs in its ability to induce the striking eye phenotype. Lastly, a first attempt was 
made to show a potentially conserved role of ASPN in eye development in Zebrafish 
Danio rerio. 
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5 CHAPTER 5 – ASPN ACTS THROUGH 
THE IGF PATHWAY AND INTERACTS 
WITH OTHER MAJOR SIGNALLING 
MOLECULES  
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5.1 Introduction 
The studies by Pera et al. (2001) and Richard-Parpaillon et al. (2002) demonstrated 
the importance of IGF signalling in head and neural development. Their IGF gain-of-
function experiments showed expanded and ectopic expression domains of several 
EFTFs such as Otx2, Pax6 and Six3, which suggests that IGF signalling modulates 
the expression of EFTFs and thereby contributes to eye induction. The ASPN 
induced ectopic eyes observed in this study were strongly reminiscent of the IGF 
induced phenotypes in Xenopus (Pera et al., 2001, Richard-Parpaillon et al., 2002). 
As previously discussed, while very similar, the IGF and ASPN induced phenotypes 
are not identical. For example IGF overexpression leads to an expansion of Otx2 
expression domain in the early embryo, as well as an expansion of the cement gland 
– the embryo’s most anterior structure. Neither of these features could be found upon 
ASPN overexpression (see Chapter 3). Nevertheless, similarities were great enough 
for me to hypothesise that at least some of ASPN’s effects are mediated through the 
IGF signalling system. In addition, previous studies showed that fellow class I SLRP 
Decorin can bind to, and activate, the IGF1R (Schaefer et al., 2007, Schonherr et al., 
2005). Decorin seems to regulate cell death and synthesis of matrix components, by 
acting as a signalling molecule for the IGF signalling system in epithelial and renal 
cells (Reed et al., 2005, Santra et al., 2002). Receptor tyrosine kinases, such as 
IGF1R and FGFR, play central roles in eye development. Signalling through the 
IGF1R receptor can lead to the activation of the two downstream signalling cascades 
Ras/MAPK and PI3/AKT, which have previously been shown to be important in 
correct eye formation (Bugner et al., 2011, La Torre et al., 2015, Wu et al., 2006). 
 
With this in mind, I started to investigate how ASPN is associated with the IGF 
signalling pathway, and the results are presented in this chapter. In the first instance, 
I show that ASPN can induce IGF mediated AKT and ERK phosphorylation in an in 
vitro system. By means of co-immunoprecipitation, I also show that ASPN associates 
with the IGF1R and forms a complex. Furthermore, I attempted to elucidate the 
relationship of ASPN and IGF signals in the context of eye development. Finally, an 
attempt was made to explain the necessary spatial and temporal selectivity of 
ASPN/IGF signals, which must contribute to the correct placement of the eye. 
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Many other signalling pathways are known to play a role in early eye development. 
BMP and Wnt signals need to be inhibited in the anterior neural plate for the eye 
field to be able to develop. As part of their study, Richard-Parpaillon et al. (2002) 
found that IGF1 inhibits Wnt-signalling and affects Wnt target genes - Siamois, Xnr-
1, Wnt-8 and β -catenin. Naturally ASPN’s relationship with other major signalling 
pathways, such as the Nodal, BMP and Wnt pathways, needed to be investigated. 
SLRPs, including ASPN, are known to interact with TGF- β family members and 
also BMP molecules. So in the second half of this chapter I will present my results 
regarding ASPN’s relationship with molecules of the Wnt, BMP and Nodal 
signalling pathways. By analysing ASPN’s effect on these signalling pathways on a 
molecular level - by means of reporter assay, qRT-PCR analysis, Western Blot and 
co-immunopreciptiation - I will present evidence that ASPN binds to and inhibits 
Wnt, BMP and Nodal signalling.  
 
 
5.2 ASPN induces eye development via the IGF receptor mediated 
signalling pathway 
As mentioned previously, due to the similarity in phenotypes induced by ASPN and 
IGF overexpression, as well as the prominent role of the IGF signalling pathway in 
eye development (Pera et al., 2001, Richard-Parpaillon et al., 2002), we hypothesised 
that ASPN may elicit its effects, at least in parts, through the IGF signalling pathway. 
To investigate this theory, I first wanted to find out whether ASPN can activate the 
same signalling pathway as IGF.  
 
5.2.1 ASPN activates the IGF downstream signalling pathway 
IGF has been shown to induce phosphorylation of ERK and AKT both in cultured 
cells and in animal cap explants (Wu et al., 2006, Rorick et al., 2007). Therefore, it 
was examined whether ASPN activates the same intracellular signalling molecules.  
This was done in an in vitro experimental setting using the cell line HEK 293 – a 
human embryonic kidney cell line. HEK 293 is widely used and popular as a 
transient expression system, due to its easily transfectable nature and effectiveness at 
producing the gene products of the artificially incorporated expression constructs 
(Lin et al., 2014, Thomas and Smart, 2005).  Initially, to ensure that the transfection 
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technique was working, a YFP containing construct (pCS2+ YFP) was transfected 
into HEK 293 cells. The successfully transfected cells, which consequently started to 
fluoresce in green, were imaged and are shown in Figure 5.1. The transfection 
efficiency was determined to be around 70-80%.  
 
 
Figure 5.1: Transfection of HEK293 cells with pCS2+ YFP after 24hrs incubation.  
Bright field image of transfected HEK293 cells (A) and the successfully YFP transfected 
cells (B) under fluorescent light both at 10x magnification. (C) shows the same cell 
population in bright field and (D) under fluorescence at 20x magnification. Scale bars shown 
equal 100μm. 
 
 
For the actual experiment, HEK 293 cells were separately transfected with ASPN 
and IGF2. Following three days of culturing in Opti-MEM medium the resulting 
conditioned media (which contained secreted ASPN and IGF2) was then applied 
onto another set of HEK293 cells. The cells treated with either ASPN or IGF2 
activated the phosphorylation of AKT and ERK within 20 minutes of the treatment 
(Figure 5.2, lanes 2,3), suggesting that ASPN and IGF share the same downstream 
intracellular signalling pathways.  
 
However, the phosphorylation of ERK and AKT was only submaximal, presumably 
because the conditioned medium did not contain maximum levels of the proteins. 
The normalised up-regulation of the intensities of the phosphorylated ERK and AKT 
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in the ASPN-treated cells was 1.85 times for pERK and 4.27 times for pAKT. 
          
 
Figure 5.2: ASPN activates ERK and AKT. Conditioned media taken from control GFP 
(lane 1), ASPN (lane 2) or IGF2 (lane 3) expressing cells were applied to HEK293 cells for 
20 minutes. Western blotting analysis was performed with antibodies for phosphorylated 
ERK (p-ERK), ERK, phosphorylated AKT (p-AKT) and AKT. 
 
 
5.2.2 ASPN forms complex with IGF1R 
The next question was - does ASPN form a complex with the IGF1 receptor? To 
address this an immunoprecipitation assay was performed. For this purpose, HEK 
293 cells were co-transfected with plasmids encoding ASPN (which had a myc tag 
attached) and the IGF1-receptor (IGF1R), and cell lysates analysed 24 hours post-
transfection. The co-immunoprecipitation analysis was carried out using the Protein 
G sepharose system with the IGF1R antibody (Cell Signaling Technology, #9750), 
and the complexes detected with the myc antibody (Cell Signaling Technology, 
#2276) following SDS-PAGE (Figure 5.3). The results seem to indicate that ASPN 
does indeed establish a complex with the IGF1R. 
 
 
	 165	
 
Figure 5.3: ASPN forms a complex with IGF1R. HEK293 cells were transfected with 
expression vectors carrying IGF1R (lanes 1,2) and ASPN (lane 2) and co-
immunoprecipitation analysis was performed using the IGF1R antibody and detected with 
the myc-antibody. IB: immunoblotting. IP: immunoprecipitation. 
 
 
5.2.3 ASPN signals through IGF1R and both ASPN and IGF are required for 
signal transduction 
After showing that ASPN forms a complex with the IGF1R, the question remained 
whether ASPN actually activates and transduces its signal via the IGF1 receptor. To 
examine this, a dominant-negative version of the IGF1 receptor (dnIGF1R) (Pera et 
al., 2001) was injected, together with ASPN mRNA, into a dorsal blastomere of the 
4-cell embryo and the eye phenotype observed at tadpole stage (Figure 5.4, A, for 
control, n=20). Upon the injection of ASPN mRNA only the typical ectopic 
formation could be observed (Figure 5.4, B, 12%, n=112). In contrast, the combined 
injection of ASPN and dnIGFR mRNAs significantly decreased the size of the eyes 
on the injected side of the embryo (Figure 5.4, C, 22.6%, n=62). 
 
To further elucidate the relationship between ASPN and IGF, we conversely 
perturbed the function of ASPN with ASPN-MO1. As reported previously, IGF2 
injection caused enlarged eyes (Figure 5.4, D, 90%, n=22) (Pera et al., 2001). 
However, when ASPN-MO1 was co-injected alongside IGF2 mRNA, the expected 
eye enlargement was blocked (Figure 5.4, E, 91%, n=23). These results suggest that 
eye development in Xenopus embryos requires both ASPN and IGF signals. IGF2 
was used here rather than IGF1 following communication with Dr. Kuroda (co-
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author of the Pera et al. (2001) paper), who suggested that IGF2 had the strongest 
effect out of IGF1 - 3. 
 
 
Figure 5.4: Embryonic eye formation requires both ASPN and IGF signals. Embryos 
were injected with 3 ng β-Galactosidase mRNA (control: A), 1 ng ASPN mRNA (B), 1 ng 
ASPN + 3 ng dnIGF1R mRNAs (C), 1 ng IGF-2 mRNA + 20 ng control-MO (D) or 1 ng 
IGF-2 mRNA + 10 ng ASPN-MO1 (E) into the dorsal animal blastomere at the 4-cell stage, 
and phenotypes were evaluated at stage 42. Affected areas are indicated with yellow 
arrowheads. 
 
 
To further confirm the necessity of both ASPN and IGF activity in eye development, 
on a molecular level, an animal cap assay was performed. IGFs and IGF1R are 
widely expressed in the early Xenopus embryo and were therefore assumed to be 
present in the ectodermal tissue of the excised animal caps. ASPN and dnIGFR 
mRNAs, or IGF2 mRNA and ASPN-MO1, were co-injected and the expression of 
EFTFs Pax6 and Rx2a assayed through quantitative RT-PCR. Un-injected control 
animal caps showed no induction of either Pax6 or Rx2a expression (Figure 5.5A(i), 
B(iv)). As expected, ASPN and IGF2 mRNA injected separately were both capable 
of up-regulating Pax6 and Rx2a expression in the animal caps (Figure 5.5A(ii), 
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B(v)). The expression of both EFTF genes was however down-regulated when ASPN 
and IGF2 were co-injected with the inhibiting constructs dnIGF1R and ASPN-MO1, 
respectively (Figure 5.5A(iii), B(vi)). These results again underpin the concept that 
ASPN and IGF are both required for the early steps of eye development. Together, 
these data demonstrate that ASPN induces eye development by regulating the IGF 
signalling pathway through an association with the IGF1-receptor. 
 
 
Figure 5.5: ASPN and IGF signals are both required for the early steps of eye 
development. (A, B) Embryos were injected with 3 ng β-Galactosidase mRNA (control (i), 
(iv)), 1 ng ASPN mRNA (ii), 1 ng ASPN + 3 ng dnIGF1R mRNAs (iii), 1 ng IGF-2 mRNA 
+ 20 ng control-MO (iv) or 1 ng IGF-2 mRNA + 10 ng ASPN-MO1 (vi) into the dorsal 
animal blastomere at the 4-cell stage. Animal caps were prepared and analysed at stage 22 
for Pax6 and Rx2a expression with qRT-PCR (*P<0.01, Student’s t-test). Error bars 
represent s.e.m.   
 
 
Bugner and colleagues (Bugner et al., 2011) recently showed that IGF1R substrate 
IRS-1 plays an important role in Xenopus eye development. They showed that IRS-1 
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is specifically expressed in the anterior neural plate including the eye field, around 
the time of eye induction. In a recent publication by Gao et al. (2014), IGF1R was 
shown to be able to transcriptionally up-regulate IRS-2 levels. Some functional 
redundancy has been reported for IRS-1 and IRS-2 (Bugner et al., 2011), which 
made me curious whether ASPN-activated IGF1R can up-regulate IRS-1 
transcription in the animal cap explant. In a preliminary attempt to determine if the 
ASPN/IGF1R signal is transduced via IRS-1; I compared IRS-1 levels in un-injected 
and ASPN injected animal caps by means of semi-quantitative RT-PCR. The results 
were unfortunately inconclusive, as some ASPN injected animal cap samples showed 
an increase and others no elevation of IRS-1 levels (Figure 5.6). 
 
 
Figure 5.6: Attempt to elucidate ASPN’s downstream effects on IRS-1 expression levels. 
Embryos were either un-injected (i), (iii), (v) or injected with 3ng of ASPN mRNA (ii), (iv), 
(vi) and animal cap explants prepared and analysed with semi-quantitative RT-PCR for 
expression levels of IRS-1.  
 
 
5.3 ASPN interacts with and antagonises Nodal, BMP and Wnt 
molecules 
There is a range of signalling molecules that are involved in the early development of 
the vertebrate eye (Ikeda et al., 2005). It has been shown that SLRP family members 
can interact with, and inhibit, the function of a number of signalling compounds in a 
context-dependent manner (Dellett et al., 2012).  With that in mind, I investigated 
ASPN’s ability to affect the important Nodal/Activin-, BMP- and Wnt–signalling 
pathways. 
 
 
	 169	
5.3.1 ASPN inhibits Nodal, BMP and Wnt signalling in luciferase assay 
In the first instance, it was important to find out how, and if, ASPN influences these 
other signalling pathways. For this purpose, reporter constructs of either the Activin-
Response Element (ARE; for Nodal/Activin), BMP-Response Element (BRE; for 
BMP signals) or TOPFLASH (for Wnt) were injected together with mRNAs of 
Activin (for ARE), BMP4 (for BRE) or Wnt8 (for TOPFLASH) into the embryos. 
This acted as a positive control and confirmed the reporter activities were elevated at 
early gastrula stage. When ASPN mRNA was co-injected with either of these 
signalling molecule mRNAs their reporter activity was significantly reduced (Figure 
5.7). This suggests an inhibitory effect of ASPN on Nodal/Activin-, BMP- and Wnt–
signalling pathways. 
 
 
Figure 5.7: ASPN blocks endogenous Activin, BMP and Wnt signals, as examined by 
luciferase assays. ARE-luc, BRE-luc or TOPFLASH reporter constructs were injected with 
1 ng β -Galactosidase mRNA (control), 100 pg Xnr1 mRNA (for ARE), 100 pg BMP4 
mRNA (for BRE), 100 pg Wnt8 mRNA (for TOPFLASH), 100 pg Xnr1 + 1 ng ASPN 
mRNAs (for ARE), 100 pg BMP4 + 1 ng ASPN mRNAs (for BRE) or 100 pg Wnt8 + 1 ng 
ASPN mRNAs (for TOPFLASH) and were assayed at stage 12. 
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In order to further confirm that ASPN indeed has the ability to inhibit these signals, 
expression analyses were performed using either whole embryos or animal cap 
extracts. The animal caps were injected with ASPN mRNA and then treated with 
Nodal for 2 hours. The expression of the Nodal target gene Mix.2 (which is up-
regulated following treatment with Nodal) was analysed with qRT-PCR. The 
expression level of Mix.2 was found to be down regulated in the ASPN injected 
animal caps, compared to control explants (Figure 5.8).  
 
 
Figure 5.8: ASPN down regulates the Nodal target gene expression Mix.2. Un-injected 
or ASPN mRNA injected animal caps were treated with human recombinant Nodal for 2 
hours at a concentration of 10 ng/ ml and then the relative expression of Nodal target gene 
Mix.2 determined via qRT-PCR (*P<0.01, Student’s t-test). Error bars represent s.e.m. 
 
 
Next, ASPN’s inhibitory effect on the BMP signal was investigated more closely. 
Either Chordin, which is a well-known BMP inhibitor (Sasai et al., 1995), or ASPN 
mRNA was injected into embryos and the expression of general neural markers 
analysed at early neurula stage. Sox2 and NCAM were expressed at stage 14 in both 
chordin and ASPN injected animal cap explants. This is consistent with the idea that 
ASPN inhibits the BMP signalling pathway and thereby promotes a neural fate 
(Figure 5.9). 
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Figure 5.9: ASPN induces general neural markers Sox2 and NCAM. When known 
BMP-inhibitor Chordin is injected into Xenopus embryos general neural markers NCAM 
and Sox2 are found to be up-regulated at neural stage (lane 3), compared to un-injected 
control animal cap (lane 2). When ASPN mRNA was injected Sox2 and NCAM were also 
found to be up-regulated (lane 4), which further suggests that ASPN may act as a BMP 
inhibitor. 
 
 
ASPN’s relationship with the Wnt signalling pathway was also investigated further. 
Wnt8 mRNA was injected either on its own or together with ASPN mRNA and the 
animal cap explant then analysed for the expression of Xnr3, which is one of the 
target genes of the Wnt signalling pathway (Yang-Snyder et al., 1996). As expected, 
the expression of Xnr3 was induced when Wnt8 was injected. However, when ASPN 
was co-injected, Xnr3 levels were found to be significantly reduced (Figure 5.10). 
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Figure 5.10: ASPN inhibits Wnt signalling pathway target Xnr3. Animal caps injected 
with Wnt8 mRNA were analysed at stage 10.5 and showed an up-regulation in Wnt pathway 
target gene Xnr3. When ASPN mRNA was co-injected Xnr3 induction in the explants was 
found to be inhibited (*P<0.01, Student’s t-test). Error bars represent s.e.m. 
 
 
5.3.2 ASPN binds to Xnr-1, BMP4 and Wnt8 
The previous results revealed that ASPN acts as a multiple inhibitor for Nodal, BMP 
and Wnt signals. As ASPN is a secreted factor, I hypothesised that ASPN forms 
complexes with the other signalling molecules. In an attempt to find out how ASPN 
exerts its inhibitory effect on the aforementioned signalling molecules binding assays 
were performed.  
 
To perform this, tagged versions of expression constructs encoding Xnr-1, BMP4 or 
Wnt8 were transfected into HEK 293 culture cells together with a tagged version of 
ASPN, and a co-immunoprecipitation analysis was performed. The results show that 
ASPN does indeed form complexes with all three tested molecules BMP4 (Figure 
5.11, A), Xnr-1 (Figure 5.11, B) and Wnt8 (Figure 5.11, C), suggesting that ASPN 
interacts with these molecules in the extracellular space and thereby impedes their 
activities.  
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Figure 5.11: ASPN forms complexes with BMP4, Xnr1 and Wnt8 proteins. In order to 
avoid artificial interactions within the same cells, each expression construct was separately 
transfected into HEK 293 cells. Cells were then combined on the following day as indicated: 
(A) BMP4-FLAG and ASPN-HA; (B) Xnr1-myc and ASPN-HA; (C) Wnt8-myc and ASPN-
HA. The cell lysates were collected after two additional days of culturing and 
immunoprecipitation (IP) was performed with the flag (A) or myc (B,C) antibodies.  
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5.4 Discussion 
5.4.1 ASPN acts via the IGF signalling pathway 
The work presented in this chapter revolved around the relationship of ASPN with 
some of the major signalling pathways, thought to be important in early eye 
development. Due to similarities in phenotypes, and known importance of IGF 
signals for anterior neural development, there was a big focus on investigating 
ASPN’s potential association with the IGF pathway.  
 
Firstly, I showed that ASPN can activate the phosphorylation of ERK and AKT in 
vitro, which are known to be downstream targets of the IGF signalling pathway 
(Figure 5.2). Following IGF treatment, cells have been shown to develop strongly 
elevated levels of AKT phosphorylation (Romanelli et al., 2007, Ye et al., 2010). The 
IGF-PI3-AKT pathway is known to be important for neural proliferation and survival 
(Johnson-Farley et al., 2007), as well as other crucial cell activities such as motility, 
metabolism and differentiation (Bugner et al., 2011). More recently, its importance 
for eye field specification has been unveiled (La Torre et al., 2015). IGF signalling 
through the Ras-Raf-MAPK-ERK is well studied and thought to be key for IGF 
mediated cell proliferation. In neural cells this pathway is believed to contribute 
mainly to cell maturation and survival processes (D'Ercole et al., 1996, Ye et al., 
2010).  
 
I have also shown, that ASPN forms a complex with the IGF1R in vitro, as seen in 
Figure 5.3. While the results show that ASPN co-immunoprecipitates with the 
IGF1R, it cannot be excluded that ASPN actually binds to IGF instead.  Bound 
ASPN might in turn promote the binding of IGF to the receptor. My colleague Dr. 
Sasai has shown in a separate experiment that ASPN also binds to IGF2 (Appendix 
Figure 7.2). However, we did not find a significant difference of IGF2 binding to its 
receptor in the absence and presence of ASPN. This needs to be analysed in a more 
quantitative way to be able to draw definite conclusions, which is beyond the scope 
of this project. However, all the co-immunoprecipitation experiments were 
performed with overexpressed constructs and therefore the environment was 
stoichiometorically in favour of the expressed constructs and not the endogenous 
proteins. It is therefore unlikely that the binding and precipitation of the two proteins 
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involved endogenous proteins. Also, the co-immunoprecipitation assays in this study 
were performed in HEK 293 cells (i.e. non-physiological conditions), which might 
be perceived as sub optimal and not as relevant as in vivo data would be. While 
experiments in physiological conditions would have been ideal, there were 
unfortunately no antibodies commercially available that gave significant signals in 
either Western blotting or immunohistochemistry. 
 
ASPN seems to mediate its effect on eye development via the IGF1R, as seen when 
ASPN function was inhibited by the co-injection of the dominant-negative form of 
the IGF1 receptor, both in the long cultures and the animal cap assay. Without a 
functioning form of the IGF1R, the ability of ASPN to induce ectopic eyes in the 
embryos was drastically reduced in whole embryos (Figure 5.4, B, C). In the animal 
cap injected ASPN mRNA in combination with dn-IGF1R lead to only a minimal 
induction of EFTFs Pax6 and Rx2a (Figure 5.5, A).  
 
Results indicate that ASPN and IGF are both required for eye development. When 
IGF2 was co-injected with ASPN-MO1, the expected IGF2 mediated expansion of 
the embryos’ eyes was diminished or eye development even inhibited (Figure 5.4, D, 
E). Also, IGF2 mediated induction of EFTFs Pax6 and Rx2a in the animal cap was 
inhibited when ASPN-MO1 was co-injected (Figure 5.5, B). This suggests that both 
ASPN and IGF are necessary and important in the early stages of eye development in 
Xenopus laevis. 
 
Lastly, I wanted to make an attempt in finding out how ASPN and IGF transduce 
their specific eye development actions, in the right temporal and spatial fashion. IGF 
and ASPN are both ubiquitously expressed in anterior regions at the time of eye 
induction in Xenopus laevis. However, they seem to fulfil crucial roles in specific 
tissue, and perform these roles in a very regulated timely fashion, during early eye 
development. The question poses itself - how this specific ASPN and IGF signalling 
is achieved at the right place and time, especially when both ligands and IGF1R are 
present in a large area at that crucial developmental stage?  
 
Adaptor proteins such as Kermit2 or IRS1 could play a role in coordinating specific 
spatial/temporal signalling patterns of ASPN and IGF (Bugner et al., 2011, Wu et al., 
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2006). IGF1R’s substrate IRS-1 in particular was shown to play an important role in 
Xenopus eye development, via activation of PI3/AKT signalling pathway. Bugner 
and colleagues showed a specific expression pattern for IRS-1, which was limited to 
the anterior neural plate and the eye field, around the time of eye induction. Loss-of-
function of IRS-1 through the use of a morpholino, resulted in the downregulation of 
EFTF expression domains and overall small eyes. It is imaginable that such a 
specifically expressed substrate of the IGF1R receptor ensures that the ASPN/IGF 
signal contributes to eye development, in the right tissues, at the correct 
developmental stage. To make a first attempt at evaluating this, I analysed un-
injected and ASPN injected animal caps for possible elevations in IRS-1 levels. 
Unfortunately my preliminary experiment proved inconclusive (Figure 5.6). 
 
In summary, ASPN seems to induce eye development by regulating the IGF 
signalling pathway through a direct or indirect interaction with the IGF1R. Both 
ASPN and IGF are required for the induced eye development. 
 
5.4.2 ASPN antagonises Nodal, BMP and Wnt proteins 
The results also show that ASPN interacts with other major signalling molecules 
such as Nodal, BMP and Wnt proteins. In the luciferase assay ASPN inhibited the 
Nodal, BMP and Wnt signalling pathways (Figure 5.7). After investigating each of 
these three pathways more closely, it turned out that ASPN down-regulates both the 
nodal target gene Mix.2 (Figure 5.8) and Wnt target gene Xnr3 (Figure 5.10) in 
animal cap explants. Furthermore, it could be shown indirectly that ASPN inhibits 
BMP signalling. Much like well-known BMP-inhibitor Chordin, ASPN induced 
general neural markers Sox2 and NCAM and therefore promotes neural fate (Figure 
5.8).  
 
Consistent with the notion that ASPN inhibits Wnt and BMP signalling, my 
colleague Dr. Kurosawa found that ASPN mRNA injections at the equator region 
resulted in a reduction of Xbra (Xenopus orthologue of Brachyury) expression 
(Appendix Figure 7.3) at gastrula stage, suggesting that mesoderm determination was 
severely disrupted by ASPN. The shortened body axis phenotype, which was 
exhibited at the tadpole stage upon ventral animal ASPN injection (Figure 3.12), 
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could be caused by disrupted Xbra expression. Xbra is a crucial factor for the 
promotion of convergent extension in the developing embryo (Kwan, 2003). 
 
ASPN also forms a complex with Xnr-1, BMP4 and Wnt8 in co-
immunoprecipitation assay (Figure 5.11, A-C). To exclude the notion that ASPN acts 
as a general ligand-binding proteoglycan, Dr. Sasai analysed the potential binding of 
ASPN to some major receptor proteins, which are shown in supplementary Figure 
7.2 (Appendix). He found that ASPN did not bind to the Activin receptor, BMP 
receptor or Frizzled receptor. While these results obviously do not exclude the 
possibility that ASPN may bind to other receptor proteins, it does suggest that ASPN 
binds to proteins in a selective manner. 
 
Together these data suggest that ASPN interacts with major signalling molecules that 
antagonise the eye formation in the extracellular space and blocks those activities. 
 
 
5.5 Summary 
Results indicate that ASPN interacts with many other regulatory molecules including 
BMP, Wnt and Nodal in addition to IGF and IGF1R, but has no (or very little) 
affinity to bind other receptor proteins, such as Activin receptor, BMP receptor and 
Frizzled receptor (supplementary Figure 7.2). It suggests that ASPN acts as a 
multiple inhibitor for Nodal, BMP and Wnt proteins. ASPN therefore interacts with 
important signalling molecules, which antagonise eye development and inhibits their 
function. This means that ASPN is not just an extracellular matrix protein that 
randomly binds to proteins, but instead an active modulator for other signal 
molecules. Furthermore, ASPN can apparently regulate bound proteins in different 
ways. BMP, Nodal and Wnt are inhibitied by ASPN while in contrast the IGF signal 
is promoted. This finding may account for the phenotypic differences following 
overexpression of IGF and ASPN; ASPN exhibits a strong phenotype specifically in 
the eye, while IGF induces the whole head structure including cement grand. 
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6 CHAPTER 6 - GENERAL DISCUSSION 
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6.1 Summary of findings in this study 
When screening SLRP family members for their effects on early development, the 
Xenopus ortholog of ASPN induced a striking eye phenotype in the developing 
tadpoles. I decided to analyse this phenotype more closely and to try and determine 
ASPN’s potential role in eye development, as well as its underlying molecular 
mechanisms. The aim of this study was to investigate the ASPN induced eye 
phenotype more closely and elucidate the molecular mechanism underlying ASPN’s 
action. 
 
In Chapter 3, I introduced ASPN as a novel factor involved in Xenopus eye 
development. ASPN is expressed in the area of the presumptive eye field around the 
time of eye induction, although detailed expression patterns around stage 11/12 could 
unfortunately not be visualised. I characterised the induced phenotype more closely 
and could show evidence that the induced structures indeed have eye character. The 
question of whether these ectopic eyes possess any functionality cannot be answered 
with certainty at this point. Furthermore, I showed that ASPN induces eye field 
transcriptions factors both in vivo and in vitro. Overall, the ASPN induced phenotype 
has many similarities to the IGF overexpression phenotype, described in detail by 
Pera et al. (2001) and Richard-Parpaillon et al. (2002), while not being identical.  
 
Results presented in Chapter 4 showed that ASPN is indeed essential for frog eye 
development. Experiments using ASPN morpholino oligos resulted in reduced or 
complete inhibition of eye formation. The ASPN morpholino injected embryos 
showed reduced levels of EFTFs on the injected sides. I investigated if ASPN’s 
effects are unique amongst SLRPs and showed that the ability to induce ectopic eye 
development is not shared with other SLRP family members. Fellow class I SLRP 
Decorin and class IV Chondroadherin had no effect on the tadpoles’ eye 
development, while Lumican and Epiphycan induced mild eye phenotypes.  
 
Molecular mechanisms were investigated in Chapter 5. I could show that ASPN 
activates the IGF signalling pathway and can bind to the IGF1R. Additionally, ASPN 
antagonises nodal, BMP and Wnt protein signalling.  
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6.2 The proposed model of ASPN’s actions during eye development  
Based on the data collected in this study, I propose the following mode of action for 
ASPN in the context of Xenopus eye development (as illustrated in Figure 6.1): At a 
specific time and in specific tissue, around the time of eye induction, ASPN (possibly 
induced by Chordin) activates the IGF signalling pathway. To enable this ASPN 
forms a complex with the IGF1R, either directly or possibly while bound to IGF. The 
ASPN/IGF1R signal then induces EFTFs, such as Rx1 and Pax6, which leads to eye 
field specification. At the same time ASPN also inhibits Wnt, Nodal and BMP 
signalling in a temporal and spatial specific manner – presumably by binding to the 
signalling proteins and thereby inhibiting them from attaching to their respective 
receptors.  
 
 
Figure 6.1: Proposed molecular mechanism of ASPN in eye development. ASPN binds 
to signalling molecules from the Wnt, Nodal and BMP families and thereby antagonises 
these signalling pathways. ASPN also binds to the IGF1R and activates downstream 
signalling, which leads to increased ERK and AKT phosphorylation.  The ASPN/IGF1R 
signal leads to an up-regulation of EFTFs, such as Rx1 and Pax6, eventually leading to 
eyefield specification and eye formation. 
 
 
The experiments presented here have demonstrated that ASPN interacts with IGF 
and IGF1R, activates the downstream signalling pathways (Figure 5.2; Figure 5.3) 
and that both IGF and ASPN are required for the activation of these pathways, which 
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leads to eye development (Figure 5.4; Figure 5.5; Appendix Figure 7.1). Since both 
IGF and ASPN need to be present, this might suggest that they bind to the IGF1R at 
the same time. Interestingly, neural inducer Chordin activated ASPN expression, 
while IGF did not (Figure 3.3 B (ii), (iii)). This suggests that two independent 
regulatory pathways (Chordin/ASPN and IGF) are involved in the induction of eye 
development. 
 
The importance of IGF1 was further shown by Mellough et al. (2015) in hESC 
(human embryonic stem cells). The addition of exogenous IGF1 to the cultured cells 
induced the formation of three-dimensional eye-like structures and primitive lens and 
cornea. However, the inhibition of IGF1R reduced the formation of these ocular 
structures. They concluded that IGF signalling must be important for both the early 
stages of eye development, as well as later stage photoreceptor maturation processes.   
 
More evidence that both an active IGF signal and inhibition of BMP, TGF-β and 
Wnt signals, are important for proper eye development, comes from recently 
published work: Zhou and colleagues (2015) showed that simultaneous inhibition of 
BMP, TGF-β and Wnt signalling is needed for eye development. Coco (Dand5), a 
Cerberus family member, is expressed in the developing and adult mouse retina. In 
human embryonic stem cells (hESC), Coco exposure was shown to induce 
differentiation into S-cone photoreceptors. Coco exhibited a synergistic, dose-
dependent activity with IGF-1 in blocking BMP, TFG-β and Wnt signalling. IGF-1 
greatly enhanced Coco’s inhibition (Zhou et al., 2015). 
 
The IGF1 receptor and IGFs are expressed widely during development and are 
involved in many cellular processes such as proliferation, maturation, survival and 
growth (O'Kusky and Ye, 2012). ASPN in situ data also showed ubiquitous 
expression around the time of eye induction. So how can be ensured that eye 
induction only takes place in specific tissues and the right time? Specification of the 
presumptive eye region may rely on spatial and temporal coordination of ASPN and 
IGF, i.e. when and where the two molecules’ signals intersect. IGF-related proteins, 
such as IGFBPs, are known to modulate IGF signalling and may contribute to 
achieving the specification. Furthermore, IGF mediator proteins IRS-1 and Kermit2 
(GIPC2) have been shown to play important roles in eye development (Bugner et al., 
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2011, Wu et al., 2006). Both are intracellular proteins that interact with the IGF1R 
and transduce downstream signals, such as the PI3/AKT and MAPK/ERK pathways, 
and may selectively modulate the IGF1 receptors downstream response to 
ASPN/IGF binding. Detecting levels of IGF, ASPN, ERK/AKT activation and 
mediators IRS-1/Kermit2 in vivo will help to better understand how the distribution 
of these molecules relates to eye development.  
 
 
6.3 Are these insights translatable to mammals and humans? 
ASPN obviously plays an important role in the Xenopus laevis eye development. The 
question remains, whether the same holds true for other vertebrates, in particular 
mammals and humans?  
 
I carried out some preliminary overexpression experiments in the Zebrafish Danio 
rerio. While not statistically significant, due to a low n-number, one embryo 
exhibited an ectopic eye-like structure (Figure 4.14). Evidence that IGF signalling 
also plays an important role in anterior development in fish comes from work carried 
out by (amongst others) Eivers et al. (2004): Injection of DN-IGF1R caused the loss 
of head and eyes, as well as an absence of the notochord. The overexpression of 
IGF1 dorsalised the embryos, resulting in an expansion of the forebrain and a 
reduction of trunk and tail. In severe cases the embryos exhibited a complete lack of 
posterior and ventral tissues. The Zebrafish phenotype is similar to that found in 
Xenopus. The question as usual is whether the same is true for mammals. Mouse 
mutants only exhibit an overall decreased size, which might suggest only a limited 
role for IGF in differentiation and cell fate regulation in the mouse (Eivers et al., 
2004, Zuber et al., 2003). Another possibility is that there is a high degree of 
redundancy in the highly complex mammalian IGF signalling system. The phenotype 
variation could also be due to differences in experimental technique. The use of 
dominant negative receptors causes a more global and unspecific blocking of the 
signalling pathways (i.e. IGF1, IGF2, In, InR). For example mice with a deficiency 
in both IGF1R and InR show a more severe phenotype (Eivers et al., 2004). 
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All components of the IGF signalling system are widely expressed in human brain 
and cerebrospinal fluid (CSF) (Chesik et al., 2006, Mashayekhi et al., 2010, O'Kusky 
and Ye, 2012). However, there is still very little information available regarding the 
role of IGF signalling in human neural development. Individuals with mutations in 
both igf1 or igf1r gene have been described, and the overall phenotype seems to be 
consistent with those observed in rodents: intrauterine growth retardation, 
microcephaly, severe deafness and mental retardation. While smaller brain size was 
observed, the overall brain architecture and myelination was found to be normal. 
Individuals with mutated igf1 gene had severely increased IGF2 serum levels, which 
might indicate a level of redundancy (Ye et al., 2002a, Ye et al., 2002b). The 
findings of relatively normal cell differentiation and development, upon IGF1R 
knockout, stands in stark contrast to the results obtained in Xenopus in this study, as 
well as by Pera et al. (2001) and Richard-Parpaillon et al. (2002), and in Zebrafish 
(Eivers et al., 2004). It might be possible that the role of IGF signalling in anterior 
neural induction and development was retained in Xenopus and Zebrafish, while it 
has been lost in mice or masked through other functions. Since the mammalian IGF 
system is very complex, one can expect a high rate of functional redundancy to 
occur.  
 
Very recently, work carried out on ASPN knockout mice has been published (Awata 
et al., 2015). The ASPN -/- mice were created using homologous recombination in 
embryonic stem cells. While the ASPN -/- mice phenotype is not described in detail, 
the animals were reported to be fertile and without any apparent developmental 
defects until 5 weeks after birth. Also, when ASPN was first characterised by Henry 
et al. (2001), they did not find ASPN expression in the eye of the developing mouse 
until 15.5 dpc (days post coitum). ASPN expression could then only be detected in 
the mouse embryos sclera (Henry et al., 2001). This might suggest, that ASPN does 
not play the same role in eye development in mouse.  
 
On the other hand, much like the mammalian IGF system, SLRP signalling might 
just be more complex in mammals. Functional redundancy and compensating 
mechanisms have often been observed. Despite their distinct functions, some SLRPs 
are similar enough, to be able to rescue the effects of another SLRP, which had been 
knocked out. For example increased levels of Lumican were found in Fibromodulin 
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deficient tendon (Svensson et al., 1995) and Decorin and Biglycan can compensate 
for each other in a bone phenotype with a synergistic effect in double knockout 
(Ameye and Young, 2002). Mutations in several SLRPs and loss-of-function has 
been shown to affect the human eye. For example mutated forms of Nyctalopin cause 
congenital stationary night blindness (Bech-Hansen et al., 2000), abnormal forms of 
Keratocan cause a corneal disorder (Pellegata et al., 2000) and changes in Opticin, 
PRELP, Lumican and Fibromodulin lead to high myopia (Lin et al., 2010, Majava et 
al., 2007). This indicates, that SLRPs are involved in human eye development, which 
might mean that ASPN also plays a role. 
 
 
6.4 Future directions 
There are still many questions left to answer. ASPN clearly interacts specifically 
with many different ligands and receptors. It would be interesting to try and identify 
other possible binding partners and interactions, via high through put screening. On a 
molecular level, more detailed analyses will be required to better understand the 
association between ASPN, IGF, IGF1R and downstream signalling components 
such as phosphorylated ERK and AKT. This will further help to understand, how 
these different players work together to facilitate frog eye development. 
 
To take this project one step further it would be important to characterise ASPN’s 
potential role in eye development in a mammalian model. Prof. Makoto Asashima 
reported in 2003 (Sedohara et al., 2003) the generation of whole Xenopus eyes in 
vitro using tissue culture. These in vitro eyes exhibited layered retina, lens and, once 
implanted into host tadpoles, successfully innervated the host’s tectum. More 
recently ground-breaking work was carried out by Prof. Yoshiki Sasai and his team, 
who showed that both human and murine ES cells are capable of generating self-
organizing optic cups in three dimensional cultures (Eiraku et al., 2011, Nakano et 
al., 2012).  
 
As previously mentioned, IGF signalling has been shown to drastically improve in 
vitro eye formation in human embryonic stem cells, as well as simultaneous 
inhibition of Wnt and TGF-β signalling (Mellough et al., 2015, Zhou et al., 2015). It 
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is imaginable that if ASPN acts in a similar fashion in mammalian cells it could 
prove a useful tool for in vitro eye induction. A range of ‘eye-maker’ proteins have 
been identified over the years. Being an extracellular protein, ASPN would have the 
advantage of easy application to treat cells to induce differentiation in vitro. 
 
Another interesting aspect relates to how the forebrain and retinal lineages are 
separated from each other during development. The work presented here suggests 
that tissues/cells that are exposed to anti-Wnt, anti-Nodal and pro-RTK (IGF) 
signals, in addition to anti-BMP signals, tend to acquire a retinal cell fate (as 
facilitated by Asporin in frog). Apart from the role of ASPN in this process per se, 
this represents an important principle. Although ASPN may not be expressed in the 
early retinal area in the mouse or human, the same mechanism may still be conserved 
in those organisms, but facilitated through other factors. My colleague Dr. Noriaki 
Sasai is currently pursuing this possibility in his laboratory, by chemical 
manipulation of the Wnt and Nodal levels in chick explants. Future studies will be 
focused on isolating such gene(s) in other species and human. 
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7 Appendix 
 
The data presented in this section were acquired by my colleagues Dr. Noriaki Sasai 
(Figure 7.1 and 7.2) and Dr. Maiko Kurosawa-Yoshida (Figure 7.3). 
 
 
Figure 7.1: Both IGF and ASPN are required for the full activation of ERK. Animal cap 
explants were prepared from 3 ng control β-Galactosidase (i,ii,iv), 3 ng dnIGFR mRNA (iii), 
20 ng control-MO (v) or 20 ng ASPN-MO (vi) injected embryos and were incubated with 
the conditioned media expressing control (i,iv), ASPN (ii,iii) or IGF2 (v,vi) for 20 minutes. 
The explants were analysed by western blotting using phospho-ERK or ERK antibodies. 
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Figure 7.2: Interactions between ASPN and other molecules. The expression plasmids 
encoding ASPN-HA and IGF2-myc (A), Activin receptor (ActR)-FLAG (B), BMP receptor 
(BMPR)-FLAG (C) and Fzd4-CRD (the cysteine-rich domain in the extracellular part of 
Frz4)-myc-FLAG (D) were transfected into HEK293 cells. The cell extracts were analysed 
by co-immunoprecipitation assays. 
 
 
 
Figure 7.3: Xbra expression was inhibited by ASPN, as analysed by in situ 
hybridisation. The β-Galactosidase mRNA (light blue product) was injected without (A) or 
with (B) ASPN mRNAs into one blastomere at the equator region of 4-cell stage embryos 
and embryos were cultured until stage 10.5. Affected areas are indicated with arrowheads. 
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